uuid stringlengths 4 8 | template_uuid stringclasses 40
values | question stringlengths 13 193 | answer stringlengths 29 2.2k | benchmark_query stringlengths 133 622 | execution_results stringlengths 2 1.14M | query_type stringclasses 2
values | sql_category stringclasses 26
values | bio_category stringclasses 14
values |
|---|---|---|---|---|---|---|---|---|
Q34.1679 | Q34 | What are the names of the genes that are targeted by the drug Voxelotor in the treatment of sickle cell anemia? | In the context of sickle cell anemia, the drug Voxelotor targets the gene hemoglobin subunit alpha 1, hemoglobin subunit alpha 2 and hemoglobin subunit beta. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%sickle cell anemia%" OR LOWER(efo_term) LIKE "%sickle cell anemia%") AND (LOWER(drugName) LIKE "%voxelotor%" OR LOWER(tradeNames_list) LIKE "%voxelotor%" OR LOWER(syns_list) LIKE "%voxelotor%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1095609', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'syns_list': "['GBT-440', 'GBT440', 'GTX-011', 'Gbt440', 'Voxelotor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia', 'approvedSymbol': 'HBA1', 'approvedName': 'hemoglobin subunit alpha 1'}, {'UUID': 'DrugTargetsIndication121923_text_1095624', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'syns_list': "['GBT-440', 'GBT440', 'GTX-011', 'Gbt440', 'Voxelotor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia', 'approvedSymbol': 'HBA1', 'approvedName': 'hemoglobin subunit alpha 1'}, {'UUID': 'DrugTargetsIndication121923_text_1095629', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'syns_list': "['GBT-440', 'GBT440', 'GTX-011', 'Gbt440', 'Voxelotor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia', 'approvedSymbol': 'HBA1', 'approvedName': 'hemoglobin subunit alpha 1'}, {'UUID': 'DrugTargetsIndication121923_text_1095634', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'syns_list': "['GBT-440', 'GBT440', 'GTX-011', 'Gbt440', 'Voxelotor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia', 'approvedSymbol': 'HBA1', 'approvedName': 'hemoglobin subunit alpha 1'}, {'UUID': 'DrugTargetsIndication121923_text_1095644', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'syns_list': "['GBT-440', 'GBT440', 'GTX-011', 'Gbt440', 'Voxelotor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia', 'approvedSymbol': 'HBA1', 'approvedName': 'hemoglobin subunit alpha 1'}, {'UUID': 'DrugTargetsIndication121923_text_1095649', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'syns_list': "['GBT-440', 'GBT440', 'GTX-011', 'Gbt440', 'Voxelotor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia', 'approvedSymbol': 'HBA1', 'approvedName': 'hemoglobin subunit alpha 1'}, {'UUID': 'DrugTargetsIndication121923_text_1095654', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'syns_list': "['GBT-440', 'GBT440', 'GTX-011', 'Gbt440', 'Voxelotor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia', 'approvedSymbol': 'HBA1', 'approvedName': 'hemoglobin subunit alpha 1'}, {'UUID': 'DrugTargetsIndication121923_text_1095664', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'syns_list': "['GBT-440', 'GBT440', 'GTX-011', 'Gbt440', 'Voxelotor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia', 'approvedSymbol': 'HBA1', 'approvedName': 'hemoglobin subunit alpha 1'}, {'UUID': 'DrugTargetsIndication121923_text_1095669', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'syns_list': "['GBT-440', 'GBT440', 'GTX-011', 'Gbt440', 'Voxelotor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia', 'approvedSymbol': 'HBA1', 'approvedName': 'hemoglobin subunit alpha 1'}, {'UUID': 'DrugTargetsIndication121923_text_1095674', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'syns_list': "['GBT-440', 'GBT440', 'GTX-011', 'Gbt440', 'Voxelotor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia', 'approvedSymbol': 'HBA1', 'approvedName': 'hemoglobin subunit alpha 1'}, {'UUID': 'DrugTargetsIndication121923_text_1095679', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'syns_list': "['GBT-440', 'GBT440', 'GTX-011', 'Gbt440', 'Voxelotor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia', 'approvedSymbol': 'HBA1', 'approvedName': 'hemoglobin subunit alpha 1'}, {'UUID': 'DrugTargetsIndication121923_text_1095689', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'syns_list': "['GBT-440', 'GBT440', 'GTX-011', 'Gbt440', 'Voxelotor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia', 'approvedSymbol': 'HBA2', 'approvedName': 'hemoglobin subunit alpha 2'}, {'UUID': 'DrugTargetsIndication121923_text_1095694', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'syns_list': "['GBT-440', 'GBT440', 'GTX-011', 'Gbt440', 'Voxelotor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia', 'approvedSymbol': 'HBA2', 'approvedName': 'hemoglobin subunit alpha 2'}, {'UUID': 'DrugTargetsIndication121923_text_1095699', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'syns_list': "['GBT-440', 'GBT440', 'GTX-011', 'Gbt440', 'Voxelotor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia', 'approvedSymbol': 'HBA2', 'approvedName': 'hemoglobin subunit alpha 2'}, {'UUID': 'DrugTargetsIndication121923_text_1095704', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'syns_list': "['GBT-440', 'GBT440', 'GTX-011', 'Gbt440', 'Voxelotor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia', 'approvedSymbol': 'HBA2', 'approvedName': 'hemoglobin subunit alpha 2'}, {'UUID': 'DrugTargetsIndication121923_text_1095709', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'syns_list': "['GBT-440', 'GBT440', 'GTX-011', 'Gbt440', 'Voxelotor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia', 'approvedSymbol': 'HBA2', 'approvedName': 'hemoglobin subunit alpha 2'}, {'UUID': 'DrugTargetsIndication121923_text_1095714', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'syns_list': "['GBT-440', 'GBT440', 'GTX-011', 'Gbt440', 'Voxelotor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia', 'approvedSymbol': 'HBA2', 'approvedName': 'hemoglobin subunit alpha 2'}, {'UUID': 'DrugTargetsIndication121923_text_1095719', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'syns_list': "['GBT-440', 'GBT440', 'GTX-011', 'Gbt440', 'Voxelotor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia', 'approvedSymbol': 'HBA2', 'approvedName': 'hemoglobin subunit alpha 2'}, {'UUID': 'DrugTargetsIndication121923_text_1095724', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'syns_list': "['GBT-440', 'GBT440', 'GTX-011', 'Gbt440', 'Voxelotor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia', 'approvedSymbol': 'HBA2', 'approvedName': 'hemoglobin subunit alpha 2'}, {'UUID': 'DrugTargetsIndication121923_text_1095729', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'syns_list': "['GBT-440', 'GBT440', 'GTX-011', 'Gbt440', 'Voxelotor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia', 'approvedSymbol': 'HBA2', 'approvedName': 'hemoglobin subunit alpha 2'}, {'UUID': 'DrugTargetsIndication121923_text_1095734', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'syns_list': "['GBT-440', 'GBT440', 'GTX-011', 'Gbt440', 'Voxelotor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia', 'approvedSymbol': 'HBA2', 'approvedName': 'hemoglobin subunit alpha 2'}, {'UUID': 'DrugTargetsIndication121923_text_1095744', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'syns_list': "['GBT-440', 'GBT440', 'GTX-011', 'Gbt440', 'Voxelotor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia', 'approvedSymbol': 'HBA2', 'approvedName': 'hemoglobin subunit alpha 2'}, {'UUID': 'DrugTargetsIndication121923_text_1095749', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'syns_list': "['GBT-440', 'GBT440', 'GTX-011', 'Gbt440', 'Voxelotor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia', 'approvedSymbol': 'HBA2', 'approvedName': 'hemoglobin subunit alpha 2'}, {'UUID': 'DrugTargetsIndication121923_text_1095754', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'syns_list': "['GBT-440', 'GBT440', 'GTX-011', 'Gbt440', 'Voxelotor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia', 'approvedSymbol': 'HBA2', 'approvedName': 'hemoglobin subunit alpha 2'}, {'UUID': 'DrugTargetsIndication121923_text_1095759', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'syns_list': "['GBT-440', 'GBT440', 'GTX-011', 'Gbt440', 'Voxelotor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia', 'approvedSymbol': 'HBA2', 'approvedName': 'hemoglobin subunit alpha 2'}, {'UUID': 'DrugTargetsIndication121923_text_1095764', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'syns_list': "['GBT-440', 'GBT440', 'GTX-011', 'Gbt440', 'Voxelotor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia', 'approvedSymbol': 'HBA2', 'approvedName': 'hemoglobin subunit alpha 2'}, {'UUID': 'DrugTargetsIndication121923_text_1095774', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'syns_list': "['GBT-440', 'GBT440', 'GTX-011', 'Gbt440', 'Voxelotor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia', 'approvedSymbol': 'HBA2', 'approvedName': 'hemoglobin subunit alpha 2'}, {'UUID': 'DrugTargetsIndication121923_text_1095779', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'syns_list': "['GBT-440', 'GBT440', 'GTX-011', 'Gbt440', 'Voxelotor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia', 'approvedSymbol': 'HBA2', 'approvedName': 'hemoglobin subunit alpha 2'}, {'UUID': 'DrugTargetsIndication121923_text_1095784', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'syns_list': "['GBT-440', 'GBT440', 'GTX-011', 'Gbt440', 'Voxelotor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia', 'approvedSymbol': 'HBA2', 'approvedName': 'hemoglobin subunit alpha 2'}, {'UUID': 'DrugTargetsIndication121923_text_1095789', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'syns_list': "['GBT-440', 'GBT440', 'GTX-011', 'Gbt440', 'Voxelotor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia', 'approvedSymbol': 'HBA2', 'approvedName': 'hemoglobin subunit alpha 2'}, {'UUID': 'DrugTargetsIndication121923_text_1095794', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'syns_list': "['GBT-440', 'GBT440', 'GTX-011', 'Gbt440', 'Voxelotor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia', 'approvedSymbol': 'HBB', 'approvedName': 'hemoglobin subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1095799', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'syns_list': "['GBT-440', 'GBT440', 'GTX-011', 'Gbt440', 'Voxelotor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia', 'approvedSymbol': 'HBB', 'approvedName': 'hemoglobin subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1095804', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'syns_list': "['GBT-440', 'GBT440', 'GTX-011', 'Gbt440', 'Voxelotor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia', 'approvedSymbol': 'HBB', 'approvedName': 'hemoglobin subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1095809', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'syns_list': "['GBT-440', 'GBT440', 'GTX-011', 'Gbt440', 'Voxelotor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia', 'approvedSymbol': 'HBB', 'approvedName': 'hemoglobin subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1095814', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'syns_list': "['GBT-440', 'GBT440', 'GTX-011', 'Gbt440', 'Voxelotor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia', 'approvedSymbol': 'HBB', 'approvedName': 'hemoglobin subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1095819', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'syns_list': "['GBT-440', 'GBT440', 'GTX-011', 'Gbt440', 'Voxelotor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia', 'approvedSymbol': 'HBB', 'approvedName': 'hemoglobin subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1095824', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'syns_list': "['GBT-440', 'GBT440', 'GTX-011', 'Gbt440', 'Voxelotor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia', 'approvedSymbol': 'HBB', 'approvedName': 'hemoglobin subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1095829', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'syns_list': "['GBT-440', 'GBT440', 'GTX-011', 'Gbt440', 'Voxelotor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia', 'approvedSymbol': 'HBB', 'approvedName': 'hemoglobin subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1095834', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'syns_list': "['GBT-440', 'GBT440', 'GTX-011', 'Gbt440', 'Voxelotor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia', 'approvedSymbol': 'HBB', 'approvedName': 'hemoglobin subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1095839', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'syns_list': "['GBT-440', 'GBT440', 'GTX-011', 'Gbt440', 'Voxelotor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia', 'approvedSymbol': 'HBB', 'approvedName': 'hemoglobin subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1095844', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'syns_list': "['GBT-440', 'GBT440', 'GTX-011', 'Gbt440', 'Voxelotor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia', 'approvedSymbol': 'HBB', 'approvedName': 'hemoglobin subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1095849', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'syns_list': "['GBT-440', 'GBT440', 'GTX-011', 'Gbt440', 'Voxelotor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia', 'approvedSymbol': 'HBB', 'approvedName': 'hemoglobin subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1095854', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'syns_list': "['GBT-440', 'GBT440', 'GTX-011', 'Gbt440', 'Voxelotor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia', 'approvedSymbol': 'HBB', 'approvedName': 'hemoglobin subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1095859', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'syns_list': "['GBT-440', 'GBT440', 'GTX-011', 'Gbt440', 'Voxelotor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia', 'approvedSymbol': 'HBB', 'approvedName': 'hemoglobin subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1095864', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'syns_list': "['GBT-440', 'GBT440', 'GTX-011', 'Gbt440', 'Voxelotor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia', 'approvedSymbol': 'HBB', 'approvedName': 'hemoglobin subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1095869', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'syns_list': "['GBT-440', 'GBT440', 'GTX-011', 'Gbt440', 'Voxelotor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia', 'approvedSymbol': 'HBB', 'approvedName': 'hemoglobin subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1095874', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'syns_list': "['GBT-440', 'GBT440', 'GTX-011', 'Gbt440', 'Voxelotor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia', 'approvedSymbol': 'HBB', 'approvedName': 'hemoglobin subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1095879', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'syns_list': "['GBT-440', 'GBT440', 'GTX-011', 'Gbt440', 'Voxelotor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia', 'approvedSymbol': 'HBB', 'approvedName': 'hemoglobin subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1095884', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'syns_list': "['GBT-440', 'GBT440', 'GTX-011', 'Gbt440', 'Voxelotor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia', 'approvedSymbol': 'HBB', 'approvedName': 'hemoglobin subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1095889', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'syns_list': "['GBT-440', 'GBT440', 'GTX-011', 'Gbt440', 'Voxelotor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia', 'approvedSymbol': 'HBB', 'approvedName': 'hemoglobin subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1095894', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'syns_list': "['GBT-440', 'GBT440', 'GTX-011', 'Gbt440', 'Voxelotor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia', 'approvedSymbol': 'HBB', 'approvedName': 'hemoglobin subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1095739', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'syns_list': "['GBT-440', 'GBT440', 'GTX-011', 'Gbt440', 'Voxelotor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia', 'approvedSymbol': 'HBA2', 'approvedName': 'hemoglobin subunit alpha 2'}, {'UUID': 'DrugTargetsIndication121923_text_1095659', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'syns_list': "['GBT-440', 'GBT440', 'GTX-011', 'Gbt440', 'Voxelotor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia', 'approvedSymbol': 'HBA1', 'approvedName': 'hemoglobin subunit alpha 1'}, {'UUID': 'DrugTargetsIndication121923_text_1095619', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'syns_list': "['GBT-440', 'GBT440', 'GTX-011', 'Gbt440', 'Voxelotor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia', 'approvedSymbol': 'HBA1', 'approvedName': 'hemoglobin subunit alpha 1'}, {'UUID': 'DrugTargetsIndication121923_text_1095599', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'syns_list': "['GBT-440', 'GBT440', 'GTX-011', 'Gbt440', 'Voxelotor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia', 'approvedSymbol': 'HBA1', 'approvedName': 'hemoglobin subunit alpha 1'}, {'UUID': 'DrugTargetsIndication121923_text_1095589', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'syns_list': "['GBT-440', 'GBT440', 'GTX-011', 'Gbt440', 'Voxelotor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia', 'approvedSymbol': 'HBA1', 'approvedName': 'hemoglobin subunit alpha 1'}, {'UUID': 'DrugTargetsIndication121923_text_1095584', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'syns_list': "['GBT-440', 'GBT440', 'GTX-011', 'Gbt440', 'Voxelotor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia', 'approvedSymbol': 'HBA1', 'approvedName': 'hemoglobin subunit alpha 1'}, {'UUID': 'DrugTargetsIndication121923_text_1095769', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'syns_list': "['GBT-440', 'GBT440', 'GTX-011', 'Gbt440', 'Voxelotor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia', 'approvedSymbol': 'HBA2', 'approvedName': 'hemoglobin subunit alpha 2'}, {'UUID': 'DrugTargetsIndication121923_text_1095684', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'syns_list': "['GBT-440', 'GBT440', 'GTX-011', 'Gbt440', 'Voxelotor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia', 'approvedSymbol': 'HBA1', 'approvedName': 'hemoglobin subunit alpha 1'}, {'UUID': 'DrugTargetsIndication121923_text_1095639', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'syns_list': "['GBT-440', 'GBT440', 'GTX-011', 'Gbt440', 'Voxelotor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia', 'approvedSymbol': 'HBA1', 'approvedName': 'hemoglobin subunit alpha 1'}, {'UUID': 'DrugTargetsIndication121923_text_1095614', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'syns_list': "['GBT-440', 'GBT440', 'GTX-011', 'Gbt440', 'Voxelotor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia', 'approvedSymbol': 'HBA1', 'approvedName': 'hemoglobin subunit alpha 1'}, {'UUID': 'DrugTargetsIndication121923_text_1095604', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'syns_list': "['GBT-440', 'GBT440', 'GTX-011', 'Gbt440', 'Voxelotor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia', 'approvedSymbol': 'HBA1', 'approvedName': 'hemoglobin subunit alpha 1'}, {'UUID': 'DrugTargetsIndication121923_text_1095594', 'drugName': 'Voxelotor', 'tradeNames_list': "['Oxbryta']", 'syns_list': "['GBT-440', 'GBT440', 'GTX-011', 'Gbt440', 'Voxelotor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Sickle Cell', 'efo_term': 'sickle cell anemia', 'approvedSymbol': 'HBA1', 'approvedName': 'hemoglobin subunit alpha 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1701 | Q34 | What are the names of the genes that are targeted by the drug Leuprolide Acetate in the treatment of Central precocious puberty? | In the context of Central precocious puberty, the drug Leuprolide Acetate targets the gene gonadotropin releasing hormone receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%central precocious puberty%" OR LOWER(efo_term) LIKE "%central precocious puberty%") AND (LOWER(drugName) LIKE "%leuprolide acetate%" OR LOWER(tradeNames_list) LIKE "%leuprolide acetate%" OR LOWER(syns_list) LIKE "%leuprolide acetate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1097052', 'drugName': 'Leuprolide Acetate', 'tradeNames_list': "['Carcinil', 'Eligard', 'Eligard kit', 'Fensolvi kit', 'Leuprolide acetateLeuprorelin', 'Lupron', 'Lupron Depot Ped', 'Lupron depotLupron depot-ped', 'Lupron depot-ped kit', 'Lutrate depot kit', 'Viadur']", 'syns_list': "['A-43818', 'ABBOTT-43818', 'Carcinil', 'Enantone', 'Fensolvi', 'LeuplinLeuporelin acetate', 'Leuprolide acetate', 'Leuprolide monoacetateLeuprorelin acetate', 'Lucrin', 'Lupaneta', 'Lutrate depot', 'ProstapTAP-144', 'Tap-144-sr', 'Trenantone']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Puberty, Precocious', 'efo_term': 'central precocious puberty', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097093', 'drugName': 'Leuprolide Acetate', 'tradeNames_list': "['Carcinil', 'Eligard', 'Eligard kit', 'Fensolvi kit', 'Leuprolide acetateLeuprorelin', 'Lupron', 'Lupron Depot Ped', 'Lupron depotLupron depot-ped', 'Lupron depot-ped kit', 'Lutrate depot kit', 'Viadur']", 'syns_list': "['A-43818', 'ABBOTT-43818', 'Carcinil', 'Enantone', 'Fensolvi', 'LeuplinLeuporelin acetate', 'Leuprolide acetate', 'Leuprolide monoacetateLeuprorelin acetate', 'Lucrin', 'Lupaneta', 'Lutrate depot', 'ProstapTAP-144', 'Tap-144-sr', 'Trenantone']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Puberty, Precocious', 'efo_term': 'Central precocious puberty', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097096', 'drugName': 'Leuprolide Acetate', 'tradeNames_list': "['Carcinil', 'Eligard', 'Eligard kit', 'Fensolvi kit', 'Leuprolide acetateLeuprorelin', 'Lupron', 'Lupron Depot Ped', 'Lupron depotLupron depot-ped', 'Lupron depot-ped kit', 'Lutrate depot kit', 'Viadur']", 'syns_list': "['A-43818', 'ABBOTT-43818', 'Carcinil', 'Enantone', 'Fensolvi', 'LeuplinLeuporelin acetate', 'Leuprolide acetate', 'Leuprolide monoacetateLeuprorelin acetate', 'Lucrin', 'Lupaneta', 'Lutrate depot', 'ProstapTAP-144', 'Tap-144-sr', 'Trenantone']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Puberty, Precocious', 'efo_term': 'central precocious puberty', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097115', 'drugName': 'Leuprolide Acetate', 'tradeNames_list': "['Carcinil', 'Eligard', 'Eligard kit', 'Fensolvi kit', 'Leuprolide acetateLeuprorelin', 'Lupron', 'Lupron Depot Ped', 'Lupron depotLupron depot-ped', 'Lupron depot-ped kit', 'Lutrate depot kit', 'Viadur']", 'syns_list': "['A-43818', 'ABBOTT-43818', 'Carcinil', 'Enantone', 'Fensolvi', 'LeuplinLeuporelin acetate', 'Leuprolide acetate', 'Leuprolide monoacetateLeuprorelin acetate', 'Lucrin', 'Lupaneta', 'Lutrate depot', 'ProstapTAP-144', 'Tap-144-sr', 'Trenantone']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Puberty, Precocious', 'efo_term': 'Central precocious puberty', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097074', 'drugName': 'Leuprolide Acetate', 'tradeNames_list': "['Carcinil', 'Eligard', 'Eligard kit', 'Fensolvi kit', 'Leuprolide acetateLeuprorelin', 'Lupron', 'Lupron Depot Ped', 'Lupron depotLupron depot-ped', 'Lupron depot-ped kit', 'Lutrate depot kit', 'Viadur']", 'syns_list': "['A-43818', 'ABBOTT-43818', 'Carcinil', 'Enantone', 'Fensolvi', 'LeuplinLeuporelin acetate', 'Leuprolide acetate', 'Leuprolide monoacetateLeuprorelin acetate', 'Lucrin', 'Lupaneta', 'Lutrate depot', 'ProstapTAP-144', 'Tap-144-sr', 'Trenantone']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Puberty, Precocious', 'efo_term': 'central precocious puberty', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097030', 'drugName': 'Leuprolide Acetate', 'tradeNames_list': "['Carcinil', 'Eligard', 'Eligard kit', 'Fensolvi kit', 'Leuprolide acetateLeuprorelin', 'Lupron', 'Lupron Depot Ped', 'Lupron depotLupron depot-ped', 'Lupron depot-ped kit', 'Lutrate depot kit', 'Viadur']", 'syns_list': "['A-43818', 'ABBOTT-43818', 'Carcinil', 'Enantone', 'Fensolvi', 'LeuplinLeuporelin acetate', 'Leuprolide acetate', 'Leuprolide monoacetateLeuprorelin acetate', 'Lucrin', 'Lupaneta', 'Lutrate depot', 'ProstapTAP-144', 'Tap-144-sr', 'Trenantone']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Puberty, Precocious', 'efo_term': 'central precocious puberty', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097008', 'drugName': 'Leuprolide Acetate', 'tradeNames_list': "['Carcinil', 'Eligard', 'Eligard kit', 'Fensolvi kit', 'Leuprolide acetateLeuprorelin', 'Lupron', 'Lupron Depot Ped', 'Lupron depotLupron depot-ped', 'Lupron depot-ped kit', 'Lutrate depot kit', 'Viadur']", 'syns_list': "['A-43818', 'ABBOTT-43818', 'Carcinil', 'Enantone', 'Fensolvi', 'LeuplinLeuporelin acetate', 'Leuprolide acetate', 'Leuprolide monoacetateLeuprorelin acetate', 'Lucrin', 'Lupaneta', 'Lutrate depot', 'ProstapTAP-144', 'Tap-144-sr', 'Trenantone']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Puberty, Precocious', 'efo_term': 'central precocious puberty', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097005', 'drugName': 'Leuprolide Acetate', 'tradeNames_list': "['Carcinil', 'Eligard', 'Eligard kit', 'Fensolvi kit', 'Leuprolide acetateLeuprorelin', 'Lupron', 'Lupron Depot Ped', 'Lupron depotLupron depot-ped', 'Lupron depot-ped kit', 'Lutrate depot kit', 'Viadur']", 'syns_list': "['A-43818', 'ABBOTT-43818', 'Carcinil', 'Enantone', 'Fensolvi', 'LeuplinLeuporelin acetate', 'Leuprolide acetate', 'Leuprolide monoacetateLeuprorelin acetate', 'Lucrin', 'Lupaneta', 'Lutrate depot', 'ProstapTAP-144', 'Tap-144-sr', 'Trenantone']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Puberty, Precocious', 'efo_term': 'Central precocious puberty', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097118', 'drugName': 'Leuprolide Acetate', 'tradeNames_list': "['Carcinil', 'Eligard', 'Eligard kit', 'Fensolvi kit', 'Leuprolide acetateLeuprorelin', 'Lupron', 'Lupron Depot Ped', 'Lupron depotLupron depot-ped', 'Lupron depot-ped kit', 'Lutrate depot kit', 'Viadur']", 'syns_list': "['A-43818', 'ABBOTT-43818', 'Carcinil', 'Enantone', 'Fensolvi', 'LeuplinLeuporelin acetate', 'Leuprolide acetate', 'Leuprolide monoacetateLeuprorelin acetate', 'Lucrin', 'Lupaneta', 'Lutrate depot', 'ProstapTAP-144', 'Tap-144-sr', 'Trenantone']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Puberty, Precocious', 'efo_term': 'central precocious puberty', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097071', 'drugName': 'Leuprolide Acetate', 'tradeNames_list': "['Carcinil', 'Eligard', 'Eligard kit', 'Fensolvi kit', 'Leuprolide acetateLeuprorelin', 'Lupron', 'Lupron Depot Ped', 'Lupron depotLupron depot-ped', 'Lupron depot-ped kit', 'Lutrate depot kit', 'Viadur']", 'syns_list': "['A-43818', 'ABBOTT-43818', 'Carcinil', 'Enantone', 'Fensolvi', 'LeuplinLeuporelin acetate', 'Leuprolide acetate', 'Leuprolide monoacetateLeuprorelin acetate', 'Lucrin', 'Lupaneta', 'Lutrate depot', 'ProstapTAP-144', 'Tap-144-sr', 'Trenantone']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Puberty, Precocious', 'efo_term': 'Central precocious puberty', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097049', 'drugName': 'Leuprolide Acetate', 'tradeNames_list': "['Carcinil', 'Eligard', 'Eligard kit', 'Fensolvi kit', 'Leuprolide acetateLeuprorelin', 'Lupron', 'Lupron Depot Ped', 'Lupron depotLupron depot-ped', 'Lupron depot-ped kit', 'Lutrate depot kit', 'Viadur']", 'syns_list': "['A-43818', 'ABBOTT-43818', 'Carcinil', 'Enantone', 'Fensolvi', 'LeuplinLeuporelin acetate', 'Leuprolide acetate', 'Leuprolide monoacetateLeuprorelin acetate', 'Lucrin', 'Lupaneta', 'Lutrate depot', 'ProstapTAP-144', 'Tap-144-sr', 'Trenantone']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Puberty, Precocious', 'efo_term': 'Central precocious puberty', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097027', 'drugName': 'Leuprolide Acetate', 'tradeNames_list': "['Carcinil', 'Eligard', 'Eligard kit', 'Fensolvi kit', 'Leuprolide acetateLeuprorelin', 'Lupron', 'Lupron Depot Ped', 'Lupron depotLupron depot-ped', 'Lupron depot-ped kit', 'Lutrate depot kit', 'Viadur']", 'syns_list': "['A-43818', 'ABBOTT-43818', 'Carcinil', 'Enantone', 'Fensolvi', 'LeuplinLeuporelin acetate', 'Leuprolide acetate', 'Leuprolide monoacetateLeuprorelin acetate', 'Lucrin', 'Lupaneta', 'Lutrate depot', 'ProstapTAP-144', 'Tap-144-sr', 'Trenantone']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Puberty, Precocious', 'efo_term': 'Central precocious puberty', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.891 | Q34 | What are the names of the genes that are targeted by the drug Naproxen Sodium in the treatment of Back pain? | In the context of Back pain, the drug Naproxen Sodium targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%back pain%" OR LOWER(efo_term) LIKE "%back pain%") AND (LOWER(drugName) LIKE "%naproxen sodium%" OR LOWER(tradeNames_list) LIKE "%naproxen sodium%" OR LOWER(syns_list) LIKE "%naproxen sodium%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_838127', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838178', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838195', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838212', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838246', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838263', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838280', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838297', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838161', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838093', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838059', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838042', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838229', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838144', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838110', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838076', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.81 | Q34 | What are the names of the genes that are targeted by the drug Bromocriptine Mesylate in the treatment of hypogonadism? | In the context of hypogonadism, the drug Bromocriptine Mesylate targets the gene dopamine receptor D2, dopamine receptor D3 and dopamine receptor D4. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%hypogonadism%" OR LOWER(efo_term) LIKE "%hypogonadism%") AND (LOWER(drugName) LIKE "%bromocriptine mesylate%" OR LOWER(tradeNames_list) LIKE "%bromocriptine mesylate%" OR LOWER(syns_list) LIKE "%bromocriptine mesylate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_201377', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201398', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201405', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201412', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201426', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201433', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201440', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201454', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201461', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201468', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201475', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201489', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201496', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201503', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201510', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201517', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201524', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201531', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201538', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201545', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201552', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201566', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201573', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201580', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201587', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201594', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201608', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201615', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201622', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201629', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201636', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201643', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201650', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201657', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201664', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201671', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201678', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201685', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201692', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201699', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201706', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201713', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201720', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201727', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201734', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201741', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201748', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201755', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201762', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201769', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201776', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201790', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201797', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201804', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201811', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201818', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201825', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201839', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201846', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201853', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201860', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201867', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201874', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201881', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201888', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201895', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201902', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201909', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201916', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201923', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201930', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201937', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201944', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201951', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201958', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201965', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201972', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201979', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201986', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201993', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_202000', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_202007', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_202014', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_202021', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_202028', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_202035', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201783', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201559', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201447', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201391', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201363', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201349', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201342', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201832', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201601', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201482', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201419', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201384', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201370', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201356', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1181 | Q34 | What are the names of the genes that are targeted by the drug Saxagliptin Hydrochloride in the treatment of type 2 diabetes mellitus? | In the context of type 2 diabetes mellitus, the drug Saxagliptin Hydrochloride targets the gene dipeptidyl peptidase 4. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%type 2 diabetes mellitus%" OR LOWER(efo_term) LIKE "%type 2 diabetes mellitus%") AND (LOWER(drugName) LIKE "%saxagliptin hydrochloride%" OR LOWER(tradeNames_list) LIKE "%saxagliptin hydrochloride%" OR LOWER(syns_list) LIKE "%saxagliptin hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_933880', 'drugName': 'Saxagliptin Hydrochloride', 'tradeNames_list': "['Onglyza']", 'syns_list': "['Saxagliptin HCl', 'Saxagliptin hcl', 'Saxagliptin hydrochloride']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933876', 'drugName': 'Saxagliptin Hydrochloride', 'tradeNames_list': "['Onglyza']", 'syns_list': "['Saxagliptin HCl', 'Saxagliptin hcl', 'Saxagliptin hydrochloride']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933875', 'drugName': 'Saxagliptin Hydrochloride', 'tradeNames_list': "['Onglyza']", 'syns_list': "['Saxagliptin HCl', 'Saxagliptin hcl', 'Saxagliptin hydrochloride']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933878', 'drugName': 'Saxagliptin Hydrochloride', 'tradeNames_list': "['Onglyza']", 'syns_list': "['Saxagliptin HCl', 'Saxagliptin hcl', 'Saxagliptin hydrochloride']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933879', 'drugName': 'Saxagliptin Hydrochloride', 'tradeNames_list': "['Onglyza']", 'syns_list': "['Saxagliptin HCl', 'Saxagliptin hcl', 'Saxagliptin hydrochloride']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933877', 'drugName': 'Saxagliptin Hydrochloride', 'tradeNames_list': "['Onglyza']", 'syns_list': "['Saxagliptin HCl', 'Saxagliptin hcl', 'Saxagliptin hydrochloride']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.820 | Q34 | What are the names of the genes that are targeted by the drug Indomethacin in the treatment of spondylitis? | In the context of spondylitis, the drug Indomethacin targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%spondylitis%" OR LOWER(efo_term) LIKE "%spondylitis%") AND (LOWER(drugName) LIKE "%indomethacin%" OR LOWER(tradeNames_list) LIKE "%indomethacin%" OR LOWER(syns_list) LIKE "%indomethacin%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_828275', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828339', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828343', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828373', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828407', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828411', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828441', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828475', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828479', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828509', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828513', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828547', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828577', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828581', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828445', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828309', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828241', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828207', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828203', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828543', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828377', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828305', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828271', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828237', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1449 | Q34 | What are the names of the genes that are targeted by the drug Exenatide in the treatment of diabetes mellitus? | In the context of diabetes mellitus, the drug Exenatide targets the gene glucagon like peptide 1 receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%diabetes mellitus%" OR LOWER(efo_term) LIKE "%diabetes mellitus%") AND (LOWER(drugName) LIKE "%exenatide%" OR LOWER(tradeNames_list) LIKE "%exenatide%" OR LOWER(syns_list) LIKE "%exenatide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1046868', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046409', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046477', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045948', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045903', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046293', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046317', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045994', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046662', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045926', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046731', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046201', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046040', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046892', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045949', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046063', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046271', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046938', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045880', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046960', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045972', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046363', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046385', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045879', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046684', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045995', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046455', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046776', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045902', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046753', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046018', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046799', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046547', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046569', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046224', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046937', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046041', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046891', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046248', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046915', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046270', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046914', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046064', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046983', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046294', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046086', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046316', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046961', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046087', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046339', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046340', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046362', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046247', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046110', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046639', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046386', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046132', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046708', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046133', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046431', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046432', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046707', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046454', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046685', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046156', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046845', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046478', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046178', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046500', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046754', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046179', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046523', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046524', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046823', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046546', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046777', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046202', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046822', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046570', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046800', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046592', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046984', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046225', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046615', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046616', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1047007', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1047006', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046846', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046730', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046661', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046638', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046109', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045925', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046408', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046155', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046501', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046869', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045971', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046017', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1046593', 'drugName': 'Exenatide', 'tradeNames_list': "['Bydureon', 'Bydureon bcise', 'Bydureon pen', 'Byetta']", 'syns_list': "['AC 2993', 'AC-002993', 'AC-2993', 'AC-2993A', 'AC-2993LAR', 'AC002993AC2993', 'AC2993A', 'DA-3091', 'EXENDIN-4', 'ExenatideExenatide Synthetic', 'Exenatide synthetic', 'Exendin 4', 'ITCA-650LY-2148568', 'LY2148568']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.676 | Q34 | What are the names of the genes that are targeted by the drug Pemigatinib in the treatment of neoplasm? | In the context of neoplasm, the drug Pemigatinib targets the gene fibroblast growth factor receptor 1, fibroblast growth factor receptor 3 and fibroblast growth factor receptor 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%neoplasm%" OR LOWER(efo_term) LIKE "%neoplasm%") AND (LOWER(drugName) LIKE "%pemigatinib%" OR LOWER(tradeNames_list) LIKE "%pemigatinib%" OR LOWER(syns_list) LIKE "%pemigatinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_706872', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_706871', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_706884', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_706962', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_706897', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_706910', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_706859', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_706924', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707080', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_707040', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_706936', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707028', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_706950', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_706989', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_706975', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707079', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_706963', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_706885', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707054', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_706858', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707001', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_706976', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_706988', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707053', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_706923', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707002', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707067', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_706898', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707014', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_706937', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707066', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_707041', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_707015', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_706911', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_706949', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707027', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_707000', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_706854', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_706857', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_706928', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pancreatic Neoplasms', 'efo_term': 'pancreatic carcinoma', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707006', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pancreatic Neoplasms', 'efo_term': 'pancreatic carcinoma', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_707008', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urogenital Neoplasms', 'efo_term': 'urogenital neoplasm', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_706945', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_706943', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urogenital Neoplasms', 'efo_term': 'urogenital neoplasm', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_706889', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pancreatic Neoplasms', 'efo_term': 'pancreatic carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_706906', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_706930', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urogenital Neoplasms', 'efo_term': 'urogenital neoplasm', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_706863', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pancreatic Neoplasms', 'efo_term': 'pancreatic carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_706947', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_706878', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urogenital Neoplasms', 'efo_term': 'urogenital neoplasm', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_706907', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_706932', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_706935', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_706934', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_706868', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_706933', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_706998', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707010', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_706869', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_706880', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_706972', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_706891', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urogenital Neoplasms', 'efo_term': 'urogenital neoplasm', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_706893', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_706870', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_706995', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urogenital Neoplasms', 'efo_term': 'urogenital neoplasm', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_706894', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_706974', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_706987', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_706986', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_706941', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pancreatic Neoplasms', 'efo_term': 'pancreatic carcinoma', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_706895', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_706984', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_706985', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_706982', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urogenital Neoplasms', 'efo_term': 'urogenital neoplasm', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_706856', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_706993', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pancreatic Neoplasms', 'efo_term': 'pancreatic carcinoma', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_706865', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urogenital Neoplasms', 'efo_term': 'urogenital neoplasm', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_706881', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_706980', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pancreatic Neoplasms', 'efo_term': 'pancreatic carcinoma', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_706915', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pancreatic Neoplasms', 'efo_term': 'pancreatic carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_706997', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_706999', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_706973', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_706909', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_706971', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_706969', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urogenital Neoplasms', 'efo_term': 'urogenital neoplasm', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_706908', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_706967', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pancreatic Neoplasms', 'efo_term': 'pancreatic carcinoma', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_706882', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_706917', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urogenital Neoplasms', 'efo_term': 'urogenital neoplasm', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_706919', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_706867', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_706961', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_706883', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_706920', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_706921', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_706922', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_706896', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_706946', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_706948', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1518 | Q34 | What are the names of the genes that are targeted by the drug Telmisartan in the treatment of cardiovascular disease? | In the context of cardiovascular disease, the drug Telmisartan targets the gene angiotensin II receptor type 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cardiovascular disease%" OR LOWER(efo_term) LIKE "%cardiovascular disease%") AND (LOWER(drugName) LIKE "%telmisartan%" OR LOWER(tradeNames_list) LIKE "%telmisartan%" OR LOWER(syns_list) LIKE "%telmisartan%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1072708', 'drugName': 'Telmisartan', 'tradeNames_list': "['Micardis', 'Telmisartan', 'Tolura']", 'syns_list': "['BIBR 277 SE', 'BIBR-277', 'BIBR-277 SE', 'BIBR-277-SE', 'BIBR-277SEC09CA07', 'Kinzalmono', 'Pritor', 'Semintra', 'TelmisartanTelmisartan actavis', 'Telmisartan teva']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.58 | Q34 | What are the names of the genes that are targeted by the drug Lurasidone Hydrochloride in the treatment of schizophrenia? | In the context of schizophrenia, the drug Lurasidone Hydrochloride targets the gene dopamine receptor D2 and 5-hydroxytryptamine receptor 2A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%schizophrenia%" OR LOWER(efo_term) LIKE "%schizophrenia%") AND (LOWER(drugName) LIKE "%lurasidone hydrochloride%" OR LOWER(tradeNames_list) LIKE "%lurasidone hydrochloride%" OR LOWER(syns_list) LIKE "%lurasidone hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_197915', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197924', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197927', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197930', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197936', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197939', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197942', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197948', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197951', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197954', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197957', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197963', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197966', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197969', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197972', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197975', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197978', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197981', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197984', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197987', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197990', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197996', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197999', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198002', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198005', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198008', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198014', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198017', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198020', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198023', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198026', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198029', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198032', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198035', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198038', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198041', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198044', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198047', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198050', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198053', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198056', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198059', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198062', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198065', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198068', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198071', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198074', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198077', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198080', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198083', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198086', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198092', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198095', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198098', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198101', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198104', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198107', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198113', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198116', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198119', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198122', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198125', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198128', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198131', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198134', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198137', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198140', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_198143', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_198146', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_198149', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_198152', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_198155', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_198158', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_198161', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_198164', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_198167', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_198170', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_198173', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_198176', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_198179', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_198182', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_198185', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_198188', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_198191', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_198194', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_198197', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_198089', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197993', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197945', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197921', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197909', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197903', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197900', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198110', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198011', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197960', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197933', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197918', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197912', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197906', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.135 | Q34 | What are the names of the genes that are targeted by the drug Afatinib in the treatment of neoplasm? | In the context of neoplasm, the drug Afatinib targets the gene epidermal growth factor receptor, erb-b2 receptor tyrosine kinase 2 and erb-b2 receptor tyrosine kinase 4. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%neoplasm%" OR LOWER(efo_term) LIKE "%neoplasm%") AND (LOWER(drugName) LIKE "%afatinib%" OR LOWER(tradeNames_list) LIKE "%afatinib%" OR LOWER(syns_list) LIKE "%afatinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_207796', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_207952', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_208107', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_207718', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_208445', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_208524', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_207379', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_207562', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_207978', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_207640', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_208133', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_207744', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_207743', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_208420', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_208393', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_208446', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_207822', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_208550', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_207848', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_208576', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_207405', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_207380', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_207587', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_207899', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_208004', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_207613', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_207639', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_208211', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_207535', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_208160', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_207691', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_208263', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_208212', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_208289', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_207431', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_208497', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_207770', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_208419', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_208394', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_208472', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_207795', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_208471', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_207821', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_208627', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_208523', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_208549', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_207847', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_208602', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_208575', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_208601', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_207457', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_207406', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_207873', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_207536', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_207926', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_207561', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_207925', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_208081', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_207977', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_208003', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_207614', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_208056', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_208029', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_208055', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_207483', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_208341', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_207666', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_208108', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_207665', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_208186', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_208159', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_208185', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_207692', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_208316', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_207717', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_208238', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_208237', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_208315', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_208264', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_208290', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_207509', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_208628', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_207432', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_208367', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_207769', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_208654', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_208653', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_208342', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_208082', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_207951', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_207874', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_207588', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_207458', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_207900', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_208030', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_208134', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_208368', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_208498', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_207484', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_207510', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1148 | Q34 | What are the names of the genes that are targeted by the drug Trametinib in the treatment of breast carcinoma? | Trametinib has not been approved by the FDA as a treatment for breast carcinoma, but it is currently undergoing evaluation in clinical trials for this purpose. However, the proposed gene target names are mitogen-activated protein kinase kinase 2 and mitogen-activated protein kinase kinase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%breast carcinoma%" OR LOWER(efo_term) LIKE "%breast carcinoma%") AND (LOWER(drugName) LIKE "%trametinib%" OR LOWER(tradeNames_list) LIKE "%trametinib%" OR LOWER(syns_list) LIKE "%trametinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_928696', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928816', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928856', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928896', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928976', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929016', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929056', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929136', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929176', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929216', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929256', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929336', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929376', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929416', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929456', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929496', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929536', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929576', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929616', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929656', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929696', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929776', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929816', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929856', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929896', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929936', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930016', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930056', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930096', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930136', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930176', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930216', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930256', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930296', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930336', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930376', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930416', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930456', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930496', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930536', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930576', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930616', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930656', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930696', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930736', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930776', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930816', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930856', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930896', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930936', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930976', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931056', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931096', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931136', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931176', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931216', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931256', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931336', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931376', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931416', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931456', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931496', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931536', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931576', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931616', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931656', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931696', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931736', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931776', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931816', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931856', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931896', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931936', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931976', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932016', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932056', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932096', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932136', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932176', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932216', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932256', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932296', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932336', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932376', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932416', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932456', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931016', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_929736', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929096', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928776', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928616', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928536', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928496', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_931296', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_929976', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929296', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928936', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928736', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928656', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928576', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.940 | Q34 | What are the names of the genes that are targeted by the drug Ibuprofen in the treatment of muscle cramp? | In the context of muscle cramp, the drug Ibuprofen targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%muscle cramp%" OR LOWER(efo_term) LIKE "%muscle cramp%") AND (LOWER(drugName) LIKE "%ibuprofen%" OR LOWER(tradeNames_list) LIKE "%ibuprofen%" OR LOWER(syns_list) LIKE "%ibuprofen%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_840171', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840408', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840487', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840566', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840724', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840803', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840882', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841040', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841119', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841198', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841277', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841435', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841514', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841593', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841672', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841751', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840961', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840329', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840013', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839855', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839776', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841356', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840645', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840250', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840092', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839934', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1670 | Q34 | What are the names of the genes that are targeted by the drug Tasimelteon in the treatment of Chromosomal anomaly? | In the context of Chromosomal anomaly, the drug Tasimelteon targets the gene melatonin receptor 1A and melatonin receptor 1B. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%chromosomal anomaly%" OR LOWER(efo_term) LIKE "%chromosomal anomaly%") AND (LOWER(drugName) LIKE "%tasimelteon%" OR LOWER(tradeNames_list) LIKE "%tasimelteon%" OR LOWER(syns_list) LIKE "%tasimelteon%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1094715', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094739', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094747', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094755', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094771', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094779', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094787', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094803', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094811', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094819', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094827', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094843', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094851', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094859', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094867', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094875', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094883', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094891', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094899', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094907', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094915', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094931', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094939', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094947', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094955', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094963', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094979', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094987', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094995', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1095003', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1095011', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1095019', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1095027', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1095035', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095043', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095051', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095059', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095067', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095075', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095083', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095091', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095099', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095107', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095115', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095123', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095131', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095139', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095147', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095155', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095163', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095171', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095187', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095195', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095203', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095211', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095219', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095227', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095243', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095251', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095259', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095267', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095275', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095283', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095291', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095299', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095307', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095315', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095323', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095331', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095339', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095347', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095355', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095363', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095371', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095379', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095387', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095179', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1094923', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094795', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094731', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094699', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094683', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094675', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1095235', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1094971', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094835', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094763', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094723', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094707', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094691', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.829 | Q34 | What are the names of the genes that are targeted by the drug Acetaminophen in the treatment of pain? | In the context of pain, the drug Acetaminophen targets the gene prostaglandin-endoperoxide synthase 2, prostaglandin-endoperoxide synthase 1, transient receptor potential cation channel subfamily V member 1 and fatty acid amide hydrolase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%pain%" OR LOWER(efo_term) LIKE "%pain%") AND (LOWER(drugName) LIKE "%acetaminophen%" OR LOWER(tradeNames_list) LIKE "%acetaminophen%" OR LOWER(syns_list) LIKE "%acetaminophen%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_830308', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_829576', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_830101', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_829786', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_831675', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_830311', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_829048', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828736', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_830520', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_829153', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_830938', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_830203', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_829258', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_831673', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831568', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831778', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_829363', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_831988', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_828735', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_831990', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_829050', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828841', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_830206', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_829573', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_830626', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_830521', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_829155', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_831148', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_830100', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_831043', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_829783', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_831255', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831150', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831256', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_829260', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_831883', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_828946', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_831571', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831570', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831781', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831676', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831780', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_829365', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_832093', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_828838', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_831886', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_831885', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_831991', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_828840', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_829468', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_829470', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_829051', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_829996', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_829993', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_830415', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_829995', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_830413', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_830833', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_830518', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_830625', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_830623', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_830731', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_830728', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_829678', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_829680', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_831361', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_829156', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_830836', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_830205', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_831046', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_830941', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831045', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_829785', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_831360', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_828943', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_831253', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831151', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831358', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_828945', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_829888', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_829890', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_832095', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_829261', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_831465', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_830310', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_832198', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_832096', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_831463', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_830835', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_830416', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_830098', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828733', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_829471', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_829575', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_830730', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_830940', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831466', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_829366', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_829681', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_829891', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1223 | Q34 | What are the names of the genes that are targeted by the drug Lasmiditan Succinate in the treatment of migraine disorder? | In the context of migraine disorder, the drug Lasmiditan Succinate targets the gene 5-hydroxytryptamine receptor 1F. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%migraine disorder%" OR LOWER(efo_term) LIKE "%migraine disorder%") AND (LOWER(drugName) LIKE "%lasmiditan succinate%" OR LOWER(tradeNames_list) LIKE "%lasmiditan succinate%" OR LOWER(syns_list) LIKE "%lasmiditan succinate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_937199', 'drugName': 'Lasmiditan Succinate', 'tradeNames_list': "['Reyvow']", 'syns_list': "['LY-573144', 'LY-683974', 'LY683974', 'Lasmiditan hemisuccinateLasmiditan succinate']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1F', 'approvedName': '5-hydroxytryptamine receptor 1F'}, {'UUID': 'DrugTargetsIndication121923_text_937202', 'drugName': 'Lasmiditan Succinate', 'tradeNames_list': "['Reyvow']", 'syns_list': "['LY-573144', 'LY-683974', 'LY683974', 'Lasmiditan hemisuccinateLasmiditan succinate']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1F', 'approvedName': '5-hydroxytryptamine receptor 1F'}, {'UUID': 'DrugTargetsIndication121923_text_937201', 'drugName': 'Lasmiditan Succinate', 'tradeNames_list': "['Reyvow']", 'syns_list': "['LY-573144', 'LY-683974', 'LY683974', 'Lasmiditan hemisuccinateLasmiditan succinate']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1F', 'approvedName': '5-hydroxytryptamine receptor 1F'}, {'UUID': 'DrugTargetsIndication121923_text_937197', 'drugName': 'Lasmiditan Succinate', 'tradeNames_list': "['Reyvow']", 'syns_list': "['LY-573144', 'LY-683974', 'LY683974', 'Lasmiditan hemisuccinateLasmiditan succinate']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1F', 'approvedName': '5-hydroxytryptamine receptor 1F'}, {'UUID': 'DrugTargetsIndication121923_text_937194', 'drugName': 'Lasmiditan Succinate', 'tradeNames_list': "['Reyvow']", 'syns_list': "['LY-573144', 'LY-683974', 'LY683974', 'Lasmiditan hemisuccinateLasmiditan succinate']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1F', 'approvedName': '5-hydroxytryptamine receptor 1F'}, {'UUID': 'DrugTargetsIndication121923_text_937195', 'drugName': 'Lasmiditan Succinate', 'tradeNames_list': "['Reyvow']", 'syns_list': "['LY-573144', 'LY-683974', 'LY683974', 'Lasmiditan hemisuccinateLasmiditan succinate']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1F', 'approvedName': '5-hydroxytryptamine receptor 1F'}, {'UUID': 'DrugTargetsIndication121923_text_937200', 'drugName': 'Lasmiditan Succinate', 'tradeNames_list': "['Reyvow']", 'syns_list': "['LY-573144', 'LY-683974', 'LY683974', 'Lasmiditan hemisuccinateLasmiditan succinate']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1F', 'approvedName': '5-hydroxytryptamine receptor 1F'}, {'UUID': 'DrugTargetsIndication121923_text_937198', 'drugName': 'Lasmiditan Succinate', 'tradeNames_list': "['Reyvow']", 'syns_list': "['LY-573144', 'LY-683974', 'LY683974', 'Lasmiditan hemisuccinateLasmiditan succinate']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1F', 'approvedName': '5-hydroxytryptamine receptor 1F'}, {'UUID': 'DrugTargetsIndication121923_text_937196', 'drugName': 'Lasmiditan Succinate', 'tradeNames_list': "['Reyvow']", 'syns_list': "['LY-573144', 'LY-683974', 'LY683974', 'Lasmiditan hemisuccinateLasmiditan succinate']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1F', 'approvedName': '5-hydroxytryptamine receptor 1F'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.508 | Q34 | What are the names of the genes that are targeted by the drug Doxepin Hydrochloride in the treatment of insomnia? | In the context of insomnia, the drug Doxepin Hydrochloride targets the gene solute carrier family 6 member 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%insomnia%" OR LOWER(efo_term) LIKE "%insomnia%") AND (LOWER(drugName) LIKE "%doxepin hydrochloride%" OR LOWER(tradeNames_list) LIKE "%doxepin hydrochloride%" OR LOWER(syns_list) LIKE "%doxepin hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_440817', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440841', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440849', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440857', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440873', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440881', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440889', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440905', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440913', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440921', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440929', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440945', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440953', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440961', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440969', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440977', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440985', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440993', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_441001', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_441009', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440897', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440833', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440801', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440785', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440777', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440937', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440865', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440825', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440809', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440793', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1758 | Q34 | What are the names of the genes that are targeted by the drug Lansoprazole in the treatment of Peptic ulcer? | In the context of Peptic ulcer, the drug Lansoprazole targets the gene ATPase H+/K+ transporting subunit alpha and ATPase H+/K+ transporting subunit beta. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%peptic ulcer%" OR LOWER(efo_term) LIKE "%peptic ulcer%") AND (LOWER(drugName) LIKE "%lansoprazole%" OR LOWER(tradeNames_list) LIKE "%lansoprazole%" OR LOWER(syns_list) LIKE "%lansoprazole%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1098429', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098453', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098461', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098469', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098485', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098493', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098501', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098517', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098525', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098533', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098541', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098557', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098565', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098573', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098581', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098589', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098597', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098605', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098613', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098621', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098629', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098645', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098653', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098661', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098669', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098677', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098693', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098701', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098709', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098717', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098725', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098733', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098741', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098749', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098757', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098765', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098773', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098781', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098789', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098797', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098805', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098813', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098821', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098829', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098837', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098845', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098853', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098861', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098869', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098877', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098885', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098901', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098909', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098917', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098925', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098933', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098941', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098957', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098965', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098973', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098981', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098989', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098997', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1099005', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1099013', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1099021', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1099029', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1099037', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1099045', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1099053', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1099061', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1099069', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1099077', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1099085', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1099093', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1099101', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1099109', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1099117', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1099125', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1099133', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1099141', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1099149', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1099157', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1099165', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1099173', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1099181', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098893', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098637', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098509', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098445', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098415', 'drugName': 'Lansoprazole', 'tradeNames_list': "['Lansoprazole', 'Opiren', 'Prevacid', 'Prevacid 24 hrPrevacid Delayed Release', 'Prevacid Solutab', 'Prevacid iv', 'Zoton']", 'syns_list': "['A-65006', 'AG-1749', 'Agopton', 'Lansoprazole', 'Lansox', 'LanzoprazoleLanzor', 'Limpidex', 'NSC-758638', 'Ogast', 'Ogastoro', 'Prevonco', 'Takepron']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098367', 'drugName': 'Lansoprazole', 'tradeNames_list': "['Lansoprazole', 'Opiren', 'Prevacid', 'Prevacid 24 hrPrevacid Delayed Release', 'Prevacid Solutab', 'Prevacid iv', 'Zoton']", 'syns_list': "['A-65006', 'AG-1749', 'Agopton', 'Lansoprazole', 'Lansox', 'LanzoprazoleLanzor', 'Limpidex', 'NSC-758638', 'Ogast', 'Ogastoro', 'Prevonco', 'Takepron']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098343', 'drugName': 'Lansoprazole', 'tradeNames_list': "['Lansoprazole', 'Opiren', 'Prevacid', 'Prevacid 24 hrPrevacid Delayed Release', 'Prevacid Solutab', 'Prevacid iv', 'Zoton']", 'syns_list': "['A-65006', 'AG-1749', 'Agopton', 'Lansoprazole', 'Lansox', 'LanzoprazoleLanzor', 'Limpidex', 'NSC-758638', 'Ogast', 'Ogastoro', 'Prevonco', 'Takepron']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098949', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098685', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098549', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098477', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098437', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098421', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098391', 'drugName': 'Lansoprazole', 'tradeNames_list': "['Lansoprazole', 'Opiren', 'Prevacid', 'Prevacid 24 hrPrevacid Delayed Release', 'Prevacid Solutab', 'Prevacid iv', 'Zoton']", 'syns_list': "['A-65006', 'AG-1749', 'Agopton', 'Lansoprazole', 'Lansox', 'LanzoprazoleLanzor', 'Limpidex', 'NSC-758638', 'Ogast', 'Ogastoro', 'Prevonco', 'Takepron']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.349 | Q34 | What are the names of the genes that are targeted by the drug Dexamethasone in the treatment of multiple sclerosis? | In the context of multiple sclerosis, the drug Dexamethasone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%multiple sclerosis%" OR LOWER(efo_term) LIKE "%multiple sclerosis%") AND (LOWER(drugName) LIKE "%dexamethasone%" OR LOWER(tradeNames_list) LIKE "%dexamethasone%" OR LOWER(syns_list) LIKE "%dexamethasone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_230370', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228660', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230940', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228375', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226380', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229515', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231225', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231510', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228945', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227235', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229230', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227520', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227805', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231795', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230085', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232080', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230655', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228090', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229800', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232365', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226665', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226950', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226550', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Multiple Sclerosis, Chronic Progressive', 'efo_term': 'primary progressive multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227975', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Multiple Sclerosis, Chronic Progressive', 'efo_term': 'primary progressive multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229685', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Multiple Sclerosis, Chronic Progressive', 'efo_term': 'primary progressive multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229400', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Multiple Sclerosis, Chronic Progressive', 'efo_term': 'primary progressive multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230540', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Multiple Sclerosis, Chronic Progressive', 'efo_term': 'primary progressive multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229970', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Multiple Sclerosis, Chronic Progressive', 'efo_term': 'primary progressive multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227120', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Multiple Sclerosis, Chronic Progressive', 'efo_term': 'primary progressive multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230255', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Multiple Sclerosis, Chronic Progressive', 'efo_term': 'primary progressive multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226265', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Multiple Sclerosis, Chronic Progressive', 'efo_term': 'primary progressive multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227405', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Multiple Sclerosis, Chronic Progressive', 'efo_term': 'primary progressive multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228545', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Multiple Sclerosis, Chronic Progressive', 'efo_term': 'primary progressive multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230825', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Multiple Sclerosis, Chronic Progressive', 'efo_term': 'primary progressive multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231110', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Multiple Sclerosis, Chronic Progressive', 'efo_term': 'primary progressive multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228830', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Multiple Sclerosis, Chronic Progressive', 'efo_term': 'primary progressive multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231395', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Multiple Sclerosis, Chronic Progressive', 'efo_term': 'primary progressive multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231680', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Multiple Sclerosis, Chronic Progressive', 'efo_term': 'primary progressive multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226835', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Multiple Sclerosis, Chronic Progressive', 'efo_term': 'primary progressive multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227690', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Multiple Sclerosis, Chronic Progressive', 'efo_term': 'primary progressive multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229115', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Multiple Sclerosis, Chronic Progressive', 'efo_term': 'primary progressive multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231965', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Multiple Sclerosis, Chronic Progressive', 'efo_term': 'primary progressive multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232250', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Multiple Sclerosis, Chronic Progressive', 'efo_term': 'primary progressive multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228260', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Multiple Sclerosis, Chronic Progressive', 'efo_term': 'primary progressive multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.389 | Q34 | What are the names of the genes that are targeted by the drug Mometasone Furoate in the treatment of asthma? | In the context of asthma, the drug Mometasone Furoate targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%asthma%" OR LOWER(efo_term) LIKE "%asthma%") AND (LOWER(drugName) LIKE "%mometasone furoate%" OR LOWER(tradeNames_list) LIKE "%mometasone furoate%" OR LOWER(syns_list) LIKE "%mometasone furoate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_242044', 'drugName': 'Mometasone Furoate', 'tradeNames_list': "['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']", 'syns_list': "['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_242122', 'drugName': 'Mometasone Furoate', 'tradeNames_list': "['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']", 'syns_list': "['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_242148', 'drugName': 'Mometasone Furoate', 'tradeNames_list': "['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']", 'syns_list': "['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_242174', 'drugName': 'Mometasone Furoate', 'tradeNames_list': "['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']", 'syns_list': "['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_242226', 'drugName': 'Mometasone Furoate', 'tradeNames_list': "['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']", 'syns_list': "['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_242096', 'drugName': 'Mometasone Furoate', 'tradeNames_list': "['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']", 'syns_list': "['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241992', 'drugName': 'Mometasone Furoate', 'tradeNames_list': "['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']", 'syns_list': "['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241940', 'drugName': 'Mometasone Furoate', 'tradeNames_list': "['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']", 'syns_list': "['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241914', 'drugName': 'Mometasone Furoate', 'tradeNames_list': "['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']", 'syns_list': "['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_242200', 'drugName': 'Mometasone Furoate', 'tradeNames_list': "['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']", 'syns_list': "['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_242070', 'drugName': 'Mometasone Furoate', 'tradeNames_list': "['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']", 'syns_list': "['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_242018', 'drugName': 'Mometasone Furoate', 'tradeNames_list': "['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']", 'syns_list': "['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241966', 'drugName': 'Mometasone Furoate', 'tradeNames_list': "['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']", 'syns_list': "['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1031 | Q34 | What are the names of the genes that are targeted by the drug Idelalisib in the treatment of neoplasm? | In the context of neoplasm, the drug Idelalisib targets the gene phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%neoplasm%" OR LOWER(efo_term) LIKE "%neoplasm%") AND (LOWER(drugName) LIKE "%idelalisib%" OR LOWER(tradeNames_list) LIKE "%idelalisib%" OR LOWER(syns_list) LIKE "%idelalisib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_858416', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'syns_list': "['CAL-101', 'GS-1101', 'GS-11CAL-101', 'Idelalisib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858435', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'syns_list': "['CAL-101', 'GS-1101', 'GS-11CAL-101', 'Idelalisib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858452', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'syns_list': "['CAL-101', 'GS-1101', 'GS-11CAL-101', 'Idelalisib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858453', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'syns_list': "['CAL-101', 'GS-1101', 'GS-11CAL-101', 'Idelalisib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858471', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'syns_list': "['CAL-101', 'GS-1101', 'GS-11CAL-101', 'Idelalisib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858472', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'syns_list': "['CAL-101', 'GS-1101', 'GS-11CAL-101', 'Idelalisib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858473', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'syns_list': "['CAL-101', 'GS-1101', 'GS-11CAL-101', 'Idelalisib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858491', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'syns_list': "['CAL-101', 'GS-1101', 'GS-11CAL-101', 'Idelalisib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858492', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'syns_list': "['CAL-101', 'GS-1101', 'GS-11CAL-101', 'Idelalisib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858509', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'syns_list': "['CAL-101', 'GS-1101', 'GS-11CAL-101', 'Idelalisib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858510', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'syns_list': "['CAL-101', 'GS-1101', 'GS-11CAL-101', 'Idelalisib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858528', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'syns_list': "['CAL-101', 'GS-1101', 'GS-11CAL-101', 'Idelalisib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858529', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'syns_list': "['CAL-101', 'GS-1101', 'GS-11CAL-101', 'Idelalisib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858530', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'syns_list': "['CAL-101', 'GS-1101', 'GS-11CAL-101', 'Idelalisib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858547', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'syns_list': "['CAL-101', 'GS-1101', 'GS-11CAL-101', 'Idelalisib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858548', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'syns_list': "['CAL-101', 'GS-1101', 'GS-11CAL-101', 'Idelalisib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858549', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'syns_list': "['CAL-101', 'GS-1101', 'GS-11CAL-101', 'Idelalisib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858566', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'syns_list': "['CAL-101', 'GS-1101', 'GS-11CAL-101', 'Idelalisib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858567', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'syns_list': "['CAL-101', 'GS-1101', 'GS-11CAL-101', 'Idelalisib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858568', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'syns_list': "['CAL-101', 'GS-1101', 'GS-11CAL-101', 'Idelalisib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858585', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'syns_list': "['CAL-101', 'GS-1101', 'GS-11CAL-101', 'Idelalisib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858587', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'syns_list': "['CAL-101', 'GS-1101', 'GS-11CAL-101', 'Idelalisib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858604', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'syns_list': "['CAL-101', 'GS-1101', 'GS-11CAL-101', 'Idelalisib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858605', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'syns_list': "['CAL-101', 'GS-1101', 'GS-11CAL-101', 'Idelalisib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858606', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'syns_list': "['CAL-101', 'GS-1101', 'GS-11CAL-101', 'Idelalisib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858623', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'syns_list': "['CAL-101', 'GS-1101', 'GS-11CAL-101', 'Idelalisib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858625', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'syns_list': "['CAL-101', 'GS-1101', 'GS-11CAL-101', 'Idelalisib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858642', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'syns_list': "['CAL-101', 'GS-1101', 'GS-11CAL-101', 'Idelalisib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858643', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'syns_list': "['CAL-101', 'GS-1101', 'GS-11CAL-101', 'Idelalisib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858644', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'syns_list': "['CAL-101', 'GS-1101', 'GS-11CAL-101', 'Idelalisib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858661', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'syns_list': "['CAL-101', 'GS-1101', 'GS-11CAL-101', 'Idelalisib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858662', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'syns_list': "['CAL-101', 'GS-1101', 'GS-11CAL-101', 'Idelalisib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858663', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'syns_list': "['CAL-101', 'GS-1101', 'GS-11CAL-101', 'Idelalisib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858680', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'syns_list': "['CAL-101', 'GS-1101', 'GS-11CAL-101', 'Idelalisib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858681', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'syns_list': "['CAL-101', 'GS-1101', 'GS-11CAL-101', 'Idelalisib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858682', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'syns_list': "['CAL-101', 'GS-1101', 'GS-11CAL-101', 'Idelalisib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858699', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'syns_list': "['CAL-101', 'GS-1101', 'GS-11CAL-101', 'Idelalisib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858700', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'syns_list': "['CAL-101', 'GS-1101', 'GS-11CAL-101', 'Idelalisib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858701', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'syns_list': "['CAL-101', 'GS-1101', 'GS-11CAL-101', 'Idelalisib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858718', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'syns_list': "['CAL-101', 'GS-1101', 'GS-11CAL-101', 'Idelalisib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858719', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'syns_list': "['CAL-101', 'GS-1101', 'GS-11CAL-101', 'Idelalisib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858720', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'syns_list': "['CAL-101', 'GS-1101', 'GS-11CAL-101', 'Idelalisib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858586', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'syns_list': "['CAL-101', 'GS-1101', 'GS-11CAL-101', 'Idelalisib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858490', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'syns_list': "['CAL-101', 'GS-1101', 'GS-11CAL-101', 'Idelalisib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858434', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'syns_list': "['CAL-101', 'GS-1101', 'GS-11CAL-101', 'Idelalisib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858414', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'syns_list': "['CAL-101', 'GS-1101', 'GS-11CAL-101', 'Idelalisib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858396', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'syns_list': "['CAL-101', 'GS-1101', 'GS-11CAL-101', 'Idelalisib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858395', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'syns_list': "['CAL-101', 'GS-1101', 'GS-11CAL-101', 'Idelalisib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858624', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'syns_list': "['CAL-101', 'GS-1101', 'GS-11CAL-101', 'Idelalisib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858511', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'syns_list': "['CAL-101', 'GS-1101', 'GS-11CAL-101', 'Idelalisib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858454', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'syns_list': "['CAL-101', 'GS-1101', 'GS-11CAL-101', 'Idelalisib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858433', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'syns_list': "['CAL-101', 'GS-1101', 'GS-11CAL-101', 'Idelalisib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858415', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'syns_list': "['CAL-101', 'GS-1101', 'GS-11CAL-101', 'Idelalisib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858397', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'syns_list': "['CAL-101', 'GS-1101', 'GS-11CAL-101', 'Idelalisib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.900 | Q34 | What are the names of the genes that are targeted by the drug Naproxen Sodium in the treatment of osteoarthritis? | In the context of osteoarthritis, the drug Naproxen Sodium targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%osteoarthritis%" OR LOWER(efo_term) LIKE "%osteoarthritis%") AND (LOWER(drugName) LIKE "%naproxen sodium%" OR LOWER(tradeNames_list) LIKE "%naproxen sodium%" OR LOWER(syns_list) LIKE "%naproxen sodium%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_838086', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838069', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838137', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838188', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838239', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838222', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838256', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838052', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838154', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838205', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838273', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838290', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838103', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838307', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838171', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838120', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838106', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838174', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838191', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838123', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838208', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838225', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838293', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838055', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838140', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838242', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838259', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838072', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838038', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838089', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838276', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838157', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.834 | Q34 | What are the names of the genes that are targeted by the drug Acetaminophen in the treatment of toothache? | In the context of toothache, the drug Acetaminophen targets the gene prostaglandin-endoperoxide synthase 2, prostaglandin-endoperoxide synthase 1, transient receptor potential cation channel subfamily V member 1 and fatty acid amide hydrolase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%toothache%" OR LOWER(efo_term) LIKE "%toothache%") AND (LOWER(drugName) LIKE "%acetaminophen%" OR LOWER(tradeNames_list) LIKE "%acetaminophen%" OR LOWER(syns_list) LIKE "%acetaminophen%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_829266', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_829581', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_829686', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_829791', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_830001', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_830106', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_830211', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_830421', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_830526', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_830631', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_830736', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_830946', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831051', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831156', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831261', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831366', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831471', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831576', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831681', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831786', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831891', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_832101', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_832206', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_832311', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_832416', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_832521', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_832731', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_832836', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_831996', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_830316', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_829476', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_829056', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828846', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828741', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_832626', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_830841', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_829896', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_829371', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_829161', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828951', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1875 | Q34 | What are the names of the genes that are targeted by the drug Pomalidomide in the treatment of multiple myeloma? | In the context of multiple myeloma, the drug Pomalidomide targets the gene cereblon, damage specific DNA binding protein 1, cullin 4A and ring-box 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%multiple myeloma%" OR LOWER(efo_term) LIKE "%multiple myeloma%") AND (LOWER(drugName) LIKE "%pomalidomide%" OR LOWER(tradeNames_list) LIKE "%pomalidomide%" OR LOWER(syns_list) LIKE "%pomalidomide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1143578', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'DDB1', 'approvedName': 'damage specific DNA binding protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1142228', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1143098', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'DDB1', 'approvedName': 'damage specific DNA binding protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1142468', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1141928', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1143848', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'DDB1', 'approvedName': 'damage specific DNA binding protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1142048', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1142168', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1142858', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1142288', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1143158', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'DDB1', 'approvedName': 'damage specific DNA binding protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1143308', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'DDB1', 'approvedName': 'damage specific DNA binding protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1142528', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1143698', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'DDB1', 'approvedName': 'damage specific DNA binding protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1141898', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1143728', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'DDB1', 'approvedName': 'damage specific DNA binding protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1141958', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1143908', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'DDB1', 'approvedName': 'damage specific DNA binding protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1142018', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1143938', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'DDB1', 'approvedName': 'damage specific DNA binding protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1142078', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1142138', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1142738', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1142198', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1142918', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1142258', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1142318', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1143278', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'DDB1', 'approvedName': 'damage specific DNA binding protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1142378', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1143188', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'DDB1', 'approvedName': 'damage specific DNA binding protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1142438', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1143368', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'DDB1', 'approvedName': 'damage specific DNA binding protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1142498', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1143398', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'DDB1', 'approvedName': 'damage specific DNA binding protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1142558', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1143818', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'DDB1', 'approvedName': 'damage specific DNA binding protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1142618', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1143668', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'DDB1', 'approvedName': 'damage specific DNA binding protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1141328', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1143788', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'DDB1', 'approvedName': 'damage specific DNA binding protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1141538', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1143758', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'DDB1', 'approvedName': 'damage specific DNA binding protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1141238', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1144058', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'DDB1', 'approvedName': 'damage specific DNA binding protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1141568', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1143878', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'DDB1', 'approvedName': 'damage specific DNA binding protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1141358', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1144028', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'DDB1', 'approvedName': 'damage specific DNA binding protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1141598', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1143998', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'DDB1', 'approvedName': 'damage specific DNA binding protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1143968', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'DDB1', 'approvedName': 'damage specific DNA binding protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1141628', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1142678', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1141388', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1142798', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1141658', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1142768', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1143038', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'DDB1', 'approvedName': 'damage specific DNA binding protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1141688', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1142888', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1141418', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1143008', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'DDB1', 'approvedName': 'damage specific DNA binding protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1141718', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1142978', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'DDB1', 'approvedName': 'damage specific DNA binding protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1141208', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1143518', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'DDB1', 'approvedName': 'damage specific DNA binding protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1141748', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1143128', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'DDB1', 'approvedName': 'damage specific DNA binding protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1141448', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1143248', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'DDB1', 'approvedName': 'damage specific DNA binding protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1141778', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1143218', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'DDB1', 'approvedName': 'damage specific DNA binding protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1141298', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1143488', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'DDB1', 'approvedName': 'damage specific DNA binding protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1141808', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1143338', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'DDB1', 'approvedName': 'damage specific DNA binding protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1141478', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1143458', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'DDB1', 'approvedName': 'damage specific DNA binding protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1141838', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1143428', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'DDB1', 'approvedName': 'damage specific DNA binding protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1141178', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1144088', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'DDB1', 'approvedName': 'damage specific DNA binding protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1141868', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1143608', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'DDB1', 'approvedName': 'damage specific DNA binding protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1141508', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1144148', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'DDB1', 'approvedName': 'damage specific DNA binding protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1144118', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'DDB1', 'approvedName': 'damage specific DNA binding protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1143548', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'DDB1', 'approvedName': 'damage specific DNA binding protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1143068', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'DDB1', 'approvedName': 'damage specific DNA binding protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1142828', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1142708', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1142648', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1142108', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1141268', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1142948', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1142408', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1143638', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'DDB1', 'approvedName': 'damage specific DNA binding protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1141988', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1142348', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1142588', 'drugName': 'Pomalidomide', 'tradeNames_list': "['Imnovid', 'Pomalyst']", 'syns_list': "['Actimid', 'CC-4047', 'IMID 3', 'IMID-3', 'Pomalidomide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.479 | Q34 | What are the names of the genes that are targeted by the drug Dextroamphetamine in the treatment of obesity? | In the context of obesity, the drug Dextroamphetamine targets the gene solute carrier family 6 member 2, solute carrier family 18 member A2 and solute carrier family 6 member 3. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%obesity%" OR LOWER(efo_term) LIKE "%obesity%") AND (LOWER(drugName) LIKE "%dextroamphetamine%" OR LOWER(tradeNames_list) LIKE "%dextroamphetamine%" OR LOWER(syns_list) LIKE "%dextroamphetamine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_418423', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418462', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418475', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418488', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418514', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418527', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418540', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418566', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418579', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418592', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418605', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418631', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418644', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418657', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418670', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418683', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418696', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418709', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418722', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418735', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418748', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418774', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418787', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418800', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418813', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418826', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418852', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418865', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418878', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_418891', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_418904', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_418917', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_418930', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_418943', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_418956', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_418969', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_418982', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_418995', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_419008', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_419021', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_419034', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_419047', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_419060', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_419073', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_419086', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_419099', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_419112', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_419125', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_418761', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418553', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418449', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418397', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418371', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418358', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418839', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418618', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418501', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418436', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418410', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418384', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Obesity', 'efo_term': 'obesity', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1457 | Q34 | What are the names of the genes that are targeted by the drug Tretinoin in the treatment of neoplasm? | In the context of neoplasm, the drug Tretinoin targets the gene retinoic acid receptor gamma, retinoic acid receptor beta and retinoic acid receptor alpha. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%neoplasm%" OR LOWER(efo_term) LIKE "%neoplasm%") AND (LOWER(drugName) LIKE "%tretinoin%" OR LOWER(tradeNames_list) LIKE "%tretinoin%" OR LOWER(syns_list) LIKE "%tretinoin%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1053600', 'drugName': 'Tretinoin', 'tradeNames_list': "['Acticin', 'Altreno', 'Atralin', 'Avita', 'Renova', 'Retin-a', 'Retin-a microRetin-a-micro', 'Tretin-X', 'Tretinoin', 'Vesanoid']", 'syns_list': "['Aberel', 'All-trans retinoic acid', 'All-trans-retinoic acid', 'EudynaKerlocal', 'NSC-122758', 'Oristar rna', 'Retin a', 'Retinoic acidTretinoin']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'RARB', 'approvedName': 'retinoic acid receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_1053518', 'drugName': 'Tretinoin', 'tradeNames_list': "['Acticin', 'Altreno', 'Atralin', 'Avita', 'Renova', 'Retin-a', 'Retin-a microRetin-a-micro', 'Tretin-X', 'Tretinoin', 'Vesanoid']", 'syns_list': "['Aberel', 'All-trans retinoic acid', 'All-trans-retinoic acid', 'EudynaKerlocal', 'NSC-122758', 'Oristar rna', 'Retin a', 'Retinoic acidTretinoin']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1053641', 'drugName': 'Tretinoin', 'tradeNames_list': "['Acticin', 'Altreno', 'Atralin', 'Avita', 'Renova', 'Retin-a', 'Retin-a microRetin-a-micro', 'Tretin-X', 'Tretinoin', 'Vesanoid']", 'syns_list': "['Aberel', 'All-trans retinoic acid', 'All-trans-retinoic acid', 'EudynaKerlocal', 'NSC-122758', 'Oristar rna', 'Retin a', 'Retinoic acidTretinoin']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'RARB', 'approvedName': 'retinoic acid receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_1053559', 'drugName': 'Tretinoin', 'tradeNames_list': "['Acticin', 'Altreno', 'Atralin', 'Avita', 'Renova', 'Retin-a', 'Retin-a microRetin-a-micro', 'Tretin-X', 'Tretinoin', 'Vesanoid']", 'syns_list': "['Aberel', 'All-trans retinoic acid', 'All-trans-retinoic acid', 'EudynaKerlocal', 'NSC-122758', 'Oristar rna', 'Retin a', 'Retinoic acidTretinoin']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1053723', 'drugName': 'Tretinoin', 'tradeNames_list': "['Acticin', 'Altreno', 'Atralin', 'Avita', 'Renova', 'Retin-a', 'Retin-a microRetin-a-micro', 'Tretin-X', 'Tretinoin', 'Vesanoid']", 'syns_list': "['Aberel', 'All-trans retinoic acid', 'All-trans-retinoic acid', 'EudynaKerlocal', 'NSC-122758', 'Oristar rna', 'Retin a', 'Retinoic acidTretinoin']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'RARA', 'approvedName': 'retinoic acid receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1053682', 'drugName': 'Tretinoin', 'tradeNames_list': "['Acticin', 'Altreno', 'Atralin', 'Avita', 'Renova', 'Retin-a', 'Retin-a microRetin-a-micro', 'Tretin-X', 'Tretinoin', 'Vesanoid']", 'syns_list': "['Aberel', 'All-trans retinoic acid', 'All-trans-retinoic acid', 'EudynaKerlocal', 'NSC-122758', 'Oristar rna', 'Retin a', 'Retinoic acidTretinoin']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'RARA', 'approvedName': 'retinoic acid receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1053591', 'drugName': 'Tretinoin', 'tradeNames_list': "['Acticin', 'Altreno', 'Atralin', 'Avita', 'Renova', 'Retin-a', 'Retin-a microRetin-a-micro', 'Tretin-X', 'Tretinoin', 'Vesanoid']", 'syns_list': "['Aberel', 'All-trans retinoic acid', 'All-trans-retinoic acid', 'EudynaKerlocal', 'NSC-122758', 'Oristar rna', 'Retin a', 'Retinoic acidTretinoin']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'RARB', 'approvedName': 'retinoic acid receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_1053555', 'drugName': 'Tretinoin', 'tradeNames_list': "['Acticin', 'Altreno', 'Atralin', 'Avita', 'Renova', 'Retin-a', 'Retin-a microRetin-a-micro', 'Tretin-X', 'Tretinoin', 'Vesanoid']", 'syns_list': "['Aberel', 'All-trans retinoic acid', 'All-trans-retinoic acid', 'EudynaKerlocal', 'NSC-122758', 'Oristar rna', 'Retin a', 'Retinoic acidTretinoin']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1053772', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1053768', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Central Nervous System Neoplasms', 'efo_term': 'Central Nervous System Neoplasm', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1053514', 'drugName': 'Tretinoin', 'tradeNames_list': "['Acticin', 'Altreno', 'Atralin', 'Avita', 'Renova', 'Retin-a', 'Retin-a microRetin-a-micro', 'Tretin-X', 'Tretinoin', 'Vesanoid']", 'syns_list': "['Aberel', 'All-trans retinoic acid', 'All-trans-retinoic acid', 'EudynaKerlocal', 'NSC-122758', 'Oristar rna', 'Retin a', 'Retinoic acidTretinoin']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1053637', 'drugName': 'Tretinoin', 'tradeNames_list': "['Acticin', 'Altreno', 'Atralin', 'Avita', 'Renova', 'Retin-a', 'Retin-a microRetin-a-micro', 'Tretin-X', 'Tretinoin', 'Vesanoid']", 'syns_list': "['Aberel', 'All-trans retinoic acid', 'All-trans-retinoic acid', 'EudynaKerlocal', 'NSC-122758', 'Oristar rna', 'Retin a', 'Retinoic acidTretinoin']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'RARB', 'approvedName': 'retinoic acid receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_1053912', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Central Nervous System Neoplasms', 'efo_term': 'Central Nervous System Neoplasm', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1053766', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Brain Neoplasms', 'efo_term': 'brain neoplasm', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1053714', 'drugName': 'Tretinoin', 'tradeNames_list': "['Acticin', 'Altreno', 'Atralin', 'Avita', 'Renova', 'Retin-a', 'Retin-a microRetin-a-micro', 'Tretin-X', 'Tretinoin', 'Vesanoid']", 'syns_list': "['Aberel', 'All-trans retinoic acid', 'All-trans-retinoic acid', 'EudynaKerlocal', 'NSC-122758', 'Oristar rna', 'Retin a', 'Retinoic acidTretinoin']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'RARA', 'approvedName': 'retinoic acid receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1054061', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1054247', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Head and Neck Neoplasms', 'efo_term': 'head and neck malignant neoplasia', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1054300', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1054295', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Head and Neck Neoplasms', 'efo_term': 'head and neck malignant neoplasia', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1054301', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1054343', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Head and Neck Neoplasms', 'efo_term': 'head and neck malignant neoplasia', 'approvedSymbol': 'RARB', 'approvedName': 'retinoic acid receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_1054348', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'RARB', 'approvedName': 'retinoic acid receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_1054390', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Brain Neoplasms', 'efo_term': 'brain neoplasm', 'approvedSymbol': 'RARB', 'approvedName': 'retinoic acid receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_1053632', 'drugName': 'Tretinoin', 'tradeNames_list': "['Acticin', 'Altreno', 'Atralin', 'Avita', 'Renova', 'Retin-a', 'Retin-a microRetin-a-micro', 'Tretin-X', 'Tretinoin', 'Vesanoid']", 'syns_list': "['Aberel', 'All-trans retinoic acid', 'All-trans-retinoic acid', 'EudynaKerlocal', 'NSC-122758', 'Oristar rna', 'Retin a', 'Retinoic acidTretinoin']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'RARB', 'approvedName': 'retinoic acid receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_1054349', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'RARB', 'approvedName': 'retinoic acid receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_1053673', 'drugName': 'Tretinoin', 'tradeNames_list': "['Acticin', 'Altreno', 'Atralin', 'Avita', 'Renova', 'Retin-a', 'Retin-a microRetin-a-micro', 'Tretin-X', 'Tretinoin', 'Vesanoid']", 'syns_list': "['Aberel', 'All-trans retinoic acid', 'All-trans-retinoic acid', 'EudynaKerlocal', 'NSC-122758', 'Oristar rna', 'Retin a', 'Retinoic acidTretinoin']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'RARA', 'approvedName': 'retinoic acid receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1054013', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1053864', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Central Nervous System Neoplasms', 'efo_term': 'Central Nervous System Neoplasm', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1053958', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Brain Neoplasms', 'efo_term': 'brain neoplasm', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1054246', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Brain Neoplasms', 'efo_term': 'brain neoplasm', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1053917', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1054151', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Head and Neck Neoplasms', 'efo_term': 'head and neck malignant neoplasia', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1053915', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Kidney Neoplasms', 'efo_term': 'kidney cancer', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1054199', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Head and Neck Neoplasms', 'efo_term': 'head and neck malignant neoplasia', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1054200', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Central Nervous System Neoplasms', 'efo_term': 'Central Nervous System Neoplasm', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1054203', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Kidney Neoplasms', 'efo_term': 'kidney cancer', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1053960', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Central Nervous System Neoplasms', 'efo_term': 'Central Nervous System Neoplasm', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1053964', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1053719', 'drugName': 'Tretinoin', 'tradeNames_list': "['Acticin', 'Altreno', 'Atralin', 'Avita', 'Renova', 'Retin-a', 'Retin-a microRetin-a-micro', 'Tretin-X', 'Tretinoin', 'Vesanoid']", 'syns_list': "['Aberel', 'All-trans retinoic acid', 'All-trans-retinoic acid', 'EudynaKerlocal', 'NSC-122758', 'Oristar rna', 'Retin a', 'Retinoic acidTretinoin']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'RARA', 'approvedName': 'retinoic acid receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1054344', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Central Nervous System Neoplasms', 'efo_term': 'Central Nervous System Neoplasm', 'approvedSymbol': 'RARB', 'approvedName': 'retinoic acid receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_1054007', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Head and Neck Neoplasms', 'efo_term': 'head and neck malignant neoplasia', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1054299', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Kidney Neoplasms', 'efo_term': 'kidney cancer', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1054296', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Central Nervous System Neoplasms', 'efo_term': 'Central Nervous System Neoplasm', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1054156', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1053767', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Head and Neck Neoplasms', 'efo_term': 'head and neck malignant neoplasia', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1054342', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Brain Neoplasms', 'efo_term': 'brain neoplasm', 'approvedSymbol': 'RARB', 'approvedName': 'retinoic acid receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_1053771', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Kidney Neoplasms', 'efo_term': 'kidney cancer', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1053773', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1054347', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Kidney Neoplasms', 'efo_term': 'kidney cancer', 'approvedSymbol': 'RARB', 'approvedName': 'retinoic acid receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_1054060', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1053814', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Brain Neoplasms', 'efo_term': 'brain neoplasm', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1053815', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Head and Neck Neoplasms', 'efo_term': 'head and neck malignant neoplasia', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1053816', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Central Nervous System Neoplasms', 'efo_term': 'Central Nervous System Neoplasm', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1053862', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Brain Neoplasms', 'efo_term': 'brain neoplasm', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1054056', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Central Nervous System Neoplasms', 'efo_term': 'Central Nervous System Neoplasm', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1053509', 'drugName': 'Tretinoin', 'tradeNames_list': "['Acticin', 'Altreno', 'Atralin', 'Avita', 'Renova', 'Retin-a', 'Retin-a microRetin-a-micro', 'Tretin-X', 'Tretinoin', 'Vesanoid']", 'syns_list': "['Aberel', 'All-trans retinoic acid', 'All-trans-retinoic acid', 'EudynaKerlocal', 'NSC-122758', 'Oristar rna', 'Retin a', 'Retinoic acidTretinoin']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1054103', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Head and Neck Neoplasms', 'efo_term': 'head and neck malignant neoplasia', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1053678', 'drugName': 'Tretinoin', 'tradeNames_list': "['Acticin', 'Altreno', 'Atralin', 'Avita', 'Renova', 'Retin-a', 'Retin-a microRetin-a-micro', 'Tretin-X', 'Tretinoin', 'Vesanoid']", 'syns_list': "['Aberel', 'All-trans retinoic acid', 'All-trans-retinoic acid', 'EudynaKerlocal', 'NSC-122758', 'Oristar rna', 'Retin a', 'Retinoic acidTretinoin']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'RARA', 'approvedName': 'retinoic acid receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1054150', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Brain Neoplasms', 'efo_term': 'brain neoplasm', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1054157', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1054107', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Kidney Neoplasms', 'efo_term': 'kidney cancer', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1053869', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1054152', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Central Nervous System Neoplasms', 'efo_term': 'Central Nervous System Neoplasm', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1054109', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1053867', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Kidney Neoplasms', 'efo_term': 'kidney cancer', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1053910', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Brain Neoplasms', 'efo_term': 'brain neoplasm', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1054253', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1054055', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Head and Neck Neoplasms', 'efo_term': 'head and neck malignant neoplasia', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1053916', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1054205', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1054198', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Brain Neoplasms', 'efo_term': 'brain neoplasm', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1054204', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1054155', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Kidney Neoplasms', 'efo_term': 'kidney cancer', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1053868', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1054252', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1053959', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Head and Neck Neoplasms', 'efo_term': 'head and neck malignant neoplasia', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1054054', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Brain Neoplasms', 'efo_term': 'brain neoplasm', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1053963', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Kidney Neoplasms', 'efo_term': 'kidney cancer', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1054251', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Kidney Neoplasms', 'efo_term': 'kidney cancer', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1053965', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1054248', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Central Nervous System Neoplasms', 'efo_term': 'Central Nervous System Neoplasm', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1053596', 'drugName': 'Tretinoin', 'tradeNames_list': "['Acticin', 'Altreno', 'Atralin', 'Avita', 'Renova', 'Retin-a', 'Retin-a microRetin-a-micro', 'Tretin-X', 'Tretinoin', 'Vesanoid']", 'syns_list': "['Aberel', 'All-trans retinoic acid', 'All-trans-retinoic acid', 'EudynaKerlocal', 'NSC-122758', 'Oristar rna', 'Retin a', 'Retinoic acidTretinoin']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'RARB', 'approvedName': 'retinoic acid receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_1054011', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Kidney Neoplasms', 'efo_term': 'kidney cancer', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1053821', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1054391', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Head and Neck Neoplasms', 'efo_term': 'head and neck malignant neoplasia', 'approvedSymbol': 'RARB', 'approvedName': 'retinoic acid receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_1054008', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Central Nervous System Neoplasms', 'efo_term': 'Central Nervous System Neoplasm', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1054395', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Kidney Neoplasms', 'efo_term': 'kidney cancer', 'approvedSymbol': 'RARB', 'approvedName': 'retinoic acid receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_1054392', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Central Nervous System Neoplasms', 'efo_term': 'Central Nervous System Neoplasm', 'approvedSymbol': 'RARB', 'approvedName': 'retinoic acid receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_1054294', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Brain Neoplasms', 'efo_term': 'brain neoplasm', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1054104', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Central Nervous System Neoplasms', 'efo_term': 'Central Nervous System Neoplasm', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1054012', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1053820', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1053819', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Kidney Neoplasms', 'efo_term': 'kidney cancer', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1053863', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Head and Neck Neoplasms', 'efo_term': 'head and neck malignant neoplasia', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1054102', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Brain Neoplasms', 'efo_term': 'brain neoplasm', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1054108', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1053911', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Head and Neck Neoplasms', 'efo_term': 'head and neck malignant neoplasia', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1054006', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Brain Neoplasms', 'efo_term': 'brain neoplasm', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1054059', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Kidney Neoplasms', 'efo_term': 'kidney cancer', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1053550', 'drugName': 'Tretinoin', 'tradeNames_list': "['Acticin', 'Altreno', 'Atralin', 'Avita', 'Renova', 'Retin-a', 'Retin-a microRetin-a-micro', 'Tretin-X', 'Tretinoin', 'Vesanoid']", 'syns_list': "['Aberel', 'All-trans retinoic acid', 'All-trans-retinoic acid', 'EudynaKerlocal', 'NSC-122758', 'Oristar rna', 'Retin a', 'Retinoic acidTretinoin']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1433 | Q34 | What are the names of the genes that are targeted by the drug Amlodipine Besylate in the treatment of coronary artery disease? | In the context of coronary artery disease, the drug Amlodipine Besylate targets the gene calcium voltage-gated channel subunit alpha1 C, calcium voltage-gated channel subunit alpha1 S, calcium voltage-gated channel subunit alpha1 D and calcium voltage-gated channel subunit alpha1 F. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%coronary artery disease%" OR LOWER(efo_term) LIKE "%coronary artery disease%") AND (LOWER(drugName) LIKE "%amlodipine besylate%" OR LOWER(tradeNames_list) LIKE "%amlodipine besylate%" OR LOWER(syns_list) LIKE "%amlodipine besylate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1043737', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043779', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043793', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043807', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043835', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043849', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043863', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043891', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043905', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043919', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043933', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043961', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043975', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043989', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043877', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043765', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043709', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043681', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043667', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043947', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043821', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043751', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043723', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043695', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1381 | Q34 | What are the names of the genes that are targeted by the drug Clonidine in the treatment of glaucoma? | In the context of glaucoma, the drug Clonidine targets the gene adrenoceptor alpha 2A, adrenoceptor alpha 2C and adrenoceptor alpha 2B. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%glaucoma%" OR LOWER(efo_term) LIKE "%glaucoma%") AND (LOWER(drugName) LIKE "%clonidine%" OR LOWER(tradeNames_list) LIKE "%clonidine%" OR LOWER(syns_list) LIKE "%clonidine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1033829', 'drugName': 'Clonidine', 'tradeNames_list': "['Catapres', 'Catapres-tts-1', 'Catapres-tts-2', 'Catapres-tts-3', 'ClonidineNexiclon xr']", 'syns_list': "['Catapres', 'Catarpres-tts', 'Clonidine', 'Clonidine extended releaseClorpres', 'Combipres', 'Duraclon', 'ST-155-BS', 'ST-155BS']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1033934', 'drugName': 'Clonidine', 'tradeNames_list': "['Catapres', 'Catapres-tts-1', 'Catapres-tts-2', 'Catapres-tts-3', 'ClonidineNexiclon xr']", 'syns_list': "['Catapres', 'Catarpres-tts', 'Clonidine', 'Clonidine extended releaseClorpres', 'Combipres', 'Duraclon', 'ST-155-BS', 'ST-155BS']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1033969', 'drugName': 'Clonidine', 'tradeNames_list': "['Catapres', 'Catapres-tts-1', 'Catapres-tts-2', 'Catapres-tts-3', 'ClonidineNexiclon xr']", 'syns_list': "['Catapres', 'Catarpres-tts', 'Clonidine', 'Clonidine extended releaseClorpres', 'Combipres', 'Duraclon', 'ST-155-BS', 'ST-155BS']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1034004', 'drugName': 'Clonidine', 'tradeNames_list': "['Catapres', 'Catapres-tts-1', 'Catapres-tts-2', 'Catapres-tts-3', 'ClonidineNexiclon xr']", 'syns_list': "['Catapres', 'Catarpres-tts', 'Clonidine', 'Clonidine extended releaseClorpres', 'Combipres', 'Duraclon', 'ST-155-BS', 'ST-155BS']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1033899', 'drugName': 'Clonidine', 'tradeNames_list': "['Catapres', 'Catapres-tts-1', 'Catapres-tts-2', 'Catapres-tts-3', 'ClonidineNexiclon xr']", 'syns_list': "['Catapres', 'Catarpres-tts', 'Clonidine', 'Clonidine extended releaseClorpres', 'Combipres', 'Duraclon', 'ST-155-BS', 'ST-155BS']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1033759', 'drugName': 'Clonidine', 'tradeNames_list': "['Catapres', 'Catapres-tts-1', 'Catapres-tts-2', 'Catapres-tts-3', 'ClonidineNexiclon xr']", 'syns_list': "['Catapres', 'Catarpres-tts', 'Clonidine', 'Clonidine extended releaseClorpres', 'Combipres', 'Duraclon', 'ST-155-BS', 'ST-155BS']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1033689', 'drugName': 'Clonidine', 'tradeNames_list': "['Catapres', 'Catapres-tts-1', 'Catapres-tts-2', 'Catapres-tts-3', 'ClonidineNexiclon xr']", 'syns_list': "['Catapres', 'Catarpres-tts', 'Clonidine', 'Clonidine extended releaseClorpres', 'Combipres', 'Duraclon', 'ST-155-BS', 'ST-155BS']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1033654', 'drugName': 'Clonidine', 'tradeNames_list': "['Catapres', 'Catapres-tts-1', 'Catapres-tts-2', 'Catapres-tts-3', 'ClonidineNexiclon xr']", 'syns_list': "['Catapres', 'Catarpres-tts', 'Clonidine', 'Clonidine extended releaseClorpres', 'Combipres', 'Duraclon', 'ST-155-BS', 'ST-155BS']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034039', 'drugName': 'Clonidine', 'tradeNames_list': "['Catapres', 'Catapres-tts-1', 'Catapres-tts-2', 'Catapres-tts-3', 'ClonidineNexiclon xr']", 'syns_list': "['Catapres', 'Catarpres-tts', 'Clonidine', 'Clonidine extended releaseClorpres', 'Combipres', 'Duraclon', 'ST-155-BS', 'ST-155BS']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1033864', 'drugName': 'Clonidine', 'tradeNames_list': "['Catapres', 'Catapres-tts-1', 'Catapres-tts-2', 'Catapres-tts-3', 'ClonidineNexiclon xr']", 'syns_list': "['Catapres', 'Catarpres-tts', 'Clonidine', 'Clonidine extended releaseClorpres', 'Combipres', 'Duraclon', 'ST-155-BS', 'ST-155BS']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1033794', 'drugName': 'Clonidine', 'tradeNames_list': "['Catapres', 'Catapres-tts-1', 'Catapres-tts-2', 'Catapres-tts-3', 'ClonidineNexiclon xr']", 'syns_list': "['Catapres', 'Catarpres-tts', 'Clonidine', 'Clonidine extended releaseClorpres', 'Combipres', 'Duraclon', 'ST-155-BS', 'ST-155BS']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1033724', 'drugName': 'Clonidine', 'tradeNames_list': "['Catapres', 'Catapres-tts-1', 'Catapres-tts-2', 'Catapres-tts-3', 'ClonidineNexiclon xr']", 'syns_list': "['Catapres', 'Catarpres-tts', 'Clonidine', 'Clonidine extended releaseClorpres', 'Combipres', 'Duraclon', 'ST-155-BS', 'ST-155BS']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.657 | Q34 | What are the names of the genes that are targeted by the drug Desmopressin Acetate in the treatment of von Willebrand disease (hereditary or acquired)? | In the context of von Willebrand disease (hereditary or acquired), the drug Desmopressin Acetate targets the gene arginine vasopressin receptor 2, arginine vasopressin receptor 1A and arginine vasopressin receptor 1B. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%von willebrand disease (hereditary or acquired)%" OR LOWER(efo_term) LIKE "%von willebrand disease (hereditary or acquired)%") AND (LOWER(drugName) LIKE "%desmopressin acetate%" OR LOWER(tradeNames_list) LIKE "%desmopressin acetate%" OR LOWER(syns_list) LIKE "%desmopressin acetate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_694456', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694489', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694500', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694511', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694533', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694544', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694555', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694577', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694588', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694599', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694610', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694632', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694643', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694654', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694665', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694676', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694687', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694698', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694709', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694720', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694731', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694753', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694764', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694775', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694786', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694797', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694819', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694830', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694841', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694852', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694863', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_694874', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_694885', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_694896', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_694907', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_694918', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_694929', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_694940', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_694951', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_694962', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_694973', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_694984', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_694995', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_695006', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_695017', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_695028', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_695039', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_695050', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_695061', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_695072', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_695083', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_694742', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694566', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694478', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694434', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694412', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694401', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694808', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694621', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694522', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694467', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694445', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694423', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Willebrand Diseases', 'efo_term': 'von Willebrand disease (hereditary or acquired)', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.174 | Q34 | What are the names of the genes that are targeted by the drug Prednisone in the treatment of psoriatic arthritis? | In the context of psoriatic arthritis, the drug Prednisone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%psoriatic arthritis%" OR LOWER(efo_term) LIKE "%psoriatic arthritis%") AND (LOWER(drugName) LIKE "%prednisone%" OR LOWER(tradeNames_list) LIKE "%prednisone%" OR LOWER(syns_list) LIKE "%prednisone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_218680', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219304', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219512', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219720', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220136', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220344', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220552', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220760', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219096', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218264', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217848', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217640', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219928', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218888', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218472', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218056', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1157 | Q34 | What are the names of the genes that are targeted by the drug Trametinib in the treatment of colorectal carcinoma? | Trametinib has not been approved by the FDA as a treatment for colorectal carcinoma, but it is currently undergoing evaluation in clinical trials for this purpose. However, the proposed gene target names are mitogen-activated protein kinase kinase 2 and mitogen-activated protein kinase kinase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%colorectal carcinoma%" OR LOWER(efo_term) LIKE "%colorectal carcinoma%") AND (LOWER(drugName) LIKE "%trametinib%" OR LOWER(tradeNames_list) LIKE "%trametinib%" OR LOWER(syns_list) LIKE "%trametinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_928705', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928825', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928865', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928905', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928985', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929025', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929065', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929145', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929185', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929225', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929265', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929345', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929385', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929425', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929465', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929505', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929545', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929585', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929625', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929665', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929705', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929785', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929825', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929865', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929905', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929945', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930025', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930065', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930105', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930145', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930185', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930225', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930265', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930305', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930345', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930385', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930425', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930465', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930505', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930545', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930585', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930625', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930665', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930705', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930745', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930785', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930825', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930865', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930905', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930945', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930985', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931065', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931105', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931145', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931185', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931225', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931265', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931345', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931385', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931425', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931465', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931505', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931545', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931585', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931625', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931665', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931705', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931745', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931785', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931825', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931865', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931905', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931945', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931985', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932025', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932065', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932105', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932145', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932185', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932225', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932265', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932305', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932345', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932385', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932425', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932465', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931025', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_929745', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929105', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928785', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928625', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928545', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928505', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_931305', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_929985', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929305', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928945', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928745', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928665', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928585', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.39 | Q34 | What are the names of the genes that are targeted by the drug Aripiprazole in the treatment of aggressive behavior? | In the context of aggressive behavior, the drug Aripiprazole targets the gene dopamine receptor D2, 5-hydroxytryptamine receptor 2A and 5-hydroxytryptamine receptor 1A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%aggressive behavior%" OR LOWER(efo_term) LIKE "%aggressive behavior%") AND (LOWER(drugName) LIKE "%aripiprazole%" OR LOWER(tradeNames_list) LIKE "%aripiprazole%" OR LOWER(syns_list) LIKE "%aripiprazole%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_159198', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159282', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159310', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159338', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159394', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159422', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159450', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159506', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159534', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159562', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159590', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159646', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159674', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159702', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159730', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159758', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159786', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159814', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159842', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159870', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159898', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159954', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159982', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160010', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160038', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160066', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160122', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160150', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160178', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160206', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160234', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160262', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160290', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160318', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160346', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160374', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160402', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160430', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160458', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160486', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160514', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160542', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160570', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160598', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160626', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160654', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160682', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160710', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160738', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160766', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160794', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160850', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160878', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160906', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160934', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160962', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160990', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161046', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161074', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161102', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161130', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161158', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161186', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161214', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161242', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161270', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161298', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161326', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161354', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161382', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161410', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161438', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161466', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161494', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161522', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161550', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161578', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161606', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161634', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161662', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161690', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161718', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161746', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161774', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161802', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161830', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160822', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159926', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159478', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159254', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159142', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159086', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159058', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161018', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160094', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159618', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159366', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159226', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159170', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159114', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.718 | Q34 | What are the names of the genes that are targeted by the drug Vemurafenib in the treatment of neoplasm? | In the context of neoplasm, the drug Vemurafenib targets the gene B-Raf proto-oncogene, serine/threonine kinase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%neoplasm%" OR LOWER(efo_term) LIKE "%neoplasm%") AND (LOWER(drugName) LIKE "%vemurafenib%" OR LOWER(tradeNames_list) LIKE "%vemurafenib%" OR LOWER(syns_list) LIKE "%vemurafenib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_752094', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752199', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752178', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752159', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752157', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752136', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752138', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752201', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752222', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752096', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752115', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752220', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752180', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752117', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752126', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752210', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752129', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752113', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752107', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pancreatic Neoplasms', 'efo_term': 'pancreatic carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752114', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752198', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752150', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752147', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752149', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pancreatic Neoplasms', 'efo_term': 'pancreatic carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752135', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752128', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pancreatic Neoplasms', 'efo_term': 'pancreatic carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752197', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752191', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pancreatic Neoplasms', 'efo_term': 'pancreatic carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752213', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752086', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pancreatic Neoplasms', 'efo_term': 'pancreatic carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752105', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752134', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752168', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752177', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752189', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752212', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pancreatic Neoplasms', 'efo_term': 'pancreatic carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752156', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752176', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752171', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752092', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752192', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752219', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752155', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752108', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752087', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752170', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pancreatic Neoplasms', 'efo_term': 'pancreatic carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752218', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752084', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752093', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752081', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Skin Neoplasms', 'efo_term': 'skin cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752122', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Skin Neoplasms', 'efo_term': 'skin carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752164', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Skin Neoplasms', 'efo_term': 'skin carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752101', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Skin Neoplasms', 'efo_term': 'skin carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752123', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Skin Neoplasms', 'efo_term': 'skin cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752102', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Skin Neoplasms', 'efo_term': 'skin cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752165', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Skin Neoplasms', 'efo_term': 'skin cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752080', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Skin Neoplasms', 'efo_term': 'skin carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752185', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Skin Neoplasms', 'efo_term': 'skin carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752186', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Skin Neoplasms', 'efo_term': 'skin cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752143', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Skin Neoplasms', 'efo_term': 'skin carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752206', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Skin Neoplasms', 'efo_term': 'skin carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752144', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Skin Neoplasms', 'efo_term': 'skin cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752207', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Skin Neoplasms', 'efo_term': 'skin cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.92 | Q34 | What are the names of the genes that are targeted by the drug Palonosetron Hydrochloride in the treatment of Nausea and vomiting? | In the context of Nausea and vomiting, the drug Palonosetron Hydrochloride targets the gene 5-hydroxytryptamine receptor 3A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%nausea and vomiting%" OR LOWER(efo_term) LIKE "%nausea and vomiting%") AND (LOWER(drugName) LIKE "%palonosetron hydrochloride%" OR LOWER(tradeNames_list) LIKE "%palonosetron hydrochloride%" OR LOWER(syns_list) LIKE "%palonosetron hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_205500', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205506', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205508', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205511', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205514', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205517', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205518', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205523', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205524', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205526', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205529', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205532', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205535', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205536', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205538', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205541', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205542', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205544', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205547', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205548', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205550', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205554', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205556', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205559', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205560', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205562', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205566', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205568', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205571', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205572', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205574', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205577', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205578', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205580', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205583', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205584', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205586', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205589', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205590', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205592', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205595', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205596', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205598', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205601', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205602', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205604', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205607', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205608', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205610', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205613', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205614', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205619', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205620', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205622', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205625', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205626', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205628', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205632', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205634', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205637', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205638', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205640', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205643', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205644', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205646', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205649', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205650', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205652', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205655', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205656', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205658', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205661', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205662', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205664', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205667', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205668', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205670', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205673', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205674', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205676', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205679', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205680', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205682', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205685', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205686', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205688', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205616', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205553', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205520', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205505', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205496', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205493', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205490', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205631', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205565', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205530', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205512', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205502', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205499', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205494', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1917 | Q34 | What are the names of the genes that are targeted by the drug Teriflunomide in the treatment of multiple sclerosis? | In the context of multiple sclerosis, the drug Teriflunomide targets the gene dihydroorotate dehydrogenase (quinone). | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%multiple sclerosis%" OR LOWER(efo_term) LIKE "%multiple sclerosis%") AND (LOWER(drugName) LIKE "%teriflunomide%" OR LOWER(tradeNames_list) LIKE "%teriflunomide%" OR LOWER(syns_list) LIKE "%teriflunomide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1191753', 'drugName': 'Teriflunomide', 'tradeNames_list': "['Aubagio']", 'syns_list': "['A77 1726', 'HMR-1726', 'HMR1726', 'Leflunomide related compound bLeflunomide related compound b rs', 'Teriflunomide']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'DHODH', 'approvedName': 'dihydroorotate dehydrogenase (quinone)'}, {'UUID': 'DrugTargetsIndication121923_text_1191768', 'drugName': 'Teriflunomide', 'tradeNames_list': "['Aubagio']", 'syns_list': "['A77 1726', 'HMR-1726', 'HMR1726', 'Leflunomide related compound bLeflunomide related compound b rs', 'Teriflunomide']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'DHODH', 'approvedName': 'dihydroorotate dehydrogenase (quinone)'}, {'UUID': 'DrugTargetsIndication121923_text_1191773', 'drugName': 'Teriflunomide', 'tradeNames_list': "['Aubagio']", 'syns_list': "['A77 1726', 'HMR-1726', 'HMR1726', 'Leflunomide related compound bLeflunomide related compound b rs', 'Teriflunomide']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'DHODH', 'approvedName': 'dihydroorotate dehydrogenase (quinone)'}, {'UUID': 'DrugTargetsIndication121923_text_1191778', 'drugName': 'Teriflunomide', 'tradeNames_list': "['Aubagio']", 'syns_list': "['A77 1726', 'HMR-1726', 'HMR1726', 'Leflunomide related compound bLeflunomide related compound b rs', 'Teriflunomide']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'DHODH', 'approvedName': 'dihydroorotate dehydrogenase (quinone)'}, {'UUID': 'DrugTargetsIndication121923_text_1191763', 'drugName': 'Teriflunomide', 'tradeNames_list': "['Aubagio']", 'syns_list': "['A77 1726', 'HMR-1726', 'HMR1726', 'Leflunomide related compound bLeflunomide related compound b rs', 'Teriflunomide']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'DHODH', 'approvedName': 'dihydroorotate dehydrogenase (quinone)'}, {'UUID': 'DrugTargetsIndication121923_text_1191743', 'drugName': 'Teriflunomide', 'tradeNames_list': "['Aubagio']", 'syns_list': "['A77 1726', 'HMR-1726', 'HMR1726', 'Leflunomide related compound bLeflunomide related compound b rs', 'Teriflunomide']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'DHODH', 'approvedName': 'dihydroorotate dehydrogenase (quinone)'}, {'UUID': 'DrugTargetsIndication121923_text_1191733', 'drugName': 'Teriflunomide', 'tradeNames_list': "['Aubagio']", 'syns_list': "['A77 1726', 'HMR-1726', 'HMR1726', 'Leflunomide related compound bLeflunomide related compound b rs', 'Teriflunomide']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'DHODH', 'approvedName': 'dihydroorotate dehydrogenase (quinone)'}, {'UUID': 'DrugTargetsIndication121923_text_1191728', 'drugName': 'Teriflunomide', 'tradeNames_list': "['Aubagio']", 'syns_list': "['A77 1726', 'HMR-1726', 'HMR1726', 'Leflunomide related compound bLeflunomide related compound b rs', 'Teriflunomide']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'DHODH', 'approvedName': 'dihydroorotate dehydrogenase (quinone)'}, {'UUID': 'DrugTargetsIndication121923_text_1191783', 'drugName': 'Teriflunomide', 'tradeNames_list': "['Aubagio']", 'syns_list': "['A77 1726', 'HMR-1726', 'HMR1726', 'Leflunomide related compound bLeflunomide related compound b rs', 'Teriflunomide']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'DHODH', 'approvedName': 'dihydroorotate dehydrogenase (quinone)'}, {'UUID': 'DrugTargetsIndication121923_text_1191758', 'drugName': 'Teriflunomide', 'tradeNames_list': "['Aubagio']", 'syns_list': "['A77 1726', 'HMR-1726', 'HMR1726', 'Leflunomide related compound bLeflunomide related compound b rs', 'Teriflunomide']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'DHODH', 'approvedName': 'dihydroorotate dehydrogenase (quinone)'}, {'UUID': 'DrugTargetsIndication121923_text_1191748', 'drugName': 'Teriflunomide', 'tradeNames_list': "['Aubagio']", 'syns_list': "['A77 1726', 'HMR-1726', 'HMR1726', 'Leflunomide related compound bLeflunomide related compound b rs', 'Teriflunomide']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'DHODH', 'approvedName': 'dihydroorotate dehydrogenase (quinone)'}, {'UUID': 'DrugTargetsIndication121923_text_1191738', 'drugName': 'Teriflunomide', 'tradeNames_list': "['Aubagio']", 'syns_list': "['A77 1726', 'HMR-1726', 'HMR1726', 'Leflunomide related compound bLeflunomide related compound b rs', 'Teriflunomide']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'DHODH', 'approvedName': 'dihydroorotate dehydrogenase (quinone)'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1214 | Q34 | What are the names of the genes that are targeted by the drug Propranolol Hydrochloride in the treatment of migraine disorder? | In the context of migraine disorder, the drug Propranolol Hydrochloride targets the gene adrenoceptor beta 2 and adrenoceptor beta 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%migraine disorder%" OR LOWER(efo_term) LIKE "%migraine disorder%") AND (LOWER(drugName) LIKE "%propranolol hydrochloride%" OR LOWER(tradeNames_list) LIKE "%propranolol hydrochloride%" OR LOWER(syns_list) LIKE "%propranolol hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_937045', 'drugName': 'Propranolol Hydrochloride', 'tradeNames_list': "['Angilol', 'Apsolol', 'Avlocardyl', 'Bedranol', 'Bedranol s.r.', 'BerkololBeta-prograne mr', 'Betadur cr', 'Cardinol', 'DupromexHalf beta-prograne mr', 'Half propanix la', 'Half propatard laHalf-beprane cr', 'Half-betadur cr', 'Half-inderal la', 'HemangeolInderal', 'Inderal la', 'Innopran', 'Innopran xl', 'LederpronolLopranol la', 'Probeta la', 'Propanix la', 'Propanix-10', 'Propanix-160Propanix-160 sr', 'Propanix-40', 'Propanix-80', 'Propatard laPropranolol hydrochloride', 'Propranolol hydrochloride intensolRapranol sr', 'Sagittol', 'Slo-blok', 'Slo-pro', 'Sloprolol', 'SyprolTesnol']", 'syns_list': "['AY 64043', 'AY-64043', 'ICI 45520', 'ICI-45520', 'NSC-91523Propranolol hydrochloride']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_937022', 'drugName': 'Propranolol Hydrochloride', 'tradeNames_list': "['Angilol', 'Apsolol', 'Avlocardyl', 'Bedranol', 'Bedranol s.r.', 'BerkololBeta-prograne mr', 'Betadur cr', 'Cardinol', 'DupromexHalf beta-prograne mr', 'Half propanix la', 'Half propatard laHalf-beprane cr', 'Half-betadur cr', 'Half-inderal la', 'HemangeolInderal', 'Inderal la', 'Innopran', 'Innopran xl', 'LederpronolLopranol la', 'Probeta la', 'Propanix la', 'Propanix-10', 'Propanix-160Propanix-160 sr', 'Propanix-40', 'Propanix-80', 'Propatard laPropranolol hydrochloride', 'Propranolol hydrochloride intensolRapranol sr', 'Sagittol', 'Slo-blok', 'Slo-pro', 'Sloprolol', 'SyprolTesnol']", 'syns_list': "['AY 64043', 'AY-64043', 'ICI 45520', 'ICI-45520', 'NSC-91523Propranolol hydrochloride']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_937091', 'drugName': 'Propranolol Hydrochloride', 'tradeNames_list': "['Angilol', 'Apsolol', 'Avlocardyl', 'Bedranol', 'Bedranol s.r.', 'BerkololBeta-prograne mr', 'Betadur cr', 'Cardinol', 'DupromexHalf beta-prograne mr', 'Half propanix la', 'Half propatard laHalf-beprane cr', 'Half-betadur cr', 'Half-inderal la', 'HemangeolInderal', 'Inderal la', 'Innopran', 'Innopran xl', 'LederpronolLopranol la', 'Probeta la', 'Propanix la', 'Propanix-10', 'Propanix-160Propanix-160 sr', 'Propanix-40', 'Propanix-80', 'Propatard laPropranolol hydrochloride', 'Propranolol hydrochloride intensolRapranol sr', 'Sagittol', 'Slo-blok', 'Slo-pro', 'Sloprolol', 'SyprolTesnol']", 'syns_list': "['AY 64043', 'AY-64043', 'ICI 45520', 'ICI-45520', 'NSC-91523Propranolol hydrochloride']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_937068', 'drugName': 'Propranolol Hydrochloride', 'tradeNames_list': "['Angilol', 'Apsolol', 'Avlocardyl', 'Bedranol', 'Bedranol s.r.', 'BerkololBeta-prograne mr', 'Betadur cr', 'Cardinol', 'DupromexHalf beta-prograne mr', 'Half propanix la', 'Half propatard laHalf-beprane cr', 'Half-betadur cr', 'Half-inderal la', 'HemangeolInderal', 'Inderal la', 'Innopran', 'Innopran xl', 'LederpronolLopranol la', 'Probeta la', 'Propanix la', 'Propanix-10', 'Propanix-160Propanix-160 sr', 'Propanix-40', 'Propanix-80', 'Propatard laPropranolol hydrochloride', 'Propranolol hydrochloride intensolRapranol sr', 'Sagittol', 'Slo-blok', 'Slo-pro', 'Sloprolol', 'SyprolTesnol']", 'syns_list': "['AY 64043', 'AY-64043', 'ICI 45520', 'ICI-45520', 'NSC-91523Propranolol hydrochloride']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.881 | Q34 | What are the names of the genes that are targeted by the drug Diclofenac in the treatment of rheumatoid arthritis? | In the context of rheumatoid arthritis, the drug Diclofenac targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%rheumatoid arthritis%" OR LOWER(efo_term) LIKE "%rheumatoid arthritis%") AND (LOWER(drugName) LIKE "%diclofenac%" OR LOWER(tradeNames_list) LIKE "%diclofenac%" OR LOWER(syns_list) LIKE "%diclofenac%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_836126', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836180', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836198', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836216', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836252', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836270', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836288', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836324', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836342', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836360', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836378', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836414', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836432', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836450', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836468', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836486', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836504', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836522', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836540', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836558', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836576', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836612', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836630', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836648', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836666', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836684', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836720', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836738', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836756', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836774', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836792', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836810', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836828', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836846', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836864', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836882', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836900', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836918', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836936', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836954', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836977', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837007', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837037', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837067', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837097', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837127', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837157', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837187', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837217', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837247', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837277', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837337', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837367', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837397', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837427', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837457', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837487', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837547', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837577', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837607', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837637', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837667', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837697', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837727', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837757', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837787', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837817', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837847', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837877', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837907', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837937', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837967', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837997', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838027', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842890', 'drugName': 'Diclofenac Potassium', 'tradeNames_list': "['Cambia', 'Cataflam', 'Diclofenac potassium', 'Voltarol joint painVoltarol pain-eze', 'Voltarol pain-eze extra strgh', 'Voltarol rapidZipsor']", 'syns_list': "['CGP 45840B', 'CGP-45840B', 'Diclofenac potassiumDiclofenac potassium salt', 'Potassium diclofenac']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842899', 'drugName': 'Diclofenac Potassium', 'tradeNames_list': "['Cambia', 'Cataflam', 'Diclofenac potassium', 'Voltarol joint painVoltarol pain-eze', 'Voltarol pain-eze extra strgh', 'Voltarol rapidZipsor']", 'syns_list': "['CGP 45840B', 'CGP-45840B', 'Diclofenac potassiumDiclofenac potassium salt', 'Potassium diclofenac']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842908', 'drugName': 'Diclofenac Potassium', 'tradeNames_list': "['Cambia', 'Cataflam', 'Diclofenac potassium', 'Voltarol joint painVoltarol pain-eze', 'Voltarol pain-eze extra strgh', 'Voltarol rapidZipsor']", 'syns_list': "['CGP 45840B', 'CGP-45840B', 'Diclofenac potassiumDiclofenac potassium salt', 'Potassium diclofenac']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842917', 'drugName': 'Diclofenac Potassium', 'tradeNames_list': "['Cambia', 'Cataflam', 'Diclofenac potassium', 'Voltarol joint painVoltarol pain-eze', 'Voltarol pain-eze extra strgh', 'Voltarol rapidZipsor']", 'syns_list': "['CGP 45840B', 'CGP-45840B', 'Diclofenac potassiumDiclofenac potassium salt', 'Potassium diclofenac']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842926', 'drugName': 'Diclofenac Potassium', 'tradeNames_list': "['Cambia', 'Cataflam', 'Diclofenac potassium', 'Voltarol joint painVoltarol pain-eze', 'Voltarol pain-eze extra strgh', 'Voltarol rapidZipsor']", 'syns_list': "['CGP 45840B', 'CGP-45840B', 'Diclofenac potassiumDiclofenac potassium salt', 'Potassium diclofenac']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842935', 'drugName': 'Diclofenac Potassium', 'tradeNames_list': "['Cambia', 'Cataflam', 'Diclofenac potassium', 'Voltarol joint painVoltarol pain-eze', 'Voltarol pain-eze extra strgh', 'Voltarol rapidZipsor']", 'syns_list': "['CGP 45840B', 'CGP-45840B', 'Diclofenac potassiumDiclofenac potassium salt', 'Potassium diclofenac']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842944', 'drugName': 'Diclofenac Potassium', 'tradeNames_list': "['Cambia', 'Cataflam', 'Diclofenac potassium', 'Voltarol joint painVoltarol pain-eze', 'Voltarol pain-eze extra strgh', 'Voltarol rapidZipsor']", 'syns_list': "['CGP 45840B', 'CGP-45840B', 'Diclofenac potassiumDiclofenac potassium salt', 'Potassium diclofenac']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842953', 'drugName': 'Diclofenac Potassium', 'tradeNames_list': "['Cambia', 'Cataflam', 'Diclofenac potassium', 'Voltarol joint painVoltarol pain-eze', 'Voltarol pain-eze extra strgh', 'Voltarol rapidZipsor']", 'syns_list': "['CGP 45840B', 'CGP-45840B', 'Diclofenac potassiumDiclofenac potassium salt', 'Potassium diclofenac']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842962', 'drugName': 'Diclofenac Potassium', 'tradeNames_list': "['Cambia', 'Cataflam', 'Diclofenac potassium', 'Voltarol joint painVoltarol pain-eze', 'Voltarol pain-eze extra strgh', 'Voltarol rapidZipsor']", 'syns_list': "['CGP 45840B', 'CGP-45840B', 'Diclofenac potassiumDiclofenac potassium salt', 'Potassium diclofenac']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842971', 'drugName': 'Diclofenac Potassium', 'tradeNames_list': "['Cambia', 'Cataflam', 'Diclofenac potassium', 'Voltarol joint painVoltarol pain-eze', 'Voltarol pain-eze extra strgh', 'Voltarol rapidZipsor']", 'syns_list': "['CGP 45840B', 'CGP-45840B', 'Diclofenac potassiumDiclofenac potassium salt', 'Potassium diclofenac']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842980', 'drugName': 'Diclofenac Potassium', 'tradeNames_list': "['Cambia', 'Cataflam', 'Diclofenac potassium', 'Voltarol joint painVoltarol pain-eze', 'Voltarol pain-eze extra strgh', 'Voltarol rapidZipsor']", 'syns_list': "['CGP 45840B', 'CGP-45840B', 'Diclofenac potassiumDiclofenac potassium salt', 'Potassium diclofenac']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842989', 'drugName': 'Diclofenac Potassium', 'tradeNames_list': "['Cambia', 'Cataflam', 'Diclofenac potassium', 'Voltarol joint painVoltarol pain-eze', 'Voltarol pain-eze extra strgh', 'Voltarol rapidZipsor']", 'syns_list': "['CGP 45840B', 'CGP-45840B', 'Diclofenac potassiumDiclofenac potassium salt', 'Potassium diclofenac']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837307', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836594', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836306', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836162', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836090', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836054', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836036', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837517', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836702', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836396', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836234', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836144', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836108', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836072', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1478 | Q34 | What are the names of the genes that are targeted by the drug Eltrombopag Olamine in the treatment of autoimmune thrombocytopenic purpura? | In the context of autoimmune thrombocytopenic purpura, the drug Eltrombopag Olamine targets the gene MPL proto-oncogene, thrombopoietin receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%autoimmune thrombocytopenic purpura%" OR LOWER(efo_term) LIKE "%autoimmune thrombocytopenic purpura%") AND (LOWER(drugName) LIKE "%eltrombopag olamine%" OR LOWER(tradeNames_list) LIKE "%eltrombopag olamine%" OR LOWER(syns_list) LIKE "%eltrombopag olamine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1055975', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1055990', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1055995', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056000', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056010', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056015', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056020', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056030', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056035', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056040', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056045', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056055', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056060', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056065', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056070', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056075', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056080', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056085', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056090', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056095', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056100', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056110', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056115', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056120', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056125', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056130', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056140', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056145', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056150', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056155', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056160', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056165', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056170', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056175', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056180', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056185', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056190', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056195', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056200', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056205', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056210', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056215', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056220', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056225', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056230', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056235', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056240', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056245', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056250', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056255', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056260', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056270', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056275', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056280', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056285', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056290', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056295', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056305', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056310', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056315', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056320', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056325', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056330', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056335', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056340', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056345', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056350', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056355', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056360', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056365', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056370', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056375', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056380', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056385', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056390', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056395', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056400', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056405', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056410', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056415', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056420', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056425', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056430', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056435', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056440', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056445', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056265', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056105', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056025', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1055985', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1055965', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1055955', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1055950', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056300', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056135', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056050', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056005', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1055980', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1055970', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1055960', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1101 | Q34 | What are the names of the genes that are targeted by the drug Clascoterone in the treatment of acne? | In the context of acne, the drug Clascoterone targets the gene androgen receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%acne%" OR LOWER(efo_term) LIKE "%acne%") AND (LOWER(drugName) LIKE "%clascoterone%" OR LOWER(tradeNames_list) LIKE "%clascoterone%" OR LOWER(syns_list) LIKE "%clascoterone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_924380', 'drugName': 'Clascoterone', 'tradeNames_list': "['Breezula', 'Winlevi']", 'syns_list': "['CB-03-01', 'Cb-03-01', 'Clascoterone', 'Cortexolone 17.alpha.-propionateCortodoxone 17.alpha.-propionate']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924384', 'drugName': 'Clascoterone', 'tradeNames_list': "['Breezula', 'Winlevi']", 'syns_list': "['CB-03-01', 'Cb-03-01', 'Clascoterone', 'Cortexolone 17.alpha.-propionateCortodoxone 17.alpha.-propionate']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924376', 'drugName': 'Clascoterone', 'tradeNames_list': "['Breezula', 'Winlevi']", 'syns_list': "['CB-03-01', 'Cb-03-01', 'Clascoterone', 'Cortexolone 17.alpha.-propionateCortodoxone 17.alpha.-propionate']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924372', 'drugName': 'Clascoterone', 'tradeNames_list': "['Breezula', 'Winlevi']", 'syns_list': "['CB-03-01', 'Cb-03-01', 'Clascoterone', 'Cortexolone 17.alpha.-propionateCortodoxone 17.alpha.-propionate']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924370', 'drugName': 'Clascoterone', 'tradeNames_list': "['Breezula', 'Winlevi']", 'syns_list': "['CB-03-01', 'Cb-03-01', 'Clascoterone', 'Cortexolone 17.alpha.-propionateCortodoxone 17.alpha.-propionate']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924382', 'drugName': 'Clascoterone', 'tradeNames_list': "['Breezula', 'Winlevi']", 'syns_list': "['CB-03-01', 'Cb-03-01', 'Clascoterone', 'Cortexolone 17.alpha.-propionateCortodoxone 17.alpha.-propionate']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924378', 'drugName': 'Clascoterone', 'tradeNames_list': "['Breezula', 'Winlevi']", 'syns_list': "['CB-03-01', 'Cb-03-01', 'Clascoterone', 'Cortexolone 17.alpha.-propionateCortodoxone 17.alpha.-propionate']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924374', 'drugName': 'Clascoterone', 'tradeNames_list': "['Breezula', 'Winlevi']", 'syns_list': "['CB-03-01', 'Cb-03-01', 'Clascoterone', 'Cortexolone 17.alpha.-propionateCortodoxone 17.alpha.-propionate']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1164 | Q34 | What are the names of the genes that are targeted by the drug Trametinib in the treatment of ameloblastoma? | Trametinib has not been approved by the FDA as a treatment for ameloblastoma, but it is currently undergoing evaluation in clinical trials for this purpose. However, the proposed gene target names are mitogen-activated protein kinase kinase 2 and mitogen-activated protein kinase kinase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%ameloblastoma%" OR LOWER(efo_term) LIKE "%ameloblastoma%") AND (LOWER(drugName) LIKE "%trametinib%" OR LOWER(tradeNames_list) LIKE "%trametinib%" OR LOWER(syns_list) LIKE "%trametinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_928712', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928832', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928872', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928912', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928992', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929032', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929072', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929152', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929192', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929232', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929272', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929352', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929392', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929432', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929472', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929512', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929552', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929592', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929632', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929672', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929712', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929792', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929832', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929872', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929912', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929952', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930032', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930072', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930112', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930152', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930192', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930232', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930272', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930312', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930352', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930392', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930432', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930472', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930512', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930552', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930592', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930632', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930672', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930712', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930752', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930792', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930832', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930872', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930912', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930952', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930992', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931072', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931112', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931152', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931192', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931232', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931272', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931352', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931392', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931432', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931472', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931512', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931552', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931592', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931632', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931672', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931712', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931752', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931792', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931832', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931872', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931912', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931952', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931992', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932032', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932072', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932112', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932152', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932192', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932232', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932272', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932312', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932352', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932392', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932432', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932472', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931032', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_929752', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929112', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928792', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928632', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928552', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928512', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_931312', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_929992', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929312', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928952', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928752', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928672', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928592', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ameloblastoma', 'efo_term': 'ameloblastoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1947 | Q34 | What are the names of the genes that are targeted by the drug Vosoritide in the treatment of bone disease? | In the context of bone disease, the drug Vosoritide targets the gene natriuretic peptide receptor 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%bone disease%" OR LOWER(efo_term) LIKE "%bone disease%") AND (LOWER(drugName) LIKE "%vosoritide%" OR LOWER(tradeNames_list) LIKE "%vosoritide%" OR LOWER(syns_list) LIKE "%vosoritide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1192675', 'drugName': 'Vosoritide', 'tradeNames_list': "['Voxzogo']", 'syns_list': "['BMN 111', 'BMN-111', 'Bmn 111', 'Vosoritide', 'Voxzogo']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bone Diseases', 'efo_term': 'bone disease', 'approvedSymbol': 'NPR2', 'approvedName': 'natriuretic peptide receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_1192684', 'drugName': 'Vosoritide', 'tradeNames_list': "['Voxzogo']", 'syns_list': "['BMN 111', 'BMN-111', 'Bmn 111', 'Vosoritide', 'Voxzogo']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bone Diseases', 'efo_term': 'bone disease', 'approvedSymbol': 'NPR2', 'approvedName': 'natriuretic peptide receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_1192687', 'drugName': 'Vosoritide', 'tradeNames_list': "['Voxzogo']", 'syns_list': "['BMN 111', 'BMN-111', 'Bmn 111', 'Vosoritide', 'Voxzogo']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bone Diseases', 'efo_term': 'bone disease', 'approvedSymbol': 'NPR2', 'approvedName': 'natriuretic peptide receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_1192690', 'drugName': 'Vosoritide', 'tradeNames_list': "['Voxzogo']", 'syns_list': "['BMN 111', 'BMN-111', 'Bmn 111', 'Vosoritide', 'Voxzogo']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bone Diseases', 'efo_term': 'bone disease', 'approvedSymbol': 'NPR2', 'approvedName': 'natriuretic peptide receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_1192681', 'drugName': 'Vosoritide', 'tradeNames_list': "['Voxzogo']", 'syns_list': "['BMN 111', 'BMN-111', 'Bmn 111', 'Vosoritide', 'Voxzogo']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bone Diseases', 'efo_term': 'bone disease', 'approvedSymbol': 'NPR2', 'approvedName': 'natriuretic peptide receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_1192669', 'drugName': 'Vosoritide', 'tradeNames_list': "['Voxzogo']", 'syns_list': "['BMN 111', 'BMN-111', 'Bmn 111', 'Vosoritide', 'Voxzogo']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bone Diseases', 'efo_term': 'bone disease', 'approvedSymbol': 'NPR2', 'approvedName': 'natriuretic peptide receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_1192663', 'drugName': 'Vosoritide', 'tradeNames_list': "['Voxzogo']", 'syns_list': "['BMN 111', 'BMN-111', 'Bmn 111', 'Vosoritide', 'Voxzogo']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bone Diseases', 'efo_term': 'bone disease', 'approvedSymbol': 'NPR2', 'approvedName': 'natriuretic peptide receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_1192660', 'drugName': 'Vosoritide', 'tradeNames_list': "['Voxzogo']", 'syns_list': "['BMN 111', 'BMN-111', 'Bmn 111', 'Vosoritide', 'Voxzogo']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bone Diseases', 'efo_term': 'bone disease', 'approvedSymbol': 'NPR2', 'approvedName': 'natriuretic peptide receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_1192693', 'drugName': 'Vosoritide', 'tradeNames_list': "['Voxzogo']", 'syns_list': "['BMN 111', 'BMN-111', 'Bmn 111', 'Vosoritide', 'Voxzogo']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bone Diseases', 'efo_term': 'bone disease', 'approvedSymbol': 'NPR2', 'approvedName': 'natriuretic peptide receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_1192678', 'drugName': 'Vosoritide', 'tradeNames_list': "['Voxzogo']", 'syns_list': "['BMN 111', 'BMN-111', 'Bmn 111', 'Vosoritide', 'Voxzogo']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bone Diseases', 'efo_term': 'bone disease', 'approvedSymbol': 'NPR2', 'approvedName': 'natriuretic peptide receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_1192672', 'drugName': 'Vosoritide', 'tradeNames_list': "['Voxzogo']", 'syns_list': "['BMN 111', 'BMN-111', 'Bmn 111', 'Vosoritide', 'Voxzogo']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bone Diseases', 'efo_term': 'bone disease', 'approvedSymbol': 'NPR2', 'approvedName': 'natriuretic peptide receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_1192666', 'drugName': 'Vosoritide', 'tradeNames_list': "['Voxzogo']", 'syns_list': "['BMN 111', 'BMN-111', 'Bmn 111', 'Vosoritide', 'Voxzogo']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bone Diseases', 'efo_term': 'bone disease', 'approvedSymbol': 'NPR2', 'approvedName': 'natriuretic peptide receptor 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1939 | Q34 | What are the names of the genes that are targeted by the drug Belzutifan in the treatment of von Hippel-Lindau disease? | In the context of von Hippel-Lindau disease, the drug Belzutifan targets the gene endothelial PAS domain protein 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%von hippel-lindau disease%" OR LOWER(efo_term) LIKE "%von hippel-lindau disease%") AND (LOWER(drugName) LIKE "%belzutifan%" OR LOWER(tradeNames_list) LIKE "%belzutifan%" OR LOWER(syns_list) LIKE "%belzutifan%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1192114', 'drugName': 'Belzutifan', 'tradeNames_list': "['Welireg']", 'syns_list': "['Belzutifan', 'MK-6482', 'MK6482', 'Mk-6482', 'PT-2977', 'PT2977', 'Pt 2977Pt2977']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Hippel-Lindau Disease', 'efo_term': 'von Hippel-Lindau disease', 'approvedSymbol': 'EPAS1', 'approvedName': 'endothelial PAS domain protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1192122', 'drugName': 'Belzutifan', 'tradeNames_list': "['Welireg']", 'syns_list': "['Belzutifan', 'MK-6482', 'MK6482', 'Mk-6482', 'PT-2977', 'PT2977', 'Pt 2977Pt2977']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'von Hippel-Lindau Disease', 'efo_term': 'von Hippel-Lindau disease', 'approvedSymbol': 'EPAS1', 'approvedName': 'endothelial PAS domain protein 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.503 | Q34 | What are the names of the genes that are targeted by the drug Amphetamine Sulfate in the treatment of attention deficit hyperactivity disorder? | In the context of attention deficit hyperactivity disorder, the drug Amphetamine Sulfate targets the gene solute carrier family 6 member 2 and solute carrier family 6 member 3. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%attention deficit hyperactivity disorder%" OR LOWER(efo_term) LIKE "%attention deficit hyperactivity disorder%") AND (LOWER(drugName) LIKE "%amphetamine sulfate%" OR LOWER(tradeNames_list) LIKE "%amphetamine sulfate%" OR LOWER(syns_list) LIKE "%amphetamine sulfate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_440697', 'drugName': 'Amphetamine Sulfate', 'tradeNames_list': "['Amphetamine sulfate', 'Benzadrine', 'Evekeo', 'Evekeo odt']", 'syns_list': "['Amfetamine sulfate', 'Amfetamine sulphate', 'Amphetamine SulfateAmphetamine sulfate', 'Astedin', 'Benzedrine', 'Dl-amphetamine sulfateDl-amphetamine sulphate', 'NSC-170999']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440706', 'drugName': 'Amphetamine Sulfate', 'tradeNames_list': "['Amphetamine sulfate', 'Benzadrine', 'Evekeo', 'Evekeo odt']", 'syns_list': "['Amfetamine sulfate', 'Amfetamine sulphate', 'Amphetamine SulfateAmphetamine sulfate', 'Astedin', 'Benzedrine', 'Dl-amphetamine sulfateDl-amphetamine sulphate', 'NSC-170999']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440709', 'drugName': 'Amphetamine Sulfate', 'tradeNames_list': "['Amphetamine sulfate', 'Benzadrine', 'Evekeo', 'Evekeo odt']", 'syns_list': "['Amfetamine sulfate', 'Amfetamine sulphate', 'Amphetamine SulfateAmphetamine sulfate', 'Astedin', 'Benzedrine', 'Dl-amphetamine sulfateDl-amphetamine sulphate', 'NSC-170999']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440712', 'drugName': 'Amphetamine Sulfate', 'tradeNames_list': "['Amphetamine sulfate', 'Benzadrine', 'Evekeo', 'Evekeo odt']", 'syns_list': "['Amfetamine sulfate', 'Amfetamine sulphate', 'Amphetamine SulfateAmphetamine sulfate', 'Astedin', 'Benzedrine', 'Dl-amphetamine sulfateDl-amphetamine sulphate', 'NSC-170999']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440718', 'drugName': 'Amphetamine Sulfate', 'tradeNames_list': "['Amphetamine sulfate', 'Benzadrine', 'Evekeo', 'Evekeo odt']", 'syns_list': "['Amfetamine sulfate', 'Amfetamine sulphate', 'Amphetamine SulfateAmphetamine sulfate', 'Astedin', 'Benzedrine', 'Dl-amphetamine sulfateDl-amphetamine sulphate', 'NSC-170999']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440721', 'drugName': 'Amphetamine Sulfate', 'tradeNames_list': "['Amphetamine sulfate', 'Benzadrine', 'Evekeo', 'Evekeo odt']", 'syns_list': "['Amfetamine sulfate', 'Amfetamine sulphate', 'Amphetamine SulfateAmphetamine sulfate', 'Astedin', 'Benzedrine', 'Dl-amphetamine sulfateDl-amphetamine sulphate', 'NSC-170999']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440724', 'drugName': 'Amphetamine Sulfate', 'tradeNames_list': "['Amphetamine sulfate', 'Benzadrine', 'Evekeo', 'Evekeo odt']", 'syns_list': "['Amfetamine sulfate', 'Amfetamine sulphate', 'Amphetamine SulfateAmphetamine sulfate', 'Astedin', 'Benzedrine', 'Dl-amphetamine sulfateDl-amphetamine sulphate', 'NSC-170999']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440730', 'drugName': 'Amphetamine Sulfate', 'tradeNames_list': "['Amphetamine sulfate', 'Benzadrine', 'Evekeo', 'Evekeo odt']", 'syns_list': "['Amfetamine sulfate', 'Amfetamine sulphate', 'Amphetamine SulfateAmphetamine sulfate', 'Astedin', 'Benzedrine', 'Dl-amphetamine sulfateDl-amphetamine sulphate', 'NSC-170999']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_440733', 'drugName': 'Amphetamine Sulfate', 'tradeNames_list': "['Amphetamine sulfate', 'Benzadrine', 'Evekeo', 'Evekeo odt']", 'syns_list': "['Amfetamine sulfate', 'Amfetamine sulphate', 'Amphetamine SulfateAmphetamine sulfate', 'Astedin', 'Benzedrine', 'Dl-amphetamine sulfateDl-amphetamine sulphate', 'NSC-170999']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_440736', 'drugName': 'Amphetamine Sulfate', 'tradeNames_list': "['Amphetamine sulfate', 'Benzadrine', 'Evekeo', 'Evekeo odt']", 'syns_list': "['Amfetamine sulfate', 'Amfetamine sulphate', 'Amphetamine SulfateAmphetamine sulfate', 'Astedin', 'Benzedrine', 'Dl-amphetamine sulfateDl-amphetamine sulphate', 'NSC-170999']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_440739', 'drugName': 'Amphetamine Sulfate', 'tradeNames_list': "['Amphetamine sulfate', 'Benzadrine', 'Evekeo', 'Evekeo odt']", 'syns_list': "['Amfetamine sulfate', 'Amfetamine sulphate', 'Amphetamine SulfateAmphetamine sulfate', 'Astedin', 'Benzedrine', 'Dl-amphetamine sulfateDl-amphetamine sulphate', 'NSC-170999']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_440745', 'drugName': 'Amphetamine Sulfate', 'tradeNames_list': "['Amphetamine sulfate', 'Benzadrine', 'Evekeo', 'Evekeo odt']", 'syns_list': "['Amfetamine sulfate', 'Amfetamine sulphate', 'Amphetamine SulfateAmphetamine sulfate', 'Astedin', 'Benzedrine', 'Dl-amphetamine sulfateDl-amphetamine sulphate', 'NSC-170999']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_440748', 'drugName': 'Amphetamine Sulfate', 'tradeNames_list': "['Amphetamine sulfate', 'Benzadrine', 'Evekeo', 'Evekeo odt']", 'syns_list': "['Amfetamine sulfate', 'Amfetamine sulphate', 'Amphetamine SulfateAmphetamine sulfate', 'Astedin', 'Benzedrine', 'Dl-amphetamine sulfateDl-amphetamine sulphate', 'NSC-170999']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_440751', 'drugName': 'Amphetamine Sulfate', 'tradeNames_list': "['Amphetamine sulfate', 'Benzadrine', 'Evekeo', 'Evekeo odt']", 'syns_list': "['Amfetamine sulfate', 'Amfetamine sulphate', 'Amphetamine SulfateAmphetamine sulfate', 'Astedin', 'Benzedrine', 'Dl-amphetamine sulfateDl-amphetamine sulphate', 'NSC-170999']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_440754', 'drugName': 'Amphetamine Sulfate', 'tradeNames_list': "['Amphetamine sulfate', 'Benzadrine', 'Evekeo', 'Evekeo odt']", 'syns_list': "['Amfetamine sulfate', 'Amfetamine sulphate', 'Amphetamine SulfateAmphetamine sulfate', 'Astedin', 'Benzedrine', 'Dl-amphetamine sulfateDl-amphetamine sulphate', 'NSC-170999']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_440757', 'drugName': 'Amphetamine Sulfate', 'tradeNames_list': "['Amphetamine sulfate', 'Benzadrine', 'Evekeo', 'Evekeo odt']", 'syns_list': "['Amfetamine sulfate', 'Amfetamine sulphate', 'Amphetamine SulfateAmphetamine sulfate', 'Astedin', 'Benzedrine', 'Dl-amphetamine sulfateDl-amphetamine sulphate', 'NSC-170999']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_440760', 'drugName': 'Amphetamine Sulfate', 'tradeNames_list': "['Amphetamine sulfate', 'Benzadrine', 'Evekeo', 'Evekeo odt']", 'syns_list': "['Amfetamine sulfate', 'Amfetamine sulphate', 'Amphetamine SulfateAmphetamine sulfate', 'Astedin', 'Benzedrine', 'Dl-amphetamine sulfateDl-amphetamine sulphate', 'NSC-170999']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_440763', 'drugName': 'Amphetamine Sulfate', 'tradeNames_list': "['Amphetamine sulfate', 'Benzadrine', 'Evekeo', 'Evekeo odt']", 'syns_list': "['Amfetamine sulfate', 'Amfetamine sulphate', 'Amphetamine SulfateAmphetamine sulfate', 'Astedin', 'Benzedrine', 'Dl-amphetamine sulfateDl-amphetamine sulphate', 'NSC-170999']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_440766', 'drugName': 'Amphetamine Sulfate', 'tradeNames_list': "['Amphetamine sulfate', 'Benzadrine', 'Evekeo', 'Evekeo odt']", 'syns_list': "['Amfetamine sulfate', 'Amfetamine sulphate', 'Amphetamine SulfateAmphetamine sulfate', 'Astedin', 'Benzedrine', 'Dl-amphetamine sulfateDl-amphetamine sulphate', 'NSC-170999']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_440769', 'drugName': 'Amphetamine Sulfate', 'tradeNames_list': "['Amphetamine sulfate', 'Benzadrine', 'Evekeo', 'Evekeo odt']", 'syns_list': "['Amfetamine sulfate', 'Amfetamine sulphate', 'Amphetamine SulfateAmphetamine sulfate', 'Astedin', 'Benzedrine', 'Dl-amphetamine sulfateDl-amphetamine sulphate', 'NSC-170999']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_440727', 'drugName': 'Amphetamine Sulfate', 'tradeNames_list': "['Amphetamine sulfate', 'Benzadrine', 'Evekeo', 'Evekeo odt']", 'syns_list': "['Amfetamine sulfate', 'Amfetamine sulphate', 'Amphetamine SulfateAmphetamine sulfate', 'Astedin', 'Benzedrine', 'Dl-amphetamine sulfateDl-amphetamine sulphate', 'NSC-170999']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_440703', 'drugName': 'Amphetamine Sulfate', 'tradeNames_list': "['Amphetamine sulfate', 'Benzadrine', 'Evekeo', 'Evekeo odt']", 'syns_list': "['Amfetamine sulfate', 'Amfetamine sulphate', 'Amphetamine SulfateAmphetamine sulfate', 'Astedin', 'Benzedrine', 'Dl-amphetamine sulfateDl-amphetamine sulphate', 'NSC-170999']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440691', 'drugName': 'Amphetamine Sulfate', 'tradeNames_list': "['Amphetamine sulfate', 'Benzadrine', 'Evekeo', 'Evekeo odt']", 'syns_list': "['Amfetamine sulfate', 'Amfetamine sulphate', 'Amphetamine SulfateAmphetamine sulfate', 'Astedin', 'Benzedrine', 'Dl-amphetamine sulfateDl-amphetamine sulphate', 'NSC-170999']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440685', 'drugName': 'Amphetamine Sulfate', 'tradeNames_list': "['Amphetamine sulfate', 'Benzadrine', 'Evekeo', 'Evekeo odt']", 'syns_list': "['Amfetamine sulfate', 'Amfetamine sulphate', 'Amphetamine SulfateAmphetamine sulfate', 'Astedin', 'Benzedrine', 'Dl-amphetamine sulfateDl-amphetamine sulphate', 'NSC-170999']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440682', 'drugName': 'Amphetamine Sulfate', 'tradeNames_list': "['Amphetamine sulfate', 'Benzadrine', 'Evekeo', 'Evekeo odt']", 'syns_list': "['Amfetamine sulfate', 'Amfetamine sulphate', 'Amphetamine SulfateAmphetamine sulfate', 'Astedin', 'Benzedrine', 'Dl-amphetamine sulfateDl-amphetamine sulphate', 'NSC-170999']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440742', 'drugName': 'Amphetamine Sulfate', 'tradeNames_list': "['Amphetamine sulfate', 'Benzadrine', 'Evekeo', 'Evekeo odt']", 'syns_list': "['Amfetamine sulfate', 'Amfetamine sulphate', 'Amphetamine SulfateAmphetamine sulfate', 'Astedin', 'Benzedrine', 'Dl-amphetamine sulfateDl-amphetamine sulphate', 'NSC-170999']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_440715', 'drugName': 'Amphetamine Sulfate', 'tradeNames_list': "['Amphetamine sulfate', 'Benzadrine', 'Evekeo', 'Evekeo odt']", 'syns_list': "['Amfetamine sulfate', 'Amfetamine sulphate', 'Amphetamine SulfateAmphetamine sulfate', 'Astedin', 'Benzedrine', 'Dl-amphetamine sulfateDl-amphetamine sulphate', 'NSC-170999']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440700', 'drugName': 'Amphetamine Sulfate', 'tradeNames_list': "['Amphetamine sulfate', 'Benzadrine', 'Evekeo', 'Evekeo odt']", 'syns_list': "['Amfetamine sulfate', 'Amfetamine sulphate', 'Amphetamine SulfateAmphetamine sulfate', 'Astedin', 'Benzedrine', 'Dl-amphetamine sulfateDl-amphetamine sulphate', 'NSC-170999']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440694', 'drugName': 'Amphetamine Sulfate', 'tradeNames_list': "['Amphetamine sulfate', 'Benzadrine', 'Evekeo', 'Evekeo odt']", 'syns_list': "['Amfetamine sulfate', 'Amfetamine sulphate', 'Amphetamine SulfateAmphetamine sulfate', 'Astedin', 'Benzedrine', 'Dl-amphetamine sulfateDl-amphetamine sulphate', 'NSC-170999']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440688', 'drugName': 'Amphetamine Sulfate', 'tradeNames_list': "['Amphetamine sulfate', 'Benzadrine', 'Evekeo', 'Evekeo odt']", 'syns_list': "['Amfetamine sulfate', 'Amfetamine sulphate', 'Amphetamine SulfateAmphetamine sulfate', 'Astedin', 'Benzedrine', 'Dl-amphetamine sulfateDl-amphetamine sulphate', 'NSC-170999']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.340 | Q34 | What are the names of the genes that are targeted by the drug Dexamethasone in the treatment of type III hypersensitivity reaction disease? | In the context of type III hypersensitivity reaction disease, the drug Dexamethasone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%type iii hypersensitivity reaction disease%" OR LOWER(efo_term) LIKE "%type iii hypersensitivity reaction disease%") AND (LOWER(drugName) LIKE "%dexamethasone%" OR LOWER(tradeNames_list) LIKE "%dexamethasone%" OR LOWER(syns_list) LIKE "%dexamethasone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_227796', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228651', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228936', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229221', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229791', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230076', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230361', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230931', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231216', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231501', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231786', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232356', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230646', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228366', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227226', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226656', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226371', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232071', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229506', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228081', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227511', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226941', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Serum Sickness', 'efo_term': 'type III hypersensitivity reaction disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1197 | Q34 | What are the names of the genes that are targeted by the drug Crizotinib in the treatment of neoplasm? | In the context of neoplasm, the drug Crizotinib targets the gene MET proto-oncogene, receptor tyrosine kinase, ALK receptor tyrosine kinase, EMAP like 4 and nucleophosmin 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%neoplasm%" OR LOWER(efo_term) LIKE "%neoplasm%") AND (LOWER(drugName) LIKE "%crizotinib%" OR LOWER(tradeNames_list) LIKE "%crizotinib%" OR LOWER(syns_list) LIKE "%crizotinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_934729', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934465', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934641', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934509', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934749', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934793', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934309', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934289', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934597', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934883', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934969', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935037', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934331', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935191', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935167', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935211', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935213', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935299', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935257', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935301', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934353', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934311', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934815', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934817', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934881', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934595', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934375', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935035', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934639', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934991', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934993', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935079', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934683', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935101', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934397', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935255', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934333', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935189', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935169', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935235', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934771', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935233', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934419', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935343', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934287', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935279', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935277', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935323', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934795', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935321', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934441', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934355', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934619', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934573', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934839', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934553', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934837', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934947', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934575', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934861', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934617', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934927', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934903', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934925', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934485', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935145', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934377', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934705', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934663', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935015', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934971', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935013', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934507', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935125', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934685', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935059', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935057', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935123', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935081', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935103', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934529', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935345', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934399', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934751', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934727', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935367', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935365', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935147', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934949', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934859', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934707', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934551', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934443', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934463', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934905', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934661', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934773', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934421', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934487', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934531', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.29 | Q34 | What are the names of the genes that are targeted by the drug Clozapine in the treatment of psychosis? | In the context of psychosis, the drug Clozapine targets the gene dopamine receptor D2 and 5-hydroxytryptamine receptor 2A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%psychosis%" OR LOWER(efo_term) LIKE "%psychosis%") AND (LOWER(drugName) LIKE "%clozapine%" OR LOWER(tradeNames_list) LIKE "%clozapine%" OR LOWER(syns_list) LIKE "%clozapine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_157984', 'drugName': 'Clozapine', 'tradeNames_list': "['Clozapine', 'Clozaril', 'Fazaclo', 'Fazaclo odt', 'Versacloz', 'Zaponex']", 'syns_list': "['Clozapine', 'Clozapine (caraco)', 'Clozapine (clozaril)Clozapine (fazaclo)', 'Clozapine (ivax)', 'Clozapine (mylan)Clozapine (teva)', 'Clozapine (udl)', 'Clozapine (versacloz)Clozapine resolution mixture', 'HF 1854', 'HF-1854', 'Leponex', 'NSC-757429']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_157993', 'drugName': 'Clozapine', 'tradeNames_list': "['Clozapine', 'Clozaril', 'Fazaclo', 'Fazaclo odt', 'Versacloz', 'Zaponex']", 'syns_list': "['Clozapine', 'Clozapine (caraco)', 'Clozapine (clozaril)Clozapine (fazaclo)', 'Clozapine (ivax)', 'Clozapine (mylan)Clozapine (teva)', 'Clozapine (udl)', 'Clozapine (versacloz)Clozapine resolution mixture', 'HF 1854', 'HF-1854', 'Leponex', 'NSC-757429']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1226 | Q34 | What are the names of the genes that are targeted by the drug Dihydroergotamine Mesylate in the treatment of migraine disorder? | In the context of migraine disorder, the drug Dihydroergotamine Mesylate targets the gene 5-hydroxytryptamine receptor 1D. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%migraine disorder%" OR LOWER(efo_term) LIKE "%migraine disorder%") AND (LOWER(drugName) LIKE "%dihydroergotamine mesylate%" OR LOWER(tradeNames_list) LIKE "%dihydroergotamine mesylate%" OR LOWER(syns_list) LIKE "%dihydroergotamine mesylate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_937542', 'drugName': 'Dihydroergotamine Mesylate', 'tradeNames_list': "['D.h.e. 45', 'Diergo', 'Dihydergot', 'Dihydroergotamine mesylate', 'TonopanTrudhesa']", 'syns_list': "['DHE-45', 'Dihydroergotamine MethanesulfonateDihydroergotamine mesilate', 'Dihydroergotamine mesylateDihydroergotamine methanesulfonate', 'Migranal', 'NSC-759848']", 'yearOfFirstApproval': 1946, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D'}, {'UUID': 'DrugTargetsIndication121923_text_937538', 'drugName': 'Dihydroergotamine Mesylate', 'tradeNames_list': "['D.h.e. 45', 'Diergo', 'Dihydergot', 'Dihydroergotamine mesylate', 'TonopanTrudhesa']", 'syns_list': "['DHE-45', 'Dihydroergotamine MethanesulfonateDihydroergotamine mesilate', 'Dihydroergotamine mesylateDihydroergotamine methanesulfonate', 'Migranal', 'NSC-759848']", 'yearOfFirstApproval': 1946, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D'}, {'UUID': 'DrugTargetsIndication121923_text_937537', 'drugName': 'Dihydroergotamine Mesylate', 'tradeNames_list': "['D.h.e. 45', 'Diergo', 'Dihydergot', 'Dihydroergotamine mesylate', 'TonopanTrudhesa']", 'syns_list': "['DHE-45', 'Dihydroergotamine MethanesulfonateDihydroergotamine mesilate', 'Dihydroergotamine mesylateDihydroergotamine methanesulfonate', 'Migranal', 'NSC-759848']", 'yearOfFirstApproval': 1946, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D'}, {'UUID': 'DrugTargetsIndication121923_text_937540', 'drugName': 'Dihydroergotamine Mesylate', 'tradeNames_list': "['D.h.e. 45', 'Diergo', 'Dihydergot', 'Dihydroergotamine mesylate', 'TonopanTrudhesa']", 'syns_list': "['DHE-45', 'Dihydroergotamine MethanesulfonateDihydroergotamine mesilate', 'Dihydroergotamine mesylateDihydroergotamine methanesulfonate', 'Migranal', 'NSC-759848']", 'yearOfFirstApproval': 1946, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D'}, {'UUID': 'DrugTargetsIndication121923_text_937541', 'drugName': 'Dihydroergotamine Mesylate', 'tradeNames_list': "['D.h.e. 45', 'Diergo', 'Dihydergot', 'Dihydroergotamine mesylate', 'TonopanTrudhesa']", 'syns_list': "['DHE-45', 'Dihydroergotamine MethanesulfonateDihydroergotamine mesilate', 'Dihydroergotamine mesylateDihydroergotamine methanesulfonate', 'Migranal', 'NSC-759848']", 'yearOfFirstApproval': 1946, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D'}, {'UUID': 'DrugTargetsIndication121923_text_937539', 'drugName': 'Dihydroergotamine Mesylate', 'tradeNames_list': "['D.h.e. 45', 'Diergo', 'Dihydergot', 'Dihydroergotamine mesylate', 'TonopanTrudhesa']", 'syns_list': "['DHE-45', 'Dihydroergotamine MethanesulfonateDihydroergotamine mesilate', 'Dihydroergotamine mesylateDihydroergotamine methanesulfonate', 'Migranal', 'NSC-759848']", 'yearOfFirstApproval': 1946, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1310 | Q34 | What are the names of the genes that are targeted by the drug Nitroglycerin in the treatment of angina pectoris? | In the context of angina pectoris, the drug Nitroglycerin targets the gene guanylate cyclase 1 soluble subunit beta 1, guanylate cyclase 1 soluble subunit beta 2 (pseudogene), guanylate cyclase 1 soluble subunit alpha 2 and guanylate cyclase 1 soluble subunit alpha 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%angina pectoris%" OR LOWER(efo_term) LIKE "%angina pectoris%") AND (LOWER(drugName) LIKE "%nitroglycerin%" OR LOWER(tradeNames_list) LIKE "%nitroglycerin%" OR LOWER(syns_list) LIKE "%nitroglycerin%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_972651', 'drugName': 'Nitroglycerin', 'tradeNames_list': "['Coro-nitro', 'Deponit 10', 'Deponit 5', 'Glytrin', 'Gonitro', 'Lenitral 7.5Minitran', 'Minitran 10', 'Minitran 15', 'Minitran 5', 'NatiroseNitriderm tts', 'Nitro iv', 'Nitro-bid', 'Nitro-dur', 'Nitro-mack retNitrocine', 'Nitrocontin continus', 'Nitroglycerin', 'NitrolNitrolingual', 'Nitrolingual pumpspray', 'Nitromin', 'Nitromist', 'NitronalNitrostat', 'Percutol', 'Rectiv', 'Rectogesic', 'Suscard buccal', 'SustacTransderm-nitro', 'Transiderm-nitro 10', 'Transiderm-nitro 5', 'TridilTrintek 10', 'Trintek 15', 'Trintek 5']", 'syns_list': "['C01DA02', 'Chlormethine oxide hydrochloride', 'Diluted nitroglycerinGlonoinum', 'Glyceryl Trinitrate', 'Glyceryl trinitrateGlyceryl trinitrate solution', 'Imx-150', 'Mechlorethamine oxide hclMitomen', 'Mustron', 'Nitora', 'Nitroglycerin', 'Nitroglycerin tabletsNitromin hydrochloride', 'Transderm-Nitro', 'TrinitrinTrinitrin tablets', 'Trinitrine']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris', 'approvedSymbol': 'GUCY1A2', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 2'}, {'UUID': 'DrugTargetsIndication121923_text_972719', 'drugName': 'Nitroglycerin', 'tradeNames_list': "['Coro-nitro', 'Deponit 10', 'Deponit 5', 'Glytrin', 'Gonitro', 'Lenitral 7.5Minitran', 'Minitran 10', 'Minitran 15', 'Minitran 5', 'NatiroseNitriderm tts', 'Nitro iv', 'Nitro-bid', 'Nitro-dur', 'Nitro-mack retNitrocine', 'Nitrocontin continus', 'Nitroglycerin', 'NitrolNitrolingual', 'Nitrolingual pumpspray', 'Nitromin', 'Nitromist', 'NitronalNitrostat', 'Percutol', 'Rectiv', 'Rectogesic', 'Suscard buccal', 'SustacTransderm-nitro', 'Transiderm-nitro 10', 'Transiderm-nitro 5', 'TridilTrintek 10', 'Trintek 15', 'Trintek 5']", 'syns_list': "['C01DA02', 'Chlormethine oxide hydrochloride', 'Diluted nitroglycerinGlonoinum', 'Glyceryl Trinitrate', 'Glyceryl trinitrateGlyceryl trinitrate solution', 'Imx-150', 'Mechlorethamine oxide hclMitomen', 'Mustron', 'Nitora', 'Nitroglycerin', 'Nitroglycerin tabletsNitromin hydrochloride', 'Transderm-Nitro', 'TrinitrinTrinitrin tablets', 'Trinitrine']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris', 'approvedSymbol': 'GUCY1A1', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 1'}, {'UUID': 'DrugTargetsIndication121923_text_972583', 'drugName': 'Nitroglycerin', 'tradeNames_list': "['Coro-nitro', 'Deponit 10', 'Deponit 5', 'Glytrin', 'Gonitro', 'Lenitral 7.5Minitran', 'Minitran 10', 'Minitran 15', 'Minitran 5', 'NatiroseNitriderm tts', 'Nitro iv', 'Nitro-bid', 'Nitro-dur', 'Nitro-mack retNitrocine', 'Nitrocontin continus', 'Nitroglycerin', 'NitrolNitrolingual', 'Nitrolingual pumpspray', 'Nitromin', 'Nitromist', 'NitronalNitrostat', 'Percutol', 'Rectiv', 'Rectogesic', 'Suscard buccal', 'SustacTransderm-nitro', 'Transiderm-nitro 10', 'Transiderm-nitro 5', 'TridilTrintek 10', 'Trintek 15', 'Trintek 5']", 'syns_list': "['C01DA02', 'Chlormethine oxide hydrochloride', 'Diluted nitroglycerinGlonoinum', 'Glyceryl Trinitrate', 'Glyceryl trinitrateGlyceryl trinitrate solution', 'Imx-150', 'Mechlorethamine oxide hclMitomen', 'Mustron', 'Nitora', 'Nitroglycerin', 'Nitroglycerin tabletsNitromin hydrochloride', 'Transderm-Nitro', 'TrinitrinTrinitrin tablets', 'Trinitrine']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_972515', 'drugName': 'Nitroglycerin', 'tradeNames_list': "['Coro-nitro', 'Deponit 10', 'Deponit 5', 'Glytrin', 'Gonitro', 'Lenitral 7.5Minitran', 'Minitran 10', 'Minitran 15', 'Minitran 5', 'NatiroseNitriderm tts', 'Nitro iv', 'Nitro-bid', 'Nitro-dur', 'Nitro-mack retNitrocine', 'Nitrocontin continus', 'Nitroglycerin', 'NitrolNitrolingual', 'Nitrolingual pumpspray', 'Nitromin', 'Nitromist', 'NitronalNitrostat', 'Percutol', 'Rectiv', 'Rectogesic', 'Suscard buccal', 'SustacTransderm-nitro', 'Transiderm-nitro 10', 'Transiderm-nitro 5', 'TridilTrintek 10', 'Trintek 15', 'Trintek 5']", 'syns_list': "['C01DA02', 'Chlormethine oxide hydrochloride', 'Diluted nitroglycerinGlonoinum', 'Glyceryl Trinitrate', 'Glyceryl trinitrateGlyceryl trinitrate solution', 'Imx-150', 'Mechlorethamine oxide hclMitomen', 'Mustron', 'Nitora', 'Nitroglycerin', 'Nitroglycerin tabletsNitromin hydrochloride', 'Transderm-Nitro', 'TrinitrinTrinitrin tablets', 'Trinitrine']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972481', 'drugName': 'Nitroglycerin', 'tradeNames_list': "['Coro-nitro', 'Deponit 10', 'Deponit 5', 'Glytrin', 'Gonitro', 'Lenitral 7.5Minitran', 'Minitran 10', 'Minitran 15', 'Minitran 5', 'NatiroseNitriderm tts', 'Nitro iv', 'Nitro-bid', 'Nitro-dur', 'Nitro-mack retNitrocine', 'Nitrocontin continus', 'Nitroglycerin', 'NitrolNitrolingual', 'Nitrolingual pumpspray', 'Nitromin', 'Nitromist', 'NitronalNitrostat', 'Percutol', 'Rectiv', 'Rectogesic', 'Suscard buccal', 'SustacTransderm-nitro', 'Transiderm-nitro 10', 'Transiderm-nitro 5', 'TridilTrintek 10', 'Trintek 15', 'Trintek 5']", 'syns_list': "['C01DA02', 'Chlormethine oxide hydrochloride', 'Diluted nitroglycerinGlonoinum', 'Glyceryl Trinitrate', 'Glyceryl trinitrateGlyceryl trinitrate solution', 'Imx-150', 'Mechlorethamine oxide hclMitomen', 'Mustron', 'Nitora', 'Nitroglycerin', 'Nitroglycerin tabletsNitromin hydrochloride', 'Transderm-Nitro', 'TrinitrinTrinitrin tablets', 'Trinitrine']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972685', 'drugName': 'Nitroglycerin', 'tradeNames_list': "['Coro-nitro', 'Deponit 10', 'Deponit 5', 'Glytrin', 'Gonitro', 'Lenitral 7.5Minitran', 'Minitran 10', 'Minitran 15', 'Minitran 5', 'NatiroseNitriderm tts', 'Nitro iv', 'Nitro-bid', 'Nitro-dur', 'Nitro-mack retNitrocine', 'Nitrocontin continus', 'Nitroglycerin', 'NitrolNitrolingual', 'Nitrolingual pumpspray', 'Nitromin', 'Nitromist', 'NitronalNitrostat', 'Percutol', 'Rectiv', 'Rectogesic', 'Suscard buccal', 'SustacTransderm-nitro', 'Transiderm-nitro 10', 'Transiderm-nitro 5', 'TridilTrintek 10', 'Trintek 15', 'Trintek 5']", 'syns_list': "['C01DA02', 'Chlormethine oxide hydrochloride', 'Diluted nitroglycerinGlonoinum', 'Glyceryl Trinitrate', 'Glyceryl trinitrateGlyceryl trinitrate solution', 'Imx-150', 'Mechlorethamine oxide hclMitomen', 'Mustron', 'Nitora', 'Nitroglycerin', 'Nitroglycerin tabletsNitromin hydrochloride', 'Transderm-Nitro', 'TrinitrinTrinitrin tablets', 'Trinitrine']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris', 'approvedSymbol': 'GUCY1A1', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 1'}, {'UUID': 'DrugTargetsIndication121923_text_972617', 'drugName': 'Nitroglycerin', 'tradeNames_list': "['Coro-nitro', 'Deponit 10', 'Deponit 5', 'Glytrin', 'Gonitro', 'Lenitral 7.5Minitran', 'Minitran 10', 'Minitran 15', 'Minitran 5', 'NatiroseNitriderm tts', 'Nitro iv', 'Nitro-bid', 'Nitro-dur', 'Nitro-mack retNitrocine', 'Nitrocontin continus', 'Nitroglycerin', 'NitrolNitrolingual', 'Nitrolingual pumpspray', 'Nitromin', 'Nitromist', 'NitronalNitrostat', 'Percutol', 'Rectiv', 'Rectogesic', 'Suscard buccal', 'SustacTransderm-nitro', 'Transiderm-nitro 10', 'Transiderm-nitro 5', 'TridilTrintek 10', 'Trintek 15', 'Trintek 5']", 'syns_list': "['C01DA02', 'Chlormethine oxide hydrochloride', 'Diluted nitroglycerinGlonoinum', 'Glyceryl Trinitrate', 'Glyceryl trinitrateGlyceryl trinitrate solution', 'Imx-150', 'Mechlorethamine oxide hclMitomen', 'Mustron', 'Nitora', 'Nitroglycerin', 'Nitroglycerin tabletsNitromin hydrochloride', 'Transderm-Nitro', 'TrinitrinTrinitrin tablets', 'Trinitrine']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris', 'approvedSymbol': 'GUCY1A2', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 2'}, {'UUID': 'DrugTargetsIndication121923_text_972549', 'drugName': 'Nitroglycerin', 'tradeNames_list': "['Coro-nitro', 'Deponit 10', 'Deponit 5', 'Glytrin', 'Gonitro', 'Lenitral 7.5Minitran', 'Minitran 10', 'Minitran 15', 'Minitran 5', 'NatiroseNitriderm tts', 'Nitro iv', 'Nitro-bid', 'Nitro-dur', 'Nitro-mack retNitrocine', 'Nitrocontin continus', 'Nitroglycerin', 'NitrolNitrolingual', 'Nitrolingual pumpspray', 'Nitromin', 'Nitromist', 'NitronalNitrostat', 'Percutol', 'Rectiv', 'Rectogesic', 'Suscard buccal', 'SustacTransderm-nitro', 'Transiderm-nitro 10', 'Transiderm-nitro 5', 'TridilTrintek 10', 'Trintek 15', 'Trintek 5']", 'syns_list': "['C01DA02', 'Chlormethine oxide hydrochloride', 'Diluted nitroglycerinGlonoinum', 'Glyceryl Trinitrate', 'Glyceryl trinitrateGlyceryl trinitrate solution', 'Imx-150', 'Mechlorethamine oxide hclMitomen', 'Mustron', 'Nitora', 'Nitroglycerin', 'Nitroglycerin tabletsNitromin hydrochloride', 'Transderm-Nitro', 'TrinitrinTrinitrin tablets', 'Trinitrine']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1804 | Q34 | What are the names of the genes that are targeted by the drug Famotidine in the treatment of gastric ulcer? | In the context of gastric ulcer, the drug Famotidine targets the gene histamine receptor H2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%gastric ulcer%" OR LOWER(efo_term) LIKE "%gastric ulcer%") AND (LOWER(drugName) LIKE "%famotidine%" OR LOWER(tradeNames_list) LIKE "%famotidine%" OR LOWER(syns_list) LIKE "%famotidine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1100338', 'drugName': 'Famotidine', 'tradeNames_list': "['Famotidine', 'Famotidine preservative freeFamotidine preservative free (pharmacy bulk)', 'Fluxid', 'PepcidPepcid ac', 'Pepcid preservative free', 'Pepcid rpd']", 'syns_list': "['Amfamox', 'Fadul', 'Famodil', 'Famosan', 'Famotidine', 'Famoxal', 'GanorGastridin', 'Gastropen', 'L 643341', 'Lecedil', 'MK-208', 'Motiax', 'MucloxNSC-757810', 'Pepcidac', 'Pepdine', 'Pepdul', 'YM-11170']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer', 'approvedSymbol': 'HRH2', 'approvedName': 'histamine receptor H2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.952 | Q34 | What are the names of the genes that are targeted by the drug Meloxicam in the treatment of juvenile idiopathic arthritis? | In the context of juvenile idiopathic arthritis, the drug Meloxicam targets the gene prostaglandin-endoperoxide synthase 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%juvenile idiopathic arthritis%" OR LOWER(efo_term) LIKE "%juvenile idiopathic arthritis%") AND (LOWER(drugName) LIKE "%meloxicam%" OR LOWER(tradeNames_list) LIKE "%meloxicam%" OR LOWER(syns_list) LIKE "%meloxicam%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_842374', 'drugName': 'Meloxicam', 'tradeNames_list': "['Anjeso', 'Meloxicam', 'Mobic', 'Qmiiz odt', 'Vivlodex']", 'syns_list': "['Acticam', 'Contacera', 'Coxicam', 'Emdocam', 'Flexicam', 'Inflacam', 'LoxicomMelfax', 'Melosus', 'Melovem', 'Meloxicam', 'Meloxidolor', 'MeloxidylMeloxivet', 'Meloxoral', 'Metacam', 'Movatec', 'N-1539', 'N1539', 'RecocamRevitacam', 'Rheumocam', 'UH-AC 62XX', 'UH-AC-62 XX', 'UHAC-62XX']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842419', 'drugName': 'Meloxicam', 'tradeNames_list': "['Anjeso', 'Meloxicam', 'Mobic', 'Qmiiz odt', 'Vivlodex']", 'syns_list': "['Acticam', 'Contacera', 'Coxicam', 'Emdocam', 'Flexicam', 'Inflacam', 'LoxicomMelfax', 'Melosus', 'Melovem', 'Meloxicam', 'Meloxidolor', 'MeloxidylMeloxivet', 'Meloxoral', 'Metacam', 'Movatec', 'N-1539', 'N1539', 'RecocamRevitacam', 'Rheumocam', 'UH-AC 62XX', 'UH-AC-62 XX', 'UHAC-62XX']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842434', 'drugName': 'Meloxicam', 'tradeNames_list': "['Anjeso', 'Meloxicam', 'Mobic', 'Qmiiz odt', 'Vivlodex']", 'syns_list': "['Acticam', 'Contacera', 'Coxicam', 'Emdocam', 'Flexicam', 'Inflacam', 'LoxicomMelfax', 'Melosus', 'Melovem', 'Meloxicam', 'Meloxidolor', 'MeloxidylMeloxivet', 'Meloxoral', 'Metacam', 'Movatec', 'N-1539', 'N1539', 'RecocamRevitacam', 'Rheumocam', 'UH-AC 62XX', 'UH-AC-62 XX', 'UHAC-62XX']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842449', 'drugName': 'Meloxicam', 'tradeNames_list': "['Anjeso', 'Meloxicam', 'Mobic', 'Qmiiz odt', 'Vivlodex']", 'syns_list': "['Acticam', 'Contacera', 'Coxicam', 'Emdocam', 'Flexicam', 'Inflacam', 'LoxicomMelfax', 'Melosus', 'Melovem', 'Meloxicam', 'Meloxidolor', 'MeloxidylMeloxivet', 'Meloxoral', 'Metacam', 'Movatec', 'N-1539', 'N1539', 'RecocamRevitacam', 'Rheumocam', 'UH-AC 62XX', 'UH-AC-62 XX', 'UHAC-62XX']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842479', 'drugName': 'Meloxicam', 'tradeNames_list': "['Anjeso', 'Meloxicam', 'Mobic', 'Qmiiz odt', 'Vivlodex']", 'syns_list': "['Acticam', 'Contacera', 'Coxicam', 'Emdocam', 'Flexicam', 'Inflacam', 'LoxicomMelfax', 'Melosus', 'Melovem', 'Meloxicam', 'Meloxidolor', 'MeloxidylMeloxivet', 'Meloxoral', 'Metacam', 'Movatec', 'N-1539', 'N1539', 'RecocamRevitacam', 'Rheumocam', 'UH-AC 62XX', 'UH-AC-62 XX', 'UHAC-62XX']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842494', 'drugName': 'Meloxicam', 'tradeNames_list': "['Anjeso', 'Meloxicam', 'Mobic', 'Qmiiz odt', 'Vivlodex']", 'syns_list': "['Acticam', 'Contacera', 'Coxicam', 'Emdocam', 'Flexicam', 'Inflacam', 'LoxicomMelfax', 'Melosus', 'Melovem', 'Meloxicam', 'Meloxidolor', 'MeloxidylMeloxivet', 'Meloxoral', 'Metacam', 'Movatec', 'N-1539', 'N1539', 'RecocamRevitacam', 'Rheumocam', 'UH-AC 62XX', 'UH-AC-62 XX', 'UHAC-62XX']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842509', 'drugName': 'Meloxicam', 'tradeNames_list': "['Anjeso', 'Meloxicam', 'Mobic', 'Qmiiz odt', 'Vivlodex']", 'syns_list': "['Acticam', 'Contacera', 'Coxicam', 'Emdocam', 'Flexicam', 'Inflacam', 'LoxicomMelfax', 'Melosus', 'Melovem', 'Meloxicam', 'Meloxidolor', 'MeloxidylMeloxivet', 'Meloxoral', 'Metacam', 'Movatec', 'N-1539', 'N1539', 'RecocamRevitacam', 'Rheumocam', 'UH-AC 62XX', 'UH-AC-62 XX', 'UHAC-62XX']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842539', 'drugName': 'Meloxicam', 'tradeNames_list': "['Anjeso', 'Meloxicam', 'Mobic', 'Qmiiz odt', 'Vivlodex']", 'syns_list': "['Acticam', 'Contacera', 'Coxicam', 'Emdocam', 'Flexicam', 'Inflacam', 'LoxicomMelfax', 'Melosus', 'Melovem', 'Meloxicam', 'Meloxidolor', 'MeloxidylMeloxivet', 'Meloxoral', 'Metacam', 'Movatec', 'N-1539', 'N1539', 'RecocamRevitacam', 'Rheumocam', 'UH-AC 62XX', 'UH-AC-62 XX', 'UHAC-62XX']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842524', 'drugName': 'Meloxicam', 'tradeNames_list': "['Anjeso', 'Meloxicam', 'Mobic', 'Qmiiz odt', 'Vivlodex']", 'syns_list': "['Acticam', 'Contacera', 'Coxicam', 'Emdocam', 'Flexicam', 'Inflacam', 'LoxicomMelfax', 'Melosus', 'Melovem', 'Meloxicam', 'Meloxidolor', 'MeloxidylMeloxivet', 'Meloxoral', 'Metacam', 'Movatec', 'N-1539', 'N1539', 'RecocamRevitacam', 'Rheumocam', 'UH-AC 62XX', 'UH-AC-62 XX', 'UHAC-62XX']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842404', 'drugName': 'Meloxicam', 'tradeNames_list': "['Anjeso', 'Meloxicam', 'Mobic', 'Qmiiz odt', 'Vivlodex']", 'syns_list': "['Acticam', 'Contacera', 'Coxicam', 'Emdocam', 'Flexicam', 'Inflacam', 'LoxicomMelfax', 'Melosus', 'Melovem', 'Meloxicam', 'Meloxidolor', 'MeloxidylMeloxivet', 'Meloxoral', 'Metacam', 'Movatec', 'N-1539', 'N1539', 'RecocamRevitacam', 'Rheumocam', 'UH-AC 62XX', 'UH-AC-62 XX', 'UHAC-62XX']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842344', 'drugName': 'Meloxicam', 'tradeNames_list': "['Anjeso', 'Meloxicam', 'Mobic', 'Qmiiz odt', 'Vivlodex']", 'syns_list': "['Acticam', 'Contacera', 'Coxicam', 'Emdocam', 'Flexicam', 'Inflacam', 'LoxicomMelfax', 'Melosus', 'Melovem', 'Meloxicam', 'Meloxidolor', 'MeloxidylMeloxivet', 'Meloxoral', 'Metacam', 'Movatec', 'N-1539', 'N1539', 'RecocamRevitacam', 'Rheumocam', 'UH-AC 62XX', 'UH-AC-62 XX', 'UHAC-62XX']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842299', 'drugName': 'Meloxicam', 'tradeNames_list': "['Anjeso', 'Meloxicam', 'Mobic', 'Qmiiz odt', 'Vivlodex']", 'syns_list': "['Acticam', 'Contacera', 'Coxicam', 'Emdocam', 'Flexicam', 'Inflacam', 'LoxicomMelfax', 'Melosus', 'Melovem', 'Meloxicam', 'Meloxidolor', 'MeloxidylMeloxivet', 'Meloxoral', 'Metacam', 'Movatec', 'N-1539', 'N1539', 'RecocamRevitacam', 'Rheumocam', 'UH-AC 62XX', 'UH-AC-62 XX', 'UHAC-62XX']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842314', 'drugName': 'Meloxicam', 'tradeNames_list': "['Anjeso', 'Meloxicam', 'Mobic', 'Qmiiz odt', 'Vivlodex']", 'syns_list': "['Acticam', 'Contacera', 'Coxicam', 'Emdocam', 'Flexicam', 'Inflacam', 'LoxicomMelfax', 'Melosus', 'Melovem', 'Meloxicam', 'Meloxidolor', 'MeloxidylMeloxivet', 'Meloxoral', 'Metacam', 'Movatec', 'N-1539', 'N1539', 'RecocamRevitacam', 'Rheumocam', 'UH-AC 62XX', 'UH-AC-62 XX', 'UHAC-62XX']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842464', 'drugName': 'Meloxicam', 'tradeNames_list': "['Anjeso', 'Meloxicam', 'Mobic', 'Qmiiz odt', 'Vivlodex']", 'syns_list': "['Acticam', 'Contacera', 'Coxicam', 'Emdocam', 'Flexicam', 'Inflacam', 'LoxicomMelfax', 'Melosus', 'Melovem', 'Meloxicam', 'Meloxidolor', 'MeloxidylMeloxivet', 'Meloxoral', 'Metacam', 'Movatec', 'N-1539', 'N1539', 'RecocamRevitacam', 'Rheumocam', 'UH-AC 62XX', 'UH-AC-62 XX', 'UHAC-62XX']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842389', 'drugName': 'Meloxicam', 'tradeNames_list': "['Anjeso', 'Meloxicam', 'Mobic', 'Qmiiz odt', 'Vivlodex']", 'syns_list': "['Acticam', 'Contacera', 'Coxicam', 'Emdocam', 'Flexicam', 'Inflacam', 'LoxicomMelfax', 'Melosus', 'Melovem', 'Meloxicam', 'Meloxidolor', 'MeloxidylMeloxivet', 'Meloxoral', 'Metacam', 'Movatec', 'N-1539', 'N1539', 'RecocamRevitacam', 'Rheumocam', 'UH-AC 62XX', 'UH-AC-62 XX', 'UHAC-62XX']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842359', 'drugName': 'Meloxicam', 'tradeNames_list': "['Anjeso', 'Meloxicam', 'Mobic', 'Qmiiz odt', 'Vivlodex']", 'syns_list': "['Acticam', 'Contacera', 'Coxicam', 'Emdocam', 'Flexicam', 'Inflacam', 'LoxicomMelfax', 'Melosus', 'Melovem', 'Meloxicam', 'Meloxidolor', 'MeloxidylMeloxivet', 'Meloxoral', 'Metacam', 'Movatec', 'N-1539', 'N1539', 'RecocamRevitacam', 'Rheumocam', 'UH-AC 62XX', 'UH-AC-62 XX', 'UHAC-62XX']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842329', 'drugName': 'Meloxicam', 'tradeNames_list': "['Anjeso', 'Meloxicam', 'Mobic', 'Qmiiz odt', 'Vivlodex']", 'syns_list': "['Acticam', 'Contacera', 'Coxicam', 'Emdocam', 'Flexicam', 'Inflacam', 'LoxicomMelfax', 'Melosus', 'Melovem', 'Meloxicam', 'Meloxidolor', 'MeloxidylMeloxivet', 'Meloxoral', 'Metacam', 'Movatec', 'N-1539', 'N1539', 'RecocamRevitacam', 'Rheumocam', 'UH-AC 62XX', 'UH-AC-62 XX', 'UHAC-62XX']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.171 | Q34 | What are the names of the genes that are targeted by the drug Prednisone in the treatment of systemic lupus erythematosus? | In the context of systemic lupus erythematosus, the drug Prednisone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%systemic lupus erythematosus%" OR LOWER(efo_term) LIKE "%systemic lupus erythematosus%") AND (LOWER(drugName) LIKE "%prednisone%" OR LOWER(tradeNames_list) LIKE "%prednisone%" OR LOWER(syns_list) LIKE "%prednisone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_218677', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lupus Erythematosus, Systemic', 'efo_term': 'systemic lupus erythematosus', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219301', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lupus Erythematosus, Systemic', 'efo_term': 'systemic lupus erythematosus', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219509', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lupus Erythematosus, Systemic', 'efo_term': 'systemic lupus erythematosus', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219717', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lupus Erythematosus, Systemic', 'efo_term': 'systemic lupus erythematosus', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220133', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lupus Erythematosus, Systemic', 'efo_term': 'systemic lupus erythematosus', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220341', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lupus Erythematosus, Systemic', 'efo_term': 'systemic lupus erythematosus', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220549', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lupus Erythematosus, Systemic', 'efo_term': 'systemic lupus erythematosus', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220757', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lupus Erythematosus, Systemic', 'efo_term': 'systemic lupus erythematosus', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219093', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lupus Erythematosus, Systemic', 'efo_term': 'systemic lupus erythematosus', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218261', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lupus Erythematosus, Systemic', 'efo_term': 'systemic lupus erythematosus', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217845', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lupus Erythematosus, Systemic', 'efo_term': 'systemic lupus erythematosus', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217637', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lupus Erythematosus, Systemic', 'efo_term': 'systemic lupus erythematosus', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219925', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lupus Erythematosus, Systemic', 'efo_term': 'systemic lupus erythematosus', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218885', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lupus Erythematosus, Systemic', 'efo_term': 'systemic lupus erythematosus', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218469', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lupus Erythematosus, Systemic', 'efo_term': 'systemic lupus erythematosus', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218053', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lupus Erythematosus, Systemic', 'efo_term': 'systemic lupus erythematosus', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1389 | Q34 | What are the names of the genes that are targeted by the drug Brimonidine Tartrate in the treatment of open-angle glaucoma? | In the context of open-angle glaucoma, the drug Brimonidine Tartrate targets the gene adrenoceptor alpha 2A, adrenoceptor alpha 2C and adrenoceptor alpha 2B. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%open-angle glaucoma%" OR LOWER(efo_term) LIKE "%open-angle glaucoma%") AND (LOWER(drugName) LIKE "%brimonidine tartrate%" OR LOWER(tradeNames_list) LIKE "%brimonidine tartrate%" OR LOWER(syns_list) LIKE "%brimonidine tartrate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1034128', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034173', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034188', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034203', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034233', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034248', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034263', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034293', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034308', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034323', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034338', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034368', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034383', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034398', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034413', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034428', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034443', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034458', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034473', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034488', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034503', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034533', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034548', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034563', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034578', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034593', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034623', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034638', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034653', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034668', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034683', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034698', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034713', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034728', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034743', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034758', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034773', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034788', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034803', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034818', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034833', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034848', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034863', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034878', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034893', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1034908', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1034923', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1034938', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1034953', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1034968', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1034983', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1035013', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1035028', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1035043', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1035058', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1035073', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1035088', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1035118', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1035133', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1035148', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1035163', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1035178', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1035193', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1035208', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1035223', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1035238', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1035253', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1035268', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1035283', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1035298', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1034998', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1034518', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034278', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034158', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034098', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034068', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034053', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1035103', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1034608', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034353', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034218', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034143', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034113', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034083', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1206 | Q34 | What are the names of the genes that are targeted by the drug Albuterol in the treatment of Bronchospasm? | In the context of Bronchospasm, the drug Albuterol targets the gene adrenoceptor beta 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%bronchospasm%" OR LOWER(efo_term) LIKE "%bronchospasm%") AND (LOWER(drugName) LIKE "%albuterol%" OR LOWER(tradeNames_list) LIKE "%albuterol%" OR LOWER(syns_list) LIKE "%albuterol%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_936282', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936273', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936345', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936246', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936309', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936255', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936219', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936318', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936354', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936291', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936300', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936390', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936399', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936704', 'drugName': 'Albuterol', 'tradeNames_list': "['Aerolin', 'Aerolin 400', 'Aerolin auto', 'Airomir', 'Airsalb', 'AlbuterolAsmasal clickhaler', 'Asmasal spacehaler', 'Asmaven', 'AsmaventCobutolin', 'Combivent', 'Combivent udvs', 'Ipramol steri-neb', 'KentamolLibetist', 'Maxivent', 'Proair Hfa', 'Proventil', 'Proventil Hfa', 'RimasalSalamol e-breathe', 'Salapin', 'Salbulin novolizer', 'SalbuventSalipraneb', 'Steri-neb salamol', 'Ventmax sr', 'Ventodisks', 'VentolinVentolin Hfa', 'Ventolin cr', 'Ventolin e-breathe', 'Volmax']", 'syns_list': "['Accuneb', 'Albuterol', 'Combivent', 'Duoneb', 'Etinoline', 'NSC-757417PROVENTIL-HFA', 'SCH 13949W', 'SCH-13949W', 'Salbutamol', 'SalbutamolumVentoline', 'Volmax']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936417', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936426', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936435', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936444', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936878', 'drugName': 'Albuterol', 'tradeNames_list': "['Aerolin', 'Aerolin 400', 'Aerolin auto', 'Airomir', 'Airsalb', 'AlbuterolAsmasal clickhaler', 'Asmasal spacehaler', 'Asmaven', 'AsmaventCobutolin', 'Combivent', 'Combivent udvs', 'Ipramol steri-neb', 'KentamolLibetist', 'Maxivent', 'Proair Hfa', 'Proventil', 'Proventil Hfa', 'RimasalSalamol e-breathe', 'Salapin', 'Salbulin novolizer', 'SalbuventSalipraneb', 'Steri-neb salamol', 'Ventmax sr', 'Ventodisks', 'VentolinVentolin Hfa', 'Ventolin cr', 'Ventolin e-breathe', 'Volmax']", 'syns_list': "['Accuneb', 'Albuterol', 'Combivent', 'Duoneb', 'Etinoline', 'NSC-757417PROVENTIL-HFA', 'SCH 13949W', 'SCH-13949W', 'Salbutamol', 'SalbutamolumVentoline', 'Volmax']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936327', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936471', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936489', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936498', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936363', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936372', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936525', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936543', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936552', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936561', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936570', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936579', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936588', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936617', 'drugName': 'Albuterol', 'tradeNames_list': "['Aerolin', 'Aerolin 400', 'Aerolin auto', 'Airomir', 'Airsalb', 'AlbuterolAsmasal clickhaler', 'Asmasal spacehaler', 'Asmaven', 'AsmaventCobutolin', 'Combivent', 'Combivent udvs', 'Ipramol steri-neb', 'KentamolLibetist', 'Maxivent', 'Proair Hfa', 'Proventil', 'Proventil Hfa', 'RimasalSalamol e-breathe', 'Salapin', 'Salbulin novolizer', 'SalbuventSalipraneb', 'Steri-neb salamol', 'Ventmax sr', 'Ventodisks', 'VentolinVentolin Hfa', 'Ventolin cr', 'Ventolin e-breathe', 'Volmax']", 'syns_list': "['Accuneb', 'Albuterol', 'Combivent', 'Duoneb', 'Etinoline', 'NSC-757417PROVENTIL-HFA', 'SCH 13949W', 'SCH-13949W', 'Salbutamol', 'SalbutamolumVentoline', 'Volmax']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936646', 'drugName': 'Albuterol', 'tradeNames_list': "['Aerolin', 'Aerolin 400', 'Aerolin auto', 'Airomir', 'Airsalb', 'AlbuterolAsmasal clickhaler', 'Asmasal spacehaler', 'Asmaven', 'AsmaventCobutolin', 'Combivent', 'Combivent udvs', 'Ipramol steri-neb', 'KentamolLibetist', 'Maxivent', 'Proair Hfa', 'Proventil', 'Proventil Hfa', 'RimasalSalamol e-breathe', 'Salapin', 'Salbulin novolizer', 'SalbuventSalipraneb', 'Steri-neb salamol', 'Ventmax sr', 'Ventodisks', 'VentolinVentolin Hfa', 'Ventolin cr', 'Ventolin e-breathe', 'Volmax']", 'syns_list': "['Accuneb', 'Albuterol', 'Combivent', 'Duoneb', 'Etinoline', 'NSC-757417PROVENTIL-HFA', 'SCH 13949W', 'SCH-13949W', 'Salbutamol', 'SalbutamolumVentoline', 'Volmax']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936675', 'drugName': 'Albuterol', 'tradeNames_list': "['Aerolin', 'Aerolin 400', 'Aerolin auto', 'Airomir', 'Airsalb', 'AlbuterolAsmasal clickhaler', 'Asmasal spacehaler', 'Asmaven', 'AsmaventCobutolin', 'Combivent', 'Combivent udvs', 'Ipramol steri-neb', 'KentamolLibetist', 'Maxivent', 'Proair Hfa', 'Proventil', 'Proventil Hfa', 'RimasalSalamol e-breathe', 'Salapin', 'Salbulin novolizer', 'SalbuventSalipraneb', 'Steri-neb salamol', 'Ventmax sr', 'Ventodisks', 'VentolinVentolin Hfa', 'Ventolin cr', 'Ventolin e-breathe', 'Volmax']", 'syns_list': "['Accuneb', 'Albuterol', 'Combivent', 'Duoneb', 'Etinoline', 'NSC-757417PROVENTIL-HFA', 'SCH 13949W', 'SCH-13949W', 'Salbutamol', 'SalbutamolumVentoline', 'Volmax']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936462', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936733', 'drugName': 'Albuterol', 'tradeNames_list': "['Aerolin', 'Aerolin 400', 'Aerolin auto', 'Airomir', 'Airsalb', 'AlbuterolAsmasal clickhaler', 'Asmasal spacehaler', 'Asmaven', 'AsmaventCobutolin', 'Combivent', 'Combivent udvs', 'Ipramol steri-neb', 'KentamolLibetist', 'Maxivent', 'Proair Hfa', 'Proventil', 'Proventil Hfa', 'RimasalSalamol e-breathe', 'Salapin', 'Salbulin novolizer', 'SalbuventSalipraneb', 'Steri-neb salamol', 'Ventmax sr', 'Ventodisks', 'VentolinVentolin Hfa', 'Ventolin cr', 'Ventolin e-breathe', 'Volmax']", 'syns_list': "['Accuneb', 'Albuterol', 'Combivent', 'Duoneb', 'Etinoline', 'NSC-757417PROVENTIL-HFA', 'SCH 13949W', 'SCH-13949W', 'Salbutamol', 'SalbutamolumVentoline', 'Volmax']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936762', 'drugName': 'Albuterol', 'tradeNames_list': "['Aerolin', 'Aerolin 400', 'Aerolin auto', 'Airomir', 'Airsalb', 'AlbuterolAsmasal clickhaler', 'Asmasal spacehaler', 'Asmaven', 'AsmaventCobutolin', 'Combivent', 'Combivent udvs', 'Ipramol steri-neb', 'KentamolLibetist', 'Maxivent', 'Proair Hfa', 'Proventil', 'Proventil Hfa', 'RimasalSalamol e-breathe', 'Salapin', 'Salbulin novolizer', 'SalbuventSalipraneb', 'Steri-neb salamol', 'Ventmax sr', 'Ventodisks', 'VentolinVentolin Hfa', 'Ventolin cr', 'Ventolin e-breathe', 'Volmax']", 'syns_list': "['Accuneb', 'Albuterol', 'Combivent', 'Duoneb', 'Etinoline', 'NSC-757417PROVENTIL-HFA', 'SCH 13949W', 'SCH-13949W', 'Salbutamol', 'SalbutamolumVentoline', 'Volmax']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936791', 'drugName': 'Albuterol', 'tradeNames_list': "['Aerolin', 'Aerolin 400', 'Aerolin auto', 'Airomir', 'Airsalb', 'AlbuterolAsmasal clickhaler', 'Asmasal spacehaler', 'Asmaven', 'AsmaventCobutolin', 'Combivent', 'Combivent udvs', 'Ipramol steri-neb', 'KentamolLibetist', 'Maxivent', 'Proair Hfa', 'Proventil', 'Proventil Hfa', 'RimasalSalamol e-breathe', 'Salapin', 'Salbulin novolizer', 'SalbuventSalipraneb', 'Steri-neb salamol', 'Ventmax sr', 'Ventodisks', 'VentolinVentolin Hfa', 'Ventolin cr', 'Ventolin e-breathe', 'Volmax']", 'syns_list': "['Accuneb', 'Albuterol', 'Combivent', 'Duoneb', 'Etinoline', 'NSC-757417PROVENTIL-HFA', 'SCH 13949W', 'SCH-13949W', 'Salbutamol', 'SalbutamolumVentoline', 'Volmax']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936820', 'drugName': 'Albuterol', 'tradeNames_list': "['Aerolin', 'Aerolin 400', 'Aerolin auto', 'Airomir', 'Airsalb', 'AlbuterolAsmasal clickhaler', 'Asmasal spacehaler', 'Asmaven', 'AsmaventCobutolin', 'Combivent', 'Combivent udvs', 'Ipramol steri-neb', 'KentamolLibetist', 'Maxivent', 'Proair Hfa', 'Proventil', 'Proventil Hfa', 'RimasalSalamol e-breathe', 'Salapin', 'Salbulin novolizer', 'SalbuventSalipraneb', 'Steri-neb salamol', 'Ventmax sr', 'Ventodisks', 'VentolinVentolin Hfa', 'Ventolin cr', 'Ventolin e-breathe', 'Volmax']", 'syns_list': "['Accuneb', 'Albuterol', 'Combivent', 'Duoneb', 'Etinoline', 'NSC-757417PROVENTIL-HFA', 'SCH 13949W', 'SCH-13949W', 'Salbutamol', 'SalbutamolumVentoline', 'Volmax']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936849', 'drugName': 'Albuterol', 'tradeNames_list': "['Aerolin', 'Aerolin 400', 'Aerolin auto', 'Airomir', 'Airsalb', 'AlbuterolAsmasal clickhaler', 'Asmasal spacehaler', 'Asmaven', 'AsmaventCobutolin', 'Combivent', 'Combivent udvs', 'Ipramol steri-neb', 'KentamolLibetist', 'Maxivent', 'Proair Hfa', 'Proventil', 'Proventil Hfa', 'RimasalSalamol e-breathe', 'Salapin', 'Salbulin novolizer', 'SalbuventSalipraneb', 'Steri-neb salamol', 'Ventmax sr', 'Ventodisks', 'VentolinVentolin Hfa', 'Ventolin cr', 'Ventolin e-breathe', 'Volmax']", 'syns_list': "['Accuneb', 'Albuterol', 'Combivent', 'Duoneb', 'Etinoline', 'NSC-757417PROVENTIL-HFA', 'SCH 13949W', 'SCH-13949W', 'Salbutamol', 'SalbutamolumVentoline', 'Volmax']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936516', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936907', 'drugName': 'Albuterol', 'tradeNames_list': "['Aerolin', 'Aerolin 400', 'Aerolin auto', 'Airomir', 'Airsalb', 'AlbuterolAsmasal clickhaler', 'Asmasal spacehaler', 'Asmaven', 'AsmaventCobutolin', 'Combivent', 'Combivent udvs', 'Ipramol steri-neb', 'KentamolLibetist', 'Maxivent', 'Proair Hfa', 'Proventil', 'Proventil Hfa', 'RimasalSalamol e-breathe', 'Salapin', 'Salbulin novolizer', 'SalbuventSalipraneb', 'Steri-neb salamol', 'Ventmax sr', 'Ventodisks', 'VentolinVentolin Hfa', 'Ventolin cr', 'Ventolin e-breathe', 'Volmax']", 'syns_list': "['Accuneb', 'Albuterol', 'Combivent', 'Duoneb', 'Etinoline', 'NSC-757417PROVENTIL-HFA', 'SCH 13949W', 'SCH-13949W', 'Salbutamol', 'SalbutamolumVentoline', 'Volmax']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936936', 'drugName': 'Albuterol', 'tradeNames_list': "['Aerolin', 'Aerolin 400', 'Aerolin auto', 'Airomir', 'Airsalb', 'AlbuterolAsmasal clickhaler', 'Asmasal spacehaler', 'Asmaven', 'AsmaventCobutolin', 'Combivent', 'Combivent udvs', 'Ipramol steri-neb', 'KentamolLibetist', 'Maxivent', 'Proair Hfa', 'Proventil', 'Proventil Hfa', 'RimasalSalamol e-breathe', 'Salapin', 'Salbulin novolizer', 'SalbuventSalipraneb', 'Steri-neb salamol', 'Ventmax sr', 'Ventodisks', 'VentolinVentolin Hfa', 'Ventolin cr', 'Ventolin e-breathe', 'Volmax']", 'syns_list': "['Accuneb', 'Albuterol', 'Combivent', 'Duoneb', 'Etinoline', 'NSC-757417PROVENTIL-HFA', 'SCH 13949W', 'SCH-13949W', 'Salbutamol', 'SalbutamolumVentoline', 'Volmax']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936965', 'drugName': 'Albuterol', 'tradeNames_list': "['Aerolin', 'Aerolin 400', 'Aerolin auto', 'Airomir', 'Airsalb', 'AlbuterolAsmasal clickhaler', 'Asmasal spacehaler', 'Asmaven', 'AsmaventCobutolin', 'Combivent', 'Combivent udvs', 'Ipramol steri-neb', 'KentamolLibetist', 'Maxivent', 'Proair Hfa', 'Proventil', 'Proventil Hfa', 'RimasalSalamol e-breathe', 'Salapin', 'Salbulin novolizer', 'SalbuventSalipraneb', 'Steri-neb salamol', 'Ventmax sr', 'Ventodisks', 'VentolinVentolin Hfa', 'Ventolin cr', 'Ventolin e-breathe', 'Volmax']", 'syns_list': "['Accuneb', 'Albuterol', 'Combivent', 'Duoneb', 'Etinoline', 'NSC-757417PROVENTIL-HFA', 'SCH 13949W', 'SCH-13949W', 'Salbutamol', 'SalbutamolumVentoline', 'Volmax']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936994', 'drugName': 'Albuterol', 'tradeNames_list': "['Aerolin', 'Aerolin 400', 'Aerolin auto', 'Airomir', 'Airsalb', 'AlbuterolAsmasal clickhaler', 'Asmasal spacehaler', 'Asmaven', 'AsmaventCobutolin', 'Combivent', 'Combivent udvs', 'Ipramol steri-neb', 'KentamolLibetist', 'Maxivent', 'Proair Hfa', 'Proventil', 'Proventil Hfa', 'RimasalSalamol e-breathe', 'Salapin', 'Salbulin novolizer', 'SalbuventSalipraneb', 'Steri-neb salamol', 'Ventmax sr', 'Ventodisks', 'VentolinVentolin Hfa', 'Ventolin cr', 'Ventolin e-breathe', 'Volmax']", 'syns_list': "['Accuneb', 'Albuterol', 'Combivent', 'Duoneb', 'Etinoline', 'NSC-757417PROVENTIL-HFA', 'SCH 13949W', 'SCH-13949W', 'Salbutamol', 'SalbutamolumVentoline', 'Volmax']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936453', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936480', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936336', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936264', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936228', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936210', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936507', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936534', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936381', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936408', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936201', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936237', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936999', 'drugName': 'Levalbuterol Tartrate', 'tradeNames_list': "['Xopenex', 'Xopenex hfa']", 'syns_list': "['Levalbuterol tartrate', 'Levosalbutamol tartrate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_937001', 'drugName': 'Levalbuterol Tartrate', 'tradeNames_list': "['Xopenex', 'Xopenex hfa']", 'syns_list': "['Levalbuterol tartrate', 'Levosalbutamol tartrate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1264 | Q34 | What are the names of the genes that are targeted by the drug Progesterone in the treatment of endometrial hyperplasia? | In the context of endometrial hyperplasia, the drug Progesterone targets the gene progesterone receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%endometrial hyperplasia%" OR LOWER(efo_term) LIKE "%endometrial hyperplasia%") AND (LOWER(drugName) LIKE "%progesterone%" OR LOWER(tradeNames_list) LIKE "%progesterone%" OR LOWER(syns_list) LIKE "%progesterone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_940056', 'drugName': 'Progesterone', 'tradeNames_list': "['Crinone', 'Cyclogest', 'Endometrin', 'Gesterol', 'Lutigest', 'MilprosaProchieve', 'Progesta-care', 'Progestasert', 'Progesterone', 'ProgestinPrometrium', 'Regumate', 'Serenity for women', 'Syngestrone', 'Utrogestan']", 'syns_list': "['NSC-64377', 'NSC-9704', 'Progesterone', 'Progesterone, micronizedProgesteronum', 'U 3672']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Endometrial Hyperplasia', 'efo_term': 'endometrial hyperplasia', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_940100', 'drugName': 'Progesterone', 'tradeNames_list': "['Crinone', 'Cyclogest', 'Endometrin', 'Gesterol', 'Lutigest', 'MilprosaProchieve', 'Progesta-care', 'Progestasert', 'Progesterone', 'ProgestinPrometrium', 'Regumate', 'Serenity for women', 'Syngestrone', 'Utrogestan']", 'syns_list': "['NSC-64377', 'NSC-9704', 'Progesterone', 'Progesterone, micronizedProgesteronum', 'U 3672']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Endometrial Hyperplasia', 'efo_term': 'endometrial hyperplasia', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_940144', 'drugName': 'Progesterone', 'tradeNames_list': "['Crinone', 'Cyclogest', 'Endometrin', 'Gesterol', 'Lutigest', 'MilprosaProchieve', 'Progesta-care', 'Progestasert', 'Progesterone', 'ProgestinPrometrium', 'Regumate', 'Serenity for women', 'Syngestrone', 'Utrogestan']", 'syns_list': "['NSC-64377', 'NSC-9704', 'Progesterone', 'Progesterone, micronizedProgesteronum', 'U 3672']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Endometrial Hyperplasia', 'efo_term': 'endometrial hyperplasia', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1562 | Q34 | What are the names of the genes that are targeted by the drug Bosentan in the treatment of congenital heart disease? | In the context of congenital heart disease, the drug Bosentan targets the gene endothelin receptor type A and endothelin receptor type B. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%congenital heart disease%" OR LOWER(efo_term) LIKE "%congenital heart disease%") AND (LOWER(drugName) LIKE "%bosentan%" OR LOWER(tradeNames_list) LIKE "%bosentan%" OR LOWER(syns_list) LIKE "%bosentan%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1084292', 'drugName': 'Bosentan', 'tradeNames_list': "['Tracleer']", 'syns_list': "['Anhydrous bosentan', 'Bosentan', 'Bosentan anhydrous', 'Bosentan hydrateBosentan monohydrate', 'RO 47-0203/029', 'RO-47-0203-029', 'RO-470203029']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Defects, Congenital', 'efo_term': 'congenital heart disease', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084208', 'drugName': 'Bosentan', 'tradeNames_list': "['Tracleer']", 'syns_list': "['Anhydrous bosentan', 'Bosentan', 'Bosentan anhydrous', 'Bosentan hydrateBosentan monohydrate', 'RO 47-0203/029', 'RO-47-0203-029', 'RO-470203029']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Defects, Congenital', 'efo_term': 'congenital heart disease', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084236', 'drugName': 'Bosentan', 'tradeNames_list': "['Tracleer']", 'syns_list': "['Anhydrous bosentan', 'Bosentan', 'Bosentan anhydrous', 'Bosentan hydrateBosentan monohydrate', 'RO 47-0203/029', 'RO-47-0203-029', 'RO-470203029']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Defects, Congenital', 'efo_term': 'congenital heart disease', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084264', 'drugName': 'Bosentan', 'tradeNames_list': "['Tracleer']", 'syns_list': "['Anhydrous bosentan', 'Bosentan', 'Bosentan anhydrous', 'Bosentan hydrateBosentan monohydrate', 'RO 47-0203/029', 'RO-47-0203-029', 'RO-470203029']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Defects, Congenital', 'efo_term': 'congenital heart disease', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084250', 'drugName': 'Bosentan', 'tradeNames_list': "['Tracleer']", 'syns_list': "['Anhydrous bosentan', 'Bosentan', 'Bosentan anhydrous', 'Bosentan hydrateBosentan monohydrate', 'RO 47-0203/029', 'RO-47-0203-029', 'RO-470203029']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hernias, Diaphragmatic, Congenital', 'efo_term': 'congenital heart disease', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084222', 'drugName': 'Bosentan', 'tradeNames_list': "['Tracleer']", 'syns_list': "['Anhydrous bosentan', 'Bosentan', 'Bosentan anhydrous', 'Bosentan hydrateBosentan monohydrate', 'RO 47-0203/029', 'RO-47-0203-029', 'RO-470203029']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hernias, Diaphragmatic, Congenital', 'efo_term': 'congenital heart disease', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084194', 'drugName': 'Bosentan', 'tradeNames_list': "['Tracleer']", 'syns_list': "['Anhydrous bosentan', 'Bosentan', 'Bosentan anhydrous', 'Bosentan hydrateBosentan monohydrate', 'RO 47-0203/029', 'RO-47-0203-029', 'RO-470203029']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hernias, Diaphragmatic, Congenital', 'efo_term': 'congenital heart disease', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084278', 'drugName': 'Bosentan', 'tradeNames_list': "['Tracleer']", 'syns_list': "['Anhydrous bosentan', 'Bosentan', 'Bosentan anhydrous', 'Bosentan hydrateBosentan monohydrate', 'RO 47-0203/029', 'RO-47-0203-029', 'RO-470203029']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hernias, Diaphragmatic, Congenital', 'efo_term': 'congenital heart disease', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.919 | Q34 | What are the names of the genes that are targeted by the drug Naproxen in the treatment of toothache? | In the context of toothache, the drug Naproxen targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%toothache%" OR LOWER(efo_term) LIKE "%toothache%") AND (LOWER(drugName) LIKE "%naproxen%" OR LOWER(tradeNames_list) LIKE "%naproxen%" OR LOWER(syns_list) LIKE "%naproxen%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_839287', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838385', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839205', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838549', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838467', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838672', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839164', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838713', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839123', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838426', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839533', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839492', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838590', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839615', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838754', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839328', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839246', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838877', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838344', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839369', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838918', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839000', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839041', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839082', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839410', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839574', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839697', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838959', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839451', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838631', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838836', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839656', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838508', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838795', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838040', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838057', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838091', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838295', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838176', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838108', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838159', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838193', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838210', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838074', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838125', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838227', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838244', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838142', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838261', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838278', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.495 | Q34 | What are the names of the genes that are targeted by the drug Tapentadol Hydrochloride in the treatment of Chronic pain? | In the context of Chronic pain, the drug Tapentadol Hydrochloride targets the gene solute carrier family 6 member 2 and opioid receptor mu 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%chronic pain%" OR LOWER(efo_term) LIKE "%chronic pain%") AND (LOWER(drugName) LIKE "%tapentadol hydrochloride%" OR LOWER(tradeNames_list) LIKE "%tapentadol hydrochloride%" OR LOWER(syns_list) LIKE "%tapentadol hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_434269', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434284', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434289', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434294', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434304', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434309', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434314', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434324', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434329', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434334', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434339', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434349', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434354', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434359', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434364', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434369', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434374', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434379', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434384', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434389', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434394', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434404', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434409', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434414', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434419', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434424', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434434', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434439', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434444', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434449', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434454', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434459', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434464', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434469', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434474', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434479', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434484', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434489', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434494', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434499', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434504', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434509', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434514', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434519', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434524', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434529', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434534', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434539', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434544', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434549', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434554', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434564', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434569', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434574', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434579', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434584', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434589', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434599', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434604', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434609', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434614', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434619', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434624', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434629', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434634', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_434639', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_434644', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_434649', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_434654', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_434659', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_434664', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_434669', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_434674', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_434679', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_434684', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_434689', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_434694', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_434699', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_434704', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_434709', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_434714', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_434719', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_434724', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_434729', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_434734', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_434739', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_434559', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434399', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434319', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434279', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434259', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434249', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434244', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434594', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434429', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434344', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434299', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434274', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434264', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434254', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.960 | Q34 | What are the names of the genes that are targeted by the drug Diclofenac Potassium in the treatment of rheumatoid arthritis? | In the context of rheumatoid arthritis, the drug Diclofenac Potassium targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%rheumatoid arthritis%" OR LOWER(efo_term) LIKE "%rheumatoid arthritis%") AND (LOWER(drugName) LIKE "%diclofenac potassium%" OR LOWER(tradeNames_list) LIKE "%diclofenac potassium%" OR LOWER(syns_list) LIKE "%diclofenac potassium%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_842935', 'drugName': 'Diclofenac Potassium', 'tradeNames_list': "['Cambia', 'Cataflam', 'Diclofenac potassium', 'Voltarol joint painVoltarol pain-eze', 'Voltarol pain-eze extra strgh', 'Voltarol rapidZipsor']", 'syns_list': "['CGP 45840B', 'CGP-45840B', 'Diclofenac potassiumDiclofenac potassium salt', 'Potassium diclofenac']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842962', 'drugName': 'Diclofenac Potassium', 'tradeNames_list': "['Cambia', 'Cataflam', 'Diclofenac potassium', 'Voltarol joint painVoltarol pain-eze', 'Voltarol pain-eze extra strgh', 'Voltarol rapidZipsor']", 'syns_list': "['CGP 45840B', 'CGP-45840B', 'Diclofenac potassiumDiclofenac potassium salt', 'Potassium diclofenac']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842971', 'drugName': 'Diclofenac Potassium', 'tradeNames_list': "['Cambia', 'Cataflam', 'Diclofenac potassium', 'Voltarol joint painVoltarol pain-eze', 'Voltarol pain-eze extra strgh', 'Voltarol rapidZipsor']", 'syns_list': "['CGP 45840B', 'CGP-45840B', 'Diclofenac potassiumDiclofenac potassium salt', 'Potassium diclofenac']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842980', 'drugName': 'Diclofenac Potassium', 'tradeNames_list': "['Cambia', 'Cataflam', 'Diclofenac potassium', 'Voltarol joint painVoltarol pain-eze', 'Voltarol pain-eze extra strgh', 'Voltarol rapidZipsor']", 'syns_list': "['CGP 45840B', 'CGP-45840B', 'Diclofenac potassiumDiclofenac potassium salt', 'Potassium diclofenac']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842998', 'drugName': 'Diclofenac Potassium', 'tradeNames_list': "['Cambia', 'Cataflam', 'Diclofenac potassium', 'Voltarol joint painVoltarol pain-eze', 'Voltarol pain-eze extra strgh', 'Voltarol rapidZipsor']", 'syns_list': "['CGP 45840B', 'CGP-45840B', 'Diclofenac potassiumDiclofenac potassium salt', 'Potassium diclofenac']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843007', 'drugName': 'Diclofenac Potassium', 'tradeNames_list': "['Cambia', 'Cataflam', 'Diclofenac potassium', 'Voltarol joint painVoltarol pain-eze', 'Voltarol pain-eze extra strgh', 'Voltarol rapidZipsor']", 'syns_list': "['CGP 45840B', 'CGP-45840B', 'Diclofenac potassiumDiclofenac potassium salt', 'Potassium diclofenac']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843016', 'drugName': 'Diclofenac Potassium', 'tradeNames_list': "['Cambia', 'Cataflam', 'Diclofenac potassium', 'Voltarol joint painVoltarol pain-eze', 'Voltarol pain-eze extra strgh', 'Voltarol rapidZipsor']", 'syns_list': "['CGP 45840B', 'CGP-45840B', 'Diclofenac potassiumDiclofenac potassium salt', 'Potassium diclofenac']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843034', 'drugName': 'Diclofenac Potassium', 'tradeNames_list': "['Cambia', 'Cataflam', 'Diclofenac potassium', 'Voltarol joint painVoltarol pain-eze', 'Voltarol pain-eze extra strgh', 'Voltarol rapidZipsor']", 'syns_list': "['CGP 45840B', 'CGP-45840B', 'Diclofenac potassiumDiclofenac potassium salt', 'Potassium diclofenac']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843043', 'drugName': 'Diclofenac Potassium', 'tradeNames_list': "['Cambia', 'Cataflam', 'Diclofenac potassium', 'Voltarol joint painVoltarol pain-eze', 'Voltarol pain-eze extra strgh', 'Voltarol rapidZipsor']", 'syns_list': "['CGP 45840B', 'CGP-45840B', 'Diclofenac potassiumDiclofenac potassium salt', 'Potassium diclofenac']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843052', 'drugName': 'Diclofenac Potassium', 'tradeNames_list': "['Cambia', 'Cataflam', 'Diclofenac potassium', 'Voltarol joint painVoltarol pain-eze', 'Voltarol pain-eze extra strgh', 'Voltarol rapidZipsor']", 'syns_list': "['CGP 45840B', 'CGP-45840B', 'Diclofenac potassiumDiclofenac potassium salt', 'Potassium diclofenac']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843061', 'drugName': 'Diclofenac Potassium', 'tradeNames_list': "['Cambia', 'Cataflam', 'Diclofenac potassium', 'Voltarol joint painVoltarol pain-eze', 'Voltarol pain-eze extra strgh', 'Voltarol rapidZipsor']", 'syns_list': "['CGP 45840B', 'CGP-45840B', 'Diclofenac potassiumDiclofenac potassium salt', 'Potassium diclofenac']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842953', 'drugName': 'Diclofenac Potassium', 'tradeNames_list': "['Cambia', 'Cataflam', 'Diclofenac potassium', 'Voltarol joint painVoltarol pain-eze', 'Voltarol pain-eze extra strgh', 'Voltarol rapidZipsor']", 'syns_list': "['CGP 45840B', 'CGP-45840B', 'Diclofenac potassiumDiclofenac potassium salt', 'Potassium diclofenac']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842917', 'drugName': 'Diclofenac Potassium', 'tradeNames_list': "['Cambia', 'Cataflam', 'Diclofenac potassium', 'Voltarol joint painVoltarol pain-eze', 'Voltarol pain-eze extra strgh', 'Voltarol rapidZipsor']", 'syns_list': "['CGP 45840B', 'CGP-45840B', 'Diclofenac potassiumDiclofenac potassium salt', 'Potassium diclofenac']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842899', 'drugName': 'Diclofenac Potassium', 'tradeNames_list': "['Cambia', 'Cataflam', 'Diclofenac potassium', 'Voltarol joint painVoltarol pain-eze', 'Voltarol pain-eze extra strgh', 'Voltarol rapidZipsor']", 'syns_list': "['CGP 45840B', 'CGP-45840B', 'Diclofenac potassiumDiclofenac potassium salt', 'Potassium diclofenac']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842890', 'drugName': 'Diclofenac Potassium', 'tradeNames_list': "['Cambia', 'Cataflam', 'Diclofenac potassium', 'Voltarol joint painVoltarol pain-eze', 'Voltarol pain-eze extra strgh', 'Voltarol rapidZipsor']", 'syns_list': "['CGP 45840B', 'CGP-45840B', 'Diclofenac potassiumDiclofenac potassium salt', 'Potassium diclofenac']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_843025', 'drugName': 'Diclofenac Potassium', 'tradeNames_list': "['Cambia', 'Cataflam', 'Diclofenac potassium', 'Voltarol joint painVoltarol pain-eze', 'Voltarol pain-eze extra strgh', 'Voltarol rapidZipsor']", 'syns_list': "['CGP 45840B', 'CGP-45840B', 'Diclofenac potassiumDiclofenac potassium salt', 'Potassium diclofenac']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842989', 'drugName': 'Diclofenac Potassium', 'tradeNames_list': "['Cambia', 'Cataflam', 'Diclofenac potassium', 'Voltarol joint painVoltarol pain-eze', 'Voltarol pain-eze extra strgh', 'Voltarol rapidZipsor']", 'syns_list': "['CGP 45840B', 'CGP-45840B', 'Diclofenac potassiumDiclofenac potassium salt', 'Potassium diclofenac']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842944', 'drugName': 'Diclofenac Potassium', 'tradeNames_list': "['Cambia', 'Cataflam', 'Diclofenac potassium', 'Voltarol joint painVoltarol pain-eze', 'Voltarol pain-eze extra strgh', 'Voltarol rapidZipsor']", 'syns_list': "['CGP 45840B', 'CGP-45840B', 'Diclofenac potassiumDiclofenac potassium salt', 'Potassium diclofenac']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842926', 'drugName': 'Diclofenac Potassium', 'tradeNames_list': "['Cambia', 'Cataflam', 'Diclofenac potassium', 'Voltarol joint painVoltarol pain-eze', 'Voltarol pain-eze extra strgh', 'Voltarol rapidZipsor']", 'syns_list': "['CGP 45840B', 'CGP-45840B', 'Diclofenac potassiumDiclofenac potassium salt', 'Potassium diclofenac']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842908', 'drugName': 'Diclofenac Potassium', 'tradeNames_list': "['Cambia', 'Cataflam', 'Diclofenac potassium', 'Voltarol joint painVoltarol pain-eze', 'Voltarol pain-eze extra strgh', 'Voltarol rapidZipsor']", 'syns_list': "['CGP 45840B', 'CGP-45840B', 'Diclofenac potassiumDiclofenac potassium salt', 'Potassium diclofenac']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1105 | Q34 | What are the names of the genes that are targeted by the drug Darolutamide in the treatment of prostate adenocarcinoma? | In the context of prostate adenocarcinoma, the drug Darolutamide targets the gene androgen receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%prostate adenocarcinoma%" OR LOWER(efo_term) LIKE "%prostate adenocarcinoma%") AND (LOWER(drugName) LIKE "%darolutamide%" OR LOWER(tradeNames_list) LIKE "%darolutamide%" OR LOWER(syns_list) LIKE "%darolutamide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_924424', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924438', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924410', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924396', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924389', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924431', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924417', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924403', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1039 | Q34 | What are the names of the genes that are targeted by the drug Ziconotide Acetate in the treatment of Fever? | In the context of Fever, the drug Ziconotide Acetate targets the gene calcium voltage-gated channel subunit alpha1 B. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%fever%" OR LOWER(efo_term) LIKE "%fever%") AND (LOWER(drugName) LIKE "%ziconotide acetate%" OR LOWER(tradeNames_list) LIKE "%ziconotide acetate%" OR LOWER(syns_list) LIKE "%ziconotide acetate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_891740', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'syns_list': "['Ziconotide acetate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_891746', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'syns_list': "['Ziconotide acetate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_891748', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'syns_list': "['Ziconotide acetate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_891750', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'syns_list': "['Ziconotide acetate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_891754', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'syns_list': "['Ziconotide acetate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_891756', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'syns_list': "['Ziconotide acetate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_891758', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'syns_list': "['Ziconotide acetate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_891762', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'syns_list': "['Ziconotide acetate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_891764', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'syns_list': "['Ziconotide acetate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_891766', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'syns_list': "['Ziconotide acetate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_891768', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'syns_list': "['Ziconotide acetate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_891744', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'syns_list': "['Ziconotide acetate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_891736', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'syns_list': "['Ziconotide acetate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_891732', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'syns_list': "['Ziconotide acetate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_891730', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'syns_list': "['Ziconotide acetate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_891760', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'syns_list': "['Ziconotide acetate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_891752', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'syns_list': "['Ziconotide acetate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_891742', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'syns_list': "['Ziconotide acetate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_891738', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'syns_list': "['Ziconotide acetate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_891734', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'syns_list': "['Ziconotide acetate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.592 | Q34 | What are the names of the genes that are targeted by the drug Rufinamide in the treatment of epilepsy? | In the context of epilepsy, the drug Rufinamide targets the gene sodium voltage-gated channel alpha subunit 1, sodium voltage-gated channel alpha subunit 5, sodium voltage-gated channel alpha subunit 4, sodium voltage-gated channel alpha subunit 7, sodium voltage-gated channel alpha subunit 2, sodium voltage-gated channel alpha subunit 9, sodium voltage-gated channel alpha subunit 3, sodium voltage-gated channel alpha subunit 11, sodium voltage-gated channel alpha subunit 8 and sodium voltage-gated channel alpha subunit 10. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%epilepsy%" OR LOWER(efo_term) LIKE "%epilepsy%") AND (LOWER(drugName) LIKE "%rufinamide%" OR LOWER(tradeNames_list) LIKE "%rufinamide%" OR LOWER(syns_list) LIKE "%rufinamide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_652674', 'drugName': 'Rufinamide', 'tradeNames_list': "['Banzel', 'Inovelon', 'Rufinamide']", 'syns_list': "['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331Rufinamide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_652686', 'drugName': 'Rufinamide', 'tradeNames_list': "['Banzel', 'Inovelon', 'Rufinamide']", 'syns_list': "['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331Rufinamide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_652690', 'drugName': 'Rufinamide', 'tradeNames_list': "['Banzel', 'Inovelon', 'Rufinamide']", 'syns_list': "['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331Rufinamide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_652694', 'drugName': 'Rufinamide', 'tradeNames_list': "['Banzel', 'Inovelon', 'Rufinamide']", 'syns_list': "['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331Rufinamide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_652702', 'drugName': 'Rufinamide', 'tradeNames_list': "['Banzel', 'Inovelon', 'Rufinamide']", 'syns_list': "['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331Rufinamide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_652706', 'drugName': 'Rufinamide', 'tradeNames_list': "['Banzel', 'Inovelon', 'Rufinamide']", 'syns_list': "['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331Rufinamide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_652710', 'drugName': 'Rufinamide', 'tradeNames_list': "['Banzel', 'Inovelon', 'Rufinamide']", 'syns_list': "['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331Rufinamide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_652718', 'drugName': 'Rufinamide', 'tradeNames_list': "['Banzel', 'Inovelon', 'Rufinamide']", 'syns_list': "['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331Rufinamide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_652722', 'drugName': 'Rufinamide', 'tradeNames_list': "['Banzel', 'Inovelon', 'Rufinamide']", 'syns_list': "['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331Rufinamide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_652726', 'drugName': 'Rufinamide', 'tradeNames_list': "['Banzel', 'Inovelon', 'Rufinamide']", 'syns_list': "['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331Rufinamide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_652730', 'drugName': 'Rufinamide', 'tradeNames_list': "['Banzel', 'Inovelon', 'Rufinamide']", 'syns_list': "['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331Rufinamide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_652738', 'drugName': 'Rufinamide', 'tradeNames_list': "['Banzel', 'Inovelon', 'Rufinamide']", 'syns_list': "['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331Rufinamide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_652742', 'drugName': 'Rufinamide', 'tradeNames_list': "['Banzel', 'Inovelon', 'Rufinamide']", 'syns_list': "['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331Rufinamide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_652746', 'drugName': 'Rufinamide', 'tradeNames_list': "['Banzel', 'Inovelon', 'Rufinamide']", 'syns_list': "['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331Rufinamide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_652750', 'drugName': 'Rufinamide', 'tradeNames_list': "['Banzel', 'Inovelon', 'Rufinamide']", 'syns_list': "['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331Rufinamide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_652754', 'drugName': 'Rufinamide', 'tradeNames_list': "['Banzel', 'Inovelon', 'Rufinamide']", 'syns_list': "['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331Rufinamide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_652758', 'drugName': 'Rufinamide', 'tradeNames_list': "['Banzel', 'Inovelon', 'Rufinamide']", 'syns_list': "['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331Rufinamide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_652762', 'drugName': 'Rufinamide', 'tradeNames_list': "['Banzel', 'Inovelon', 'Rufinamide']", 'syns_list': "['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331Rufinamide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_652766', 'drugName': 'Rufinamide', 'tradeNames_list': "['Banzel', 'Inovelon', 'Rufinamide']", 'syns_list': "['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331Rufinamide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_652770', 'drugName': 'Rufinamide', 'tradeNames_list': "['Banzel', 'Inovelon', 'Rufinamide']", 'syns_list': "['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331Rufinamide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_652774', 'drugName': 'Rufinamide', 'tradeNames_list': "['Banzel', 'Inovelon', 'Rufinamide']", 'syns_list': "['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331Rufinamide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_652782', 'drugName': 'Rufinamide', 'tradeNames_list': "['Banzel', 'Inovelon', 'Rufinamide']", 'syns_list': "['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331Rufinamide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_652786', 'drugName': 'Rufinamide', 'tradeNames_list': "['Banzel', 'Inovelon', 'Rufinamide']", 'syns_list': "['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331Rufinamide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_652790', 'drugName': 'Rufinamide', 'tradeNames_list': "['Banzel', 'Inovelon', 'Rufinamide']", 'syns_list': "['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331Rufinamide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_652794', 'drugName': 'Rufinamide', 'tradeNames_list': "['Banzel', 'Inovelon', 'Rufinamide']", 'syns_list': "['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331Rufinamide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_652798', 'drugName': 'Rufinamide', 'tradeNames_list': "['Banzel', 'Inovelon', 'Rufinamide']", 'syns_list': "['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331Rufinamide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_652806', 'drugName': 'Rufinamide', 'tradeNames_list': "['Banzel', 'Inovelon', 'Rufinamide']", 'syns_list': "['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331Rufinamide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_652810', 'drugName': 'Rufinamide', 'tradeNames_list': "['Banzel', 'Inovelon', 'Rufinamide']", 'syns_list': "['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331Rufinamide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_652814', 'drugName': 'Rufinamide', 'tradeNames_list': "['Banzel', 'Inovelon', 'Rufinamide']", 'syns_list': "['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331Rufinamide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_652818', 'drugName': 'Rufinamide', 'tradeNames_list': "['Banzel', 'Inovelon', 'Rufinamide']", 'syns_list': "['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331Rufinamide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_652822', 'drugName': 'Rufinamide', 'tradeNames_list': "['Banzel', 'Inovelon', 'Rufinamide']", 'syns_list': "['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331Rufinamide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_652826', 'drugName': 'Rufinamide', 'tradeNames_list': "['Banzel', 'Inovelon', 'Rufinamide']", 'syns_list': "['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331Rufinamide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_652830', 'drugName': 'Rufinamide', 'tradeNames_list': "['Banzel', 'Inovelon', 'Rufinamide']", 'syns_list': "['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331Rufinamide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_652834', 'drugName': 'Rufinamide', 'tradeNames_list': "['Banzel', 'Inovelon', 'Rufinamide']", 'syns_list': "['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331Rufinamide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_652838', 'drugName': 'Rufinamide', 'tradeNames_list': "['Banzel', 'Inovelon', 'Rufinamide']", 'syns_list': "['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331Rufinamide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_652842', 'drugName': 'Rufinamide', 'tradeNames_list': "['Banzel', 'Inovelon', 'Rufinamide']", 'syns_list': "['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331Rufinamide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_652846', 'drugName': 'Rufinamide', 'tradeNames_list': "['Banzel', 'Inovelon', 'Rufinamide']", 'syns_list': "['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331Rufinamide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_652850', 'drugName': 'Rufinamide', 'tradeNames_list': "['Banzel', 'Inovelon', 'Rufinamide']", 'syns_list': "['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331Rufinamide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_652854', 'drugName': 'Rufinamide', 'tradeNames_list': "['Banzel', 'Inovelon', 'Rufinamide']", 'syns_list': "['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331Rufinamide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_652858', 'drugName': 'Rufinamide', 'tradeNames_list': "['Banzel', 'Inovelon', 'Rufinamide']", 'syns_list': "['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331Rufinamide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_652862', 'drugName': 'Rufinamide', 'tradeNames_list': "['Banzel', 'Inovelon', 'Rufinamide']", 'syns_list': "['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331Rufinamide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_652866', 'drugName': 'Rufinamide', 'tradeNames_list': "['Banzel', 'Inovelon', 'Rufinamide']", 'syns_list': "['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331Rufinamide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_652870', 'drugName': 'Rufinamide', 'tradeNames_list': "['Banzel', 'Inovelon', 'Rufinamide']", 'syns_list': "['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331Rufinamide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_652874', 'drugName': 'Rufinamide', 'tradeNames_list': "['Banzel', 'Inovelon', 'Rufinamide']", 'syns_list': "['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331Rufinamide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_652878', 'drugName': 'Rufinamide', 'tradeNames_list': "['Banzel', 'Inovelon', 'Rufinamide']", 'syns_list': "['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331Rufinamide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_652882', 'drugName': 'Rufinamide', 'tradeNames_list': "['Banzel', 'Inovelon', 'Rufinamide']", 'syns_list': "['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331Rufinamide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_652886', 'drugName': 'Rufinamide', 'tradeNames_list': "['Banzel', 'Inovelon', 'Rufinamide']", 'syns_list': "['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331Rufinamide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_652890', 'drugName': 'Rufinamide', 'tradeNames_list': "['Banzel', 'Inovelon', 'Rufinamide']", 'syns_list': "['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331Rufinamide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_652894', 'drugName': 'Rufinamide', 'tradeNames_list': "['Banzel', 'Inovelon', 'Rufinamide']", 'syns_list': "['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331Rufinamide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_652898', 'drugName': 'Rufinamide', 'tradeNames_list': "['Banzel', 'Inovelon', 'Rufinamide']", 'syns_list': "['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331Rufinamide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_652902', 'drugName': 'Rufinamide', 'tradeNames_list': "['Banzel', 'Inovelon', 'Rufinamide']", 'syns_list': "['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331Rufinamide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_652910', 'drugName': 'Rufinamide', 'tradeNames_list': "['Banzel', 'Inovelon', 'Rufinamide']", 'syns_list': "['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331Rufinamide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_652914', 'drugName': 'Rufinamide', 'tradeNames_list': "['Banzel', 'Inovelon', 'Rufinamide']", 'syns_list': "['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331Rufinamide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_652918', 'drugName': 'Rufinamide', 'tradeNames_list': "['Banzel', 'Inovelon', 'Rufinamide']", 'syns_list': "['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331Rufinamide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_652922', 'drugName': 'Rufinamide', 'tradeNames_list': "['Banzel', 'Inovelon', 'Rufinamide']", 'syns_list': "['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331Rufinamide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_652926', 'drugName': 'Rufinamide', 'tradeNames_list': "['Banzel', 'Inovelon', 'Rufinamide']", 'syns_list': "['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331Rufinamide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_652930', 'drugName': 'Rufinamide', 'tradeNames_list': "['Banzel', 'Inovelon', 'Rufinamide']", 'syns_list': "['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331Rufinamide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_652938', 'drugName': 'Rufinamide', 'tradeNames_list': "['Banzel', 'Inovelon', 'Rufinamide']", 'syns_list': "['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331Rufinamide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_652942', 'drugName': 'Rufinamide', 'tradeNames_list': "['Banzel', 'Inovelon', 'Rufinamide']", 'syns_list': "['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331Rufinamide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_652946', 'drugName': 'Rufinamide', 'tradeNames_list': "['Banzel', 'Inovelon', 'Rufinamide']", 'syns_list': "['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331Rufinamide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_652950', 'drugName': 'Rufinamide', 'tradeNames_list': "['Banzel', 'Inovelon', 'Rufinamide']", 'syns_list': "['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331Rufinamide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_652954', 'drugName': 'Rufinamide', 'tradeNames_list': "['Banzel', 'Inovelon', 'Rufinamide']", 'syns_list': "['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331Rufinamide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_652958', 'drugName': 'Rufinamide', 'tradeNames_list': "['Banzel', 'Inovelon', 'Rufinamide']", 'syns_list': "['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331Rufinamide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_652962', 'drugName': 'Rufinamide', 'tradeNames_list': "['Banzel', 'Inovelon', 'Rufinamide']", 'syns_list': "['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331Rufinamide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_652966', 'drugName': 'Rufinamide', 'tradeNames_list': "['Banzel', 'Inovelon', 'Rufinamide']", 'syns_list': "['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331Rufinamide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_652970', 'drugName': 'Rufinamide', 'tradeNames_list': "['Banzel', 'Inovelon', 'Rufinamide']", 'syns_list': "['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331Rufinamide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_652906', 'drugName': 'Rufinamide', 'tradeNames_list': "['Banzel', 'Inovelon', 'Rufinamide']", 'syns_list': "['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331Rufinamide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_652778', 'drugName': 'Rufinamide', 'tradeNames_list': "['Banzel', 'Inovelon', 'Rufinamide']", 'syns_list': "['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331Rufinamide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_652714', 'drugName': 'Rufinamide', 'tradeNames_list': "['Banzel', 'Inovelon', 'Rufinamide']", 'syns_list': "['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331Rufinamide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_652682', 'drugName': 'Rufinamide', 'tradeNames_list': "['Banzel', 'Inovelon', 'Rufinamide']", 'syns_list': "['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331Rufinamide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_652666', 'drugName': 'Rufinamide', 'tradeNames_list': "['Banzel', 'Inovelon', 'Rufinamide']", 'syns_list': "['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331Rufinamide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_652658', 'drugName': 'Rufinamide', 'tradeNames_list': "['Banzel', 'Inovelon', 'Rufinamide']", 'syns_list': "['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331Rufinamide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_652654', 'drugName': 'Rufinamide', 'tradeNames_list': "['Banzel', 'Inovelon', 'Rufinamide']", 'syns_list': "['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331Rufinamide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_652934', 'drugName': 'Rufinamide', 'tradeNames_list': "['Banzel', 'Inovelon', 'Rufinamide']", 'syns_list': "['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331Rufinamide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_652802', 'drugName': 'Rufinamide', 'tradeNames_list': "['Banzel', 'Inovelon', 'Rufinamide']", 'syns_list': "['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331Rufinamide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_652734', 'drugName': 'Rufinamide', 'tradeNames_list': "['Banzel', 'Inovelon', 'Rufinamide']", 'syns_list': "['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331Rufinamide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_652698', 'drugName': 'Rufinamide', 'tradeNames_list': "['Banzel', 'Inovelon', 'Rufinamide']", 'syns_list': "['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331Rufinamide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_652678', 'drugName': 'Rufinamide', 'tradeNames_list': "['Banzel', 'Inovelon', 'Rufinamide']", 'syns_list': "['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331Rufinamide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_652670', 'drugName': 'Rufinamide', 'tradeNames_list': "['Banzel', 'Inovelon', 'Rufinamide']", 'syns_list': "['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331Rufinamide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_652662', 'drugName': 'Rufinamide', 'tradeNames_list': "['Banzel', 'Inovelon', 'Rufinamide']", 'syns_list': "['60231/4', 'CGP 33101', 'CGP-33101', 'E-2080', 'E2080', 'RUF 331', 'RUF-331Rufinamide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.755 | Q34 | What are the names of the genes that are targeted by the drug Oxycodone Hydrochloride in the treatment of pain? | In the context of pain, the drug Oxycodone Hydrochloride targets the gene opioid receptor mu 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%pain%" OR LOWER(efo_term) LIKE "%pain%") AND (LOWER(drugName) LIKE "%oxycodone hydrochloride%" OR LOWER(tradeNames_list) LIKE "%oxycodone hydrochloride%" OR LOWER(syns_list) LIKE "%oxycodone hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_766861', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766806', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766905', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766855', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766798', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766833', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766804', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766841', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766819', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766820', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766944', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766917', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766800', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766958', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766811', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766812', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766832', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766960', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766834', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766877', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766814', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766805', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766889', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766818', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766895', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766846', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766848', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766946', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766821', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766911', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766807', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766947', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766825', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766826', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766860', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766959', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766862', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766863', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766828', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766867', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766868', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766869', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766870', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766965', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766874', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766875', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766876', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766961', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766835', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766881', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766882', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766884', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766840', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766888', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766933', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766890', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766891', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766939', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766896', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766897', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766898', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766938', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766902', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766903', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766904', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766952', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766849', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766909', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766910', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766945', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766912', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766854', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766916', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766951', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766918', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766919', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766856', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766923', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766924', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766925', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766926', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766966', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766930', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766931', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766932', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766968', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766967', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766953', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766940', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766937', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766883', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766839', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766799', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766842', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766847', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766853', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766954', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766813', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766797', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766827', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_list': "['Abtard', 'Candox', 'Carexil', 'Dolocodon pr', 'Leveraxo', 'Longtec', 'LynlorOxaydo', 'Oxecta', 'Oxeltra', 'Oxycodone hydrochloride', 'OxycontinOxylan', 'Oxynorm', 'Reltebon', 'Roxicodone', 'Roxybond', 'ShortecZomestine']", 'syns_list': "['Anhydrous oxycodone hydrochloride', 'Endocodone', 'Oxecta', 'Oxycodone hclOxycodone hydrochloride', 'Oxycodone hydrochloride cii']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.662 | Q34 | What are the names of the genes that are targeted by the drug Tolvaptan in the treatment of Polycystic Kidney Disease? | In the context of Polycystic Kidney Disease, the drug Tolvaptan targets the gene arginine vasopressin receptor 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%polycystic kidney disease%" OR LOWER(efo_term) LIKE "%polycystic kidney disease%") AND (LOWER(drugName) LIKE "%tolvaptan%" OR LOWER(tradeNames_list) LIKE "%tolvaptan%" OR LOWER(syns_list) LIKE "%tolvaptan%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_695277', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polycystic Kidney Diseases', 'efo_term': 'Polycystic Kidney Disease', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695263', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polycystic Kidney Diseases', 'efo_term': 'polycystic kidney disease', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695187', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polycystic Kidney Diseases', 'efo_term': 'Polycystic Kidney Disease', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695142', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polycystic Kidney Diseases', 'efo_term': 'Polycystic Kidney Disease', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695307', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polycystic Kidney Diseases', 'efo_term': 'Polycystic Kidney Disease', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695143', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polycystic Kidney Diseases', 'efo_term': 'polycystic kidney disease', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695262', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polycystic Kidney Diseases', 'efo_term': 'Polycystic Kidney Disease', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695097', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polycystic Kidney Diseases', 'efo_term': 'Polycystic Kidney Disease', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695322', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polycystic Kidney Diseases', 'efo_term': 'Polycystic Kidney Disease', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695128', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polycystic Kidney Diseases', 'efo_term': 'polycystic kidney disease', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695188', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polycystic Kidney Diseases', 'efo_term': 'polycystic kidney disease', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695112', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polycystic Kidney Diseases', 'efo_term': 'Polycystic Kidney Disease', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695232', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polycystic Kidney Diseases', 'efo_term': 'Polycystic Kidney Disease', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695172', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polycystic Kidney Diseases', 'efo_term': 'Polycystic Kidney Disease', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695218', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polycystic Kidney Diseases', 'efo_term': 'polycystic kidney disease', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695157', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polycystic Kidney Diseases', 'efo_term': 'Polycystic Kidney Disease', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695113', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polycystic Kidney Diseases', 'efo_term': 'polycystic kidney disease', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695233', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polycystic Kidney Diseases', 'efo_term': 'polycystic kidney disease', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695292', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polycystic Kidney Diseases', 'efo_term': 'Polycystic Kidney Disease', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695202', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polycystic Kidney Diseases', 'efo_term': 'Polycystic Kidney Disease', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695158', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polycystic Kidney Diseases', 'efo_term': 'polycystic kidney disease', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695248', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polycystic Kidney Diseases', 'efo_term': 'polycystic kidney disease', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695278', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polycystic Kidney Diseases', 'efo_term': 'polycystic kidney disease', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695308', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polycystic Kidney Diseases', 'efo_term': 'polycystic kidney disease', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695323', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polycystic Kidney Diseases', 'efo_term': 'polycystic kidney disease', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695247', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polycystic Kidney Diseases', 'efo_term': 'Polycystic Kidney Disease', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695293', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polycystic Kidney Diseases', 'efo_term': 'polycystic kidney disease', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695098', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polycystic Kidney Diseases', 'efo_term': 'polycystic kidney disease', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695217', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polycystic Kidney Diseases', 'efo_term': 'Polycystic Kidney Disease', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695127', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polycystic Kidney Diseases', 'efo_term': 'Polycystic Kidney Disease', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695173', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polycystic Kidney Diseases', 'efo_term': 'polycystic kidney disease', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695203', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polycystic Kidney Diseases', 'efo_term': 'polycystic kidney disease', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695091', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Polycystic Kidney, Autosomal Dominant', 'efo_term': 'Autosomal dominant polycystic kidney disease', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695166', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Polycystic Kidney, Autosomal Dominant', 'efo_term': 'Autosomal dominant polycystic kidney disease', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695256', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Polycystic Kidney, Autosomal Dominant', 'efo_term': 'Autosomal dominant polycystic kidney disease', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695181', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Polycystic Kidney, Autosomal Dominant', 'efo_term': 'Autosomal dominant polycystic kidney disease', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695136', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Polycystic Kidney, Autosomal Dominant', 'efo_term': 'Autosomal dominant polycystic kidney disease', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695286', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Polycystic Kidney, Autosomal Dominant', 'efo_term': 'Autosomal dominant polycystic kidney disease', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695301', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Polycystic Kidney, Autosomal Dominant', 'efo_term': 'Autosomal dominant polycystic kidney disease', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695271', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Polycystic Kidney, Autosomal Dominant', 'efo_term': 'Autosomal dominant polycystic kidney disease', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695106', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Polycystic Kidney, Autosomal Dominant', 'efo_term': 'Autosomal dominant polycystic kidney disease', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695196', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Polycystic Kidney, Autosomal Dominant', 'efo_term': 'Autosomal dominant polycystic kidney disease', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695316', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Polycystic Kidney, Autosomal Dominant', 'efo_term': 'Autosomal dominant polycystic kidney disease', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695121', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Polycystic Kidney, Autosomal Dominant', 'efo_term': 'Autosomal dominant polycystic kidney disease', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695151', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Polycystic Kidney, Autosomal Dominant', 'efo_term': 'Autosomal dominant polycystic kidney disease', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695211', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Polycystic Kidney, Autosomal Dominant', 'efo_term': 'Autosomal dominant polycystic kidney disease', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695226', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Polycystic Kidney, Autosomal Dominant', 'efo_term': 'Autosomal dominant polycystic kidney disease', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_695241', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'syns_list': "['OPC-41061', 'OPC-41061(TOLVAPTAN)', 'Tolvaptan']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Polycystic Kidney, Autosomal Dominant', 'efo_term': 'Autosomal dominant polycystic kidney disease', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.236 | Q34 | What are the names of the genes that are targeted by the drug Beclomethasone Dipropionate in the treatment of asthma? | In the context of asthma, the drug Beclomethasone Dipropionate targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%asthma%" OR LOWER(efo_term) LIKE "%asthma%") AND (LOWER(drugName) LIKE "%beclomethasone dipropionate%" OR LOWER(tradeNames_list) LIKE "%beclomethasone dipropionate%" OR LOWER(syns_list) LIKE "%beclomethasone dipropionate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_221047', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221116', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221139', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221162', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221208', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221231', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221254', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221300', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221323', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221346', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221369', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221415', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221438', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221461', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221484', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221507', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221530', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221553', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221576', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221599', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221622', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221668', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221691', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221714', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221737', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221760', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221806', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221829', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221645', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221277', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221093', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221001', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220955', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220932', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221783', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221392', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221185', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221070', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221024', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220978', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.737 | Q34 | What are the names of the genes that are targeted by the drug Naldemedine Tosylate in the treatment of pain? | In the context of pain, the drug Naldemedine Tosylate targets the gene opioid receptor mu 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%pain%" OR LOWER(efo_term) LIKE "%pain%") AND (LOWER(drugName) LIKE "%naldemedine tosylate%" OR LOWER(tradeNames_list) LIKE "%naldemedine tosylate%" OR LOWER(syns_list) LIKE "%naldemedine tosylate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_763378', 'drugName': 'Naldemedine Tosylate', 'tradeNames_list': "['Symproic']", 'syns_list': "['Naldemedine tosilate', 'Naldemedine tosylate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cancer Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763375', 'drugName': 'Naldemedine Tosylate', 'tradeNames_list': "['Symproic']", 'syns_list': "['Naldemedine tosilate', 'Naldemedine tosylate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cancer Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763384', 'drugName': 'Naldemedine Tosylate', 'tradeNames_list': "['Symproic']", 'syns_list': "['Naldemedine tosilate', 'Naldemedine tosylate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cancer Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763381', 'drugName': 'Naldemedine Tosylate', 'tradeNames_list': "['Symproic']", 'syns_list': "['Naldemedine tosilate', 'Naldemedine tosylate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cancer Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1971 | Q34 | What are the names of the genes that are targeted by the drug Topotecan Hydrochloride in the treatment of ovarian carcinoma? | In the context of ovarian carcinoma, the drug Topotecan Hydrochloride targets the gene DNA topoisomerase I mitochondrial. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%ovarian carcinoma%" OR LOWER(efo_term) LIKE "%ovarian carcinoma%") AND (LOWER(drugName) LIKE "%topotecan hydrochloride%" OR LOWER(tradeNames_list) LIKE "%topotecan hydrochloride%" OR LOWER(syns_list) LIKE "%topotecan hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1193574', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193646', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1617 | Q34 | What are the names of the genes that are targeted by the drug Bivalirudin in the treatment of syndromic disease? | In the context of syndromic disease, the drug Bivalirudin targets the gene coagulation factor II, thrombin. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%syndromic disease%" OR LOWER(efo_term) LIKE "%syndromic disease%") AND (LOWER(drugName) LIKE "%bivalirudin%" OR LOWER(tradeNames_list) LIKE "%bivalirudin%" OR LOWER(syns_list) LIKE "%bivalirudin%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1092331', 'drugName': 'Bivalirudin', 'tradeNames_list': "['Angiomax', 'Angiomax rtu', 'BivalirudinBivalirudin in 0.9% sodium chloride']", 'syns_list': "['BG-8967', 'BG8967', 'Bivalirudin']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Syndrome', 'efo_term': 'syndromic disease', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092314', 'drugName': 'Bivalirudin', 'tradeNames_list': "['Angiomax', 'Angiomax rtu', 'BivalirudinBivalirudin in 0.9% sodium chloride']", 'syns_list': "['BG-8967', 'BG8967', 'Bivalirudin']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Syndrome', 'efo_term': 'syndromic disease', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092365', 'drugName': 'Bivalirudin', 'tradeNames_list': "['Angiomax', 'Angiomax rtu', 'BivalirudinBivalirudin in 0.9% sodium chloride']", 'syns_list': "['BG-8967', 'BG8967', 'Bivalirudin']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Syndrome', 'efo_term': 'syndromic disease', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092348', 'drugName': 'Bivalirudin', 'tradeNames_list': "['Angiomax', 'Angiomax rtu', 'BivalirudinBivalirudin in 0.9% sodium chloride']", 'syns_list': "['BG-8967', 'BG8967', 'Bivalirudin']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Syndrome', 'efo_term': 'syndromic disease', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1165 | Q34 | What are the names of the genes that are targeted by the drug Trametinib in the treatment of malignant colon neoplasm? | Trametinib has not been approved by the FDA as a treatment for malignant colon neoplasm, but it is currently undergoing evaluation in clinical trials for this purpose. However, the proposed gene target names are mitogen-activated protein kinase kinase 2 and mitogen-activated protein kinase kinase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%malignant colon neoplasm%" OR LOWER(efo_term) LIKE "%malignant colon neoplasm%") AND (LOWER(drugName) LIKE "%trametinib%" OR LOWER(tradeNames_list) LIKE "%trametinib%" OR LOWER(syns_list) LIKE "%trametinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_928713', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928833', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928873', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928913', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928993', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929033', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929073', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929153', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929193', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929233', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929273', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929353', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929393', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929433', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929473', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929513', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929553', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929593', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929633', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929673', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929713', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929793', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929833', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929873', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929913', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929953', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930033', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930073', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930113', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930153', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930193', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930233', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930273', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930313', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930353', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930393', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930433', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930473', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930513', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930553', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930593', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930633', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930673', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930713', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930753', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930793', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930833', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930873', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930913', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930953', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930993', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931073', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931113', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931153', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931193', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931233', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931273', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931353', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931393', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931433', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931473', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931513', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931553', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931593', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931633', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931673', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931713', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931753', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931793', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931833', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931873', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931913', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931953', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931993', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932033', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932073', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932113', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932153', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932193', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932233', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932273', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932313', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932353', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932393', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932433', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932473', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931033', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_929753', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929113', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928793', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928633', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928553', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928513', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_931313', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_929993', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929313', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928953', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928753', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928673', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928593', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1632 | Q34 | What are the names of the genes that are targeted by the drug Dabigatran in the treatment of atrial fibrillation? | Dabigatran has not been approved by the FDA as a treatment for atrial fibrillation, but it is currently undergoing evaluation in clinical trials for this purpose. However, the proposed gene target name is coagulation factor II, thrombin. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%atrial fibrillation%" OR LOWER(efo_term) LIKE "%atrial fibrillation%") AND (LOWER(drugName) LIKE "%dabigatran%" OR LOWER(tradeNames_list) LIKE "%dabigatran%" OR LOWER(syns_list) LIKE "%dabigatran%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1092533', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092503', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092378', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092383', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092428', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092573', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092368', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092463', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092543', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092393', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092423', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092483', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092578', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092608', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092448', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092488', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092643', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092623', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092478', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092513', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092518', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092373', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092523', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092418', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092588', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092548', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092413', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092563', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092568', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092618', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092583', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092498', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092468', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092398', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092453', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092603', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092528', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092638', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092493', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092433', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092593', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092553', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092633', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092558', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092648', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092508', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092388', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092598', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092613', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092458', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092403', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092538', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092408', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092628', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092438', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092473', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092443', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093192', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093205', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092685', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092698', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092659', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092737', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092750', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092763', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092776', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092711', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092802', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092815', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092828', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092841', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092854', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092867', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093088', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092893', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092906', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092919', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092932', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093036', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092945', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092880', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092958', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092971', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092984', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092997', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093140', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093010', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093023', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093049', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093062', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092789', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093075', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093101', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093114', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093127', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092672', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093153', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093166', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093179', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092724', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1599 | Q34 | What are the names of the genes that are targeted by the drug Lisinopril in the treatment of diabetes mellitus? | In the context of diabetes mellitus, the drug Lisinopril targets the gene angiotensin I converting enzyme. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%diabetes mellitus%" OR LOWER(efo_term) LIKE "%diabetes mellitus%") AND (LOWER(drugName) LIKE "%lisinopril%" OR LOWER(tradeNames_list) LIKE "%lisinopril%" OR LOWER(syns_list) LIKE "%lisinopril%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1091709', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'syns_list': "['Lisinopril', 'Lisinopril dihydrate', 'Lisinopril hydrate', 'MK-521Ranolip']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091730', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'syns_list': "['Lisinopril', 'Lisinopril dihydrate', 'Lisinopril hydrate', 'MK-521Ranolip']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091737', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'syns_list': "['Lisinopril', 'Lisinopril dihydrate', 'Lisinopril hydrate', 'MK-521Ranolip']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091744', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'syns_list': "['Lisinopril', 'Lisinopril dihydrate', 'Lisinopril hydrate', 'MK-521Ranolip']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091758', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'syns_list': "['Lisinopril', 'Lisinopril dihydrate', 'Lisinopril hydrate', 'MK-521Ranolip']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091765', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'syns_list': "['Lisinopril', 'Lisinopril dihydrate', 'Lisinopril hydrate', 'MK-521Ranolip']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091772', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'syns_list': "['Lisinopril', 'Lisinopril dihydrate', 'Lisinopril hydrate', 'MK-521Ranolip']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091786', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'syns_list': "['Lisinopril', 'Lisinopril dihydrate', 'Lisinopril hydrate', 'MK-521Ranolip']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091793', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'syns_list': "['Lisinopril', 'Lisinopril dihydrate', 'Lisinopril hydrate', 'MK-521Ranolip']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091800', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'syns_list': "['Lisinopril', 'Lisinopril dihydrate', 'Lisinopril hydrate', 'MK-521Ranolip']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091807', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'syns_list': "['Lisinopril', 'Lisinopril dihydrate', 'Lisinopril hydrate', 'MK-521Ranolip']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091821', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'syns_list': "['Lisinopril', 'Lisinopril dihydrate', 'Lisinopril hydrate', 'MK-521Ranolip']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091828', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'syns_list': "['Lisinopril', 'Lisinopril dihydrate', 'Lisinopril hydrate', 'MK-521Ranolip']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091835', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'syns_list': "['Lisinopril', 'Lisinopril dihydrate', 'Lisinopril hydrate', 'MK-521Ranolip']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091842', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'syns_list': "['Lisinopril', 'Lisinopril dihydrate', 'Lisinopril hydrate', 'MK-521Ranolip']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091849', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'syns_list': "['Lisinopril', 'Lisinopril dihydrate', 'Lisinopril hydrate', 'MK-521Ranolip']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091779', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'syns_list': "['Lisinopril', 'Lisinopril dihydrate', 'Lisinopril hydrate', 'MK-521Ranolip']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091723', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'syns_list': "['Lisinopril', 'Lisinopril dihydrate', 'Lisinopril hydrate', 'MK-521Ranolip']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091695', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'syns_list': "['Lisinopril', 'Lisinopril dihydrate', 'Lisinopril hydrate', 'MK-521Ranolip']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091681', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'syns_list': "['Lisinopril', 'Lisinopril dihydrate', 'Lisinopril hydrate', 'MK-521Ranolip']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091674', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'syns_list': "['Lisinopril', 'Lisinopril dihydrate', 'Lisinopril hydrate', 'MK-521Ranolip']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091814', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'syns_list': "['Lisinopril', 'Lisinopril dihydrate', 'Lisinopril hydrate', 'MK-521Ranolip']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091751', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'syns_list': "['Lisinopril', 'Lisinopril dihydrate', 'Lisinopril hydrate', 'MK-521Ranolip']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091716', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'syns_list': "['Lisinopril', 'Lisinopril dihydrate', 'Lisinopril hydrate', 'MK-521Ranolip']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091702', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'syns_list': "['Lisinopril', 'Lisinopril dihydrate', 'Lisinopril hydrate', 'MK-521Ranolip']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091688', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'syns_list': "['Lisinopril', 'Lisinopril dihydrate', 'Lisinopril hydrate', 'MK-521Ranolip']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1613 | Q34 | What are the names of the genes that are targeted by the drug Bivalirudin in the treatment of Thrombocytopenia? | In the context of Thrombocytopenia, the drug Bivalirudin targets the gene coagulation factor II, thrombin. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%thrombocytopenia%" OR LOWER(efo_term) LIKE "%thrombocytopenia%") AND (LOWER(drugName) LIKE "%bivalirudin%" OR LOWER(tradeNames_list) LIKE "%bivalirudin%" OR LOWER(syns_list) LIKE "%bivalirudin%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1092327', 'drugName': 'Bivalirudin', 'tradeNames_list': "['Angiomax', 'Angiomax rtu', 'BivalirudinBivalirudin in 0.9% sodium chloride']", 'syns_list': "['BG-8967', 'BG8967', 'Bivalirudin']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092310', 'drugName': 'Bivalirudin', 'tradeNames_list': "['Angiomax', 'Angiomax rtu', 'BivalirudinBivalirudin in 0.9% sodium chloride']", 'syns_list': "['BG-8967', 'BG8967', 'Bivalirudin']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092361', 'drugName': 'Bivalirudin', 'tradeNames_list': "['Angiomax', 'Angiomax rtu', 'BivalirudinBivalirudin in 0.9% sodium chloride']", 'syns_list': "['BG-8967', 'BG8967', 'Bivalirudin']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092344', 'drugName': 'Bivalirudin', 'tradeNames_list': "['Angiomax', 'Angiomax rtu', 'BivalirudinBivalirudin in 0.9% sodium chloride']", 'syns_list': "['BG-8967', 'BG8967', 'Bivalirudin']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.941 | Q34 | What are the names of the genes that are targeted by the drug Ibuprofen in the treatment of toothache? | In the context of toothache, the drug Ibuprofen targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%toothache%" OR LOWER(efo_term) LIKE "%toothache%") AND (LOWER(drugName) LIKE "%ibuprofen%" OR LOWER(tradeNames_list) LIKE "%ibuprofen%" OR LOWER(syns_list) LIKE "%ibuprofen%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_840172', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840409', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840488', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840567', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840725', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840804', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840883', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841041', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841120', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841199', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841278', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841436', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841515', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841594', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841673', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841752', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840962', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840330', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840014', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839856', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839777', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841357', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840646', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840251', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840093', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839935', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1218 | Q34 | What are the names of the genes that are targeted by the drug Olodaterol Hydrochloride in the treatment of chronic bronchitis? | In the context of chronic bronchitis, the drug Olodaterol Hydrochloride targets the gene adrenoceptor beta 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%chronic bronchitis%" OR LOWER(efo_term) LIKE "%chronic bronchitis%") AND (LOWER(drugName) LIKE "%olodaterol hydrochloride%" OR LOWER(tradeNames_list) LIKE "%olodaterol hydrochloride%" OR LOWER(syns_list) LIKE "%olodaterol hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_937112', 'drugName': 'Olodaterol Hydrochloride', 'tradeNames_list': "['Striverdi respimat']", 'syns_list': "['BI 1744 CL', 'BI-1744 CL', 'BI-1744-CL', 'Olodaterol hydrochloride']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_937121', 'drugName': 'Olodaterol Hydrochloride', 'tradeNames_list': "['Striverdi respimat']", 'syns_list': "['BI 1744 CL', 'BI-1744 CL', 'BI-1744-CL', 'Olodaterol hydrochloride']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_937124', 'drugName': 'Olodaterol Hydrochloride', 'tradeNames_list': "['Striverdi respimat']", 'syns_list': "['BI 1744 CL', 'BI-1744 CL', 'BI-1744-CL', 'Olodaterol hydrochloride']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_937127', 'drugName': 'Olodaterol Hydrochloride', 'tradeNames_list': "['Striverdi respimat']", 'syns_list': "['BI 1744 CL', 'BI-1744 CL', 'BI-1744-CL', 'Olodaterol hydrochloride']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_937133', 'drugName': 'Olodaterol Hydrochloride', 'tradeNames_list': "['Striverdi respimat']", 'syns_list': "['BI 1744 CL', 'BI-1744 CL', 'BI-1744-CL', 'Olodaterol hydrochloride']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_937118', 'drugName': 'Olodaterol Hydrochloride', 'tradeNames_list': "['Striverdi respimat']", 'syns_list': "['BI 1744 CL', 'BI-1744 CL', 'BI-1744-CL', 'Olodaterol hydrochloride']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_937106', 'drugName': 'Olodaterol Hydrochloride', 'tradeNames_list': "['Striverdi respimat']", 'syns_list': "['BI 1744 CL', 'BI-1744 CL', 'BI-1744-CL', 'Olodaterol hydrochloride']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_937100', 'drugName': 'Olodaterol Hydrochloride', 'tradeNames_list': "['Striverdi respimat']", 'syns_list': "['BI 1744 CL', 'BI-1744 CL', 'BI-1744-CL', 'Olodaterol hydrochloride']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_937097', 'drugName': 'Olodaterol Hydrochloride', 'tradeNames_list': "['Striverdi respimat']", 'syns_list': "['BI 1744 CL', 'BI-1744 CL', 'BI-1744-CL', 'Olodaterol hydrochloride']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_937130', 'drugName': 'Olodaterol Hydrochloride', 'tradeNames_list': "['Striverdi respimat']", 'syns_list': "['BI 1744 CL', 'BI-1744 CL', 'BI-1744-CL', 'Olodaterol hydrochloride']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_937115', 'drugName': 'Olodaterol Hydrochloride', 'tradeNames_list': "['Striverdi respimat']", 'syns_list': "['BI 1744 CL', 'BI-1744 CL', 'BI-1744-CL', 'Olodaterol hydrochloride']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_937109', 'drugName': 'Olodaterol Hydrochloride', 'tradeNames_list': "['Striverdi respimat']", 'syns_list': "['BI 1744 CL', 'BI-1744 CL', 'BI-1744-CL', 'Olodaterol hydrochloride']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_937103', 'drugName': 'Olodaterol Hydrochloride', 'tradeNames_list': "['Striverdi respimat']", 'syns_list': "['BI 1744 CL', 'BI-1744 CL', 'BI-1744-CL', 'Olodaterol hydrochloride']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1072 | Q34 | What are the names of the genes that are targeted by the drug Ticagrelor in the treatment of type 2 diabetes mellitus? | In the context of type 2 diabetes mellitus, the drug Ticagrelor targets the gene purinergic receptor P2Y12. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%type 2 diabetes mellitus%" OR LOWER(efo_term) LIKE "%type 2 diabetes mellitus%") AND (LOWER(drugName) LIKE "%ticagrelor%" OR LOWER(tradeNames_list) LIKE "%ticagrelor%" OR LOWER(syns_list) LIKE "%ticagrelor%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_920471', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920549', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920575', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920601', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920653', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920679', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920705', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920757', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920783', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920809', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920835', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920887', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920913', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920939', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920965', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920991', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920731', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920523', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920419', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920367', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920341', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920861', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920627', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920497', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920445', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920393', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.110 | Q34 | What are the names of the genes that are targeted by the drug Duloxetine Hydrochloride in the treatment of muscular disease? | In the context of muscular disease, the drug Duloxetine Hydrochloride targets the gene solute carrier family 6 member 4 and solute carrier family 6 member 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%muscular disease%" OR LOWER(efo_term) LIKE "%muscular disease%") AND (LOWER(drugName) LIKE "%duloxetine hydrochloride%" OR LOWER(tradeNames_list) LIKE "%duloxetine hydrochloride%" OR LOWER(syns_list) LIKE "%duloxetine hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_206075', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Musculoskeletal Pain', 'efo_term': 'muscular disease', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206123', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Musculoskeletal Pain', 'efo_term': 'muscular disease', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206139', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Musculoskeletal Pain', 'efo_term': 'muscular disease', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206155', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Musculoskeletal Pain', 'efo_term': 'muscular disease', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206187', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Musculoskeletal Pain', 'efo_term': 'muscular disease', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206203', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Musculoskeletal Pain', 'efo_term': 'muscular disease', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206219', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Musculoskeletal Pain', 'efo_term': 'muscular disease', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206251', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Musculoskeletal Pain', 'efo_term': 'muscular disease', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206267', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Musculoskeletal Pain', 'efo_term': 'muscular disease', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206283', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Musculoskeletal Pain', 'efo_term': 'muscular disease', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206299', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Musculoskeletal Pain', 'efo_term': 'muscular disease', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206331', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Musculoskeletal Pain', 'efo_term': 'muscular disease', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206347', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Musculoskeletal Pain', 'efo_term': 'muscular disease', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206363', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Musculoskeletal Pain', 'efo_term': 'muscular disease', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206379', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Musculoskeletal Pain', 'efo_term': 'muscular disease', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206395', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Musculoskeletal Pain', 'efo_term': 'muscular disease', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206411', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Musculoskeletal Pain', 'efo_term': 'muscular disease', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206427', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Musculoskeletal Pain', 'efo_term': 'muscular disease', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206443', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Musculoskeletal Pain', 'efo_term': 'muscular disease', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206459', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Musculoskeletal Pain', 'efo_term': 'muscular disease', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206475', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Musculoskeletal Pain', 'efo_term': 'muscular disease', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206491', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Musculoskeletal Pain', 'efo_term': 'muscular disease', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206235', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Musculoskeletal Pain', 'efo_term': 'muscular disease', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206107', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Musculoskeletal Pain', 'efo_term': 'muscular disease', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206043', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Musculoskeletal Pain', 'efo_term': 'muscular disease', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206011', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Musculoskeletal Pain', 'efo_term': 'muscular disease', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_205995', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Musculoskeletal Pain', 'efo_term': 'muscular disease', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206315', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Musculoskeletal Pain', 'efo_term': 'muscular disease', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206171', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Musculoskeletal Pain', 'efo_term': 'muscular disease', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206091', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Musculoskeletal Pain', 'efo_term': 'muscular disease', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206059', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Musculoskeletal Pain', 'efo_term': 'muscular disease', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206027', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Musculoskeletal Pain', 'efo_term': 'muscular disease', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1956 | Q34 | What are the names of the genes that are targeted by the drug Baclofen in the treatment of multiple sclerosis? | In the context of multiple sclerosis, the drug Baclofen targets the gene gamma-aminobutyric acid type B receptor subunit 1 and gamma-aminobutyric acid type B receptor subunit 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%multiple sclerosis%" OR LOWER(efo_term) LIKE "%multiple sclerosis%") AND (LOWER(drugName) LIKE "%baclofen%" OR LOWER(tradeNames_list) LIKE "%baclofen%" OR LOWER(syns_list) LIKE "%baclofen%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1193248', 'drugName': 'Baclofen', 'tradeNames_list': "['Baclofen', 'Baclospas-10', 'Fleqsuvy', 'Gablofen', 'Kemstro', 'LioresalLioresal intrath', 'Lyflex', 'Lyvispah', 'Ozobax']", 'syns_list': "['(rs)-baclofen', 'BA-34,647', 'BA-34647', 'Baclofen', 'Fleqsuvy', 'LyvispahNSC-755906']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193323', 'drugName': 'Baclofen', 'tradeNames_list': "['Baclofen', 'Baclospas-10', 'Fleqsuvy', 'Gablofen', 'Kemstro', 'LioresalLioresal intrath', 'Lyflex', 'Lyvispah', 'Ozobax']", 'syns_list': "['(rs)-baclofen', 'BA-34,647', 'BA-34647', 'Baclofen', 'Fleqsuvy', 'LyvispahNSC-755906']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193348', 'drugName': 'Baclofen', 'tradeNames_list': "['Baclofen', 'Baclospas-10', 'Fleqsuvy', 'Gablofen', 'Kemstro', 'LioresalLioresal intrath', 'Lyflex', 'Lyvispah', 'Ozobax']", 'syns_list': "['(rs)-baclofen', 'BA-34,647', 'BA-34647', 'Baclofen', 'Fleqsuvy', 'LyvispahNSC-755906']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193298', 'drugName': 'Baclofen', 'tradeNames_list': "['Baclofen', 'Baclospas-10', 'Fleqsuvy', 'Gablofen', 'Kemstro', 'LioresalLioresal intrath', 'Lyflex', 'Lyvispah', 'Ozobax']", 'syns_list': "['(rs)-baclofen', 'BA-34,647', 'BA-34647', 'Baclofen', 'Fleqsuvy', 'LyvispahNSC-755906']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193148', 'drugName': 'Baclofen', 'tradeNames_list': "['Baclofen', 'Baclospas-10', 'Fleqsuvy', 'Gablofen', 'Kemstro', 'LioresalLioresal intrath', 'Lyflex', 'Lyvispah', 'Ozobax']", 'syns_list': "['(rs)-baclofen', 'BA-34,647', 'BA-34647', 'Baclofen', 'Fleqsuvy', 'LyvispahNSC-755906']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_1193123', 'drugName': 'Baclofen', 'tradeNames_list': "['Baclofen', 'Baclospas-10', 'Fleqsuvy', 'Gablofen', 'Kemstro', 'LioresalLioresal intrath', 'Lyflex', 'Lyvispah', 'Ozobax']", 'syns_list': "['(rs)-baclofen', 'BA-34,647', 'BA-34647', 'Baclofen', 'Fleqsuvy', 'LyvispahNSC-755906']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_1193198', 'drugName': 'Baclofen', 'tradeNames_list': "['Baclofen', 'Baclospas-10', 'Fleqsuvy', 'Gablofen', 'Kemstro', 'LioresalLioresal intrath', 'Lyflex', 'Lyvispah', 'Ozobax']", 'syns_list': "['(rs)-baclofen', 'BA-34,647', 'BA-34647', 'Baclofen', 'Fleqsuvy', 'LyvispahNSC-755906']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_1193273', 'drugName': 'Baclofen', 'tradeNames_list': "['Baclofen', 'Baclospas-10', 'Fleqsuvy', 'Gablofen', 'Kemstro', 'LioresalLioresal intrath', 'Lyflex', 'Lyvispah', 'Ozobax']", 'syns_list': "['(rs)-baclofen', 'BA-34,647', 'BA-34647', 'Baclofen', 'Fleqsuvy', 'LyvispahNSC-755906']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193223', 'drugName': 'Baclofen', 'tradeNames_list': "['Baclofen', 'Baclospas-10', 'Fleqsuvy', 'Gablofen', 'Kemstro', 'LioresalLioresal intrath', 'Lyflex', 'Lyvispah', 'Ozobax']", 'syns_list': "['(rs)-baclofen', 'BA-34,647', 'BA-34647', 'Baclofen', 'Fleqsuvy', 'LyvispahNSC-755906']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_1193173', 'drugName': 'Baclofen', 'tradeNames_list': "['Baclofen', 'Baclospas-10', 'Fleqsuvy', 'Gablofen', 'Kemstro', 'LioresalLioresal intrath', 'Lyflex', 'Lyvispah', 'Ozobax']", 'syns_list': "['(rs)-baclofen', 'BA-34,647', 'BA-34647', 'Baclofen', 'Fleqsuvy', 'LyvispahNSC-755906']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.572 | Q34 | What are the names of the genes that are targeted by the drug Lidocaine in the treatment of neuropathic pain? | In the context of neuropathic pain, the drug Lidocaine targets the gene sodium voltage-gated channel alpha subunit 1, sodium voltage-gated channel alpha subunit 5, sodium voltage-gated channel alpha subunit 4, sodium voltage-gated channel alpha subunit 7, sodium voltage-gated channel alpha subunit 2, sodium voltage-gated channel alpha subunit 9, sodium voltage-gated channel alpha subunit 3, sodium voltage-gated channel alpha subunit 11, sodium voltage-gated channel alpha subunit 8 and sodium voltage-gated channel alpha subunit 10. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%neuropathic pain%" OR LOWER(efo_term) LIKE "%neuropathic pain%") AND (LOWER(drugName) LIKE "%lidocaine%" OR LOWER(tradeNames_list) LIKE "%lidocaine%" OR LOWER(syns_list) LIKE "%lidocaine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_638361', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_638706', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638821', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638936', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_639166', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639281', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639396', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639626', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639741', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639856', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_639971', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_640201', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_640316', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_640431', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_640546', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_640661', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_640776', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_640891', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_641006', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_641121', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_641236', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_641466', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_641581', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_641696', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_641811', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_641926', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_642156', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_642271', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_642386', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_642501', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_642616', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_642731', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_642846', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_642961', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_643076', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_643191', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_643306', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_643421', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_643536', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_643651', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_643766', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_643881', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_643996', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_644111', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_644226', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_644341', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_644456', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_644571', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_641351', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_639511', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_638591', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638131', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_637901', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_637786', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_642041', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_640086', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_639051', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638476', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638246', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_638016', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1176 | Q34 | What are the names of the genes that are targeted by the drug Sitagliptin Phosphate in the treatment of myocardial infarction? | In the context of myocardial infarction, the drug Sitagliptin Phosphate targets the gene dipeptidyl peptidase 4. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%myocardial infarction%" OR LOWER(efo_term) LIKE "%myocardial infarction%") AND (LOWER(drugName) LIKE "%sitagliptin phosphate%" OR LOWER(tradeNames_list) LIKE "%sitagliptin phosphate%" OR LOWER(syns_list) LIKE "%sitagliptin phosphate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_933070', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933088', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933094', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933100', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933112', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933118', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933124', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933136', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933142', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933148', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933154', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933166', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933172', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933178', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933184', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933190', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933196', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933202', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933208', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933214', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933220', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933232', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933238', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933244', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933250', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933256', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933268', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933274', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933280', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933286', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933292', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933298', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933304', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933226', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933130', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933082', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933058', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933046', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933040', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933262', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933160', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933106', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933076', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933064', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933052', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1183 | Q34 | What are the names of the genes that are targeted by the drug Pexidartinib Hydrochloride in the treatment of Tenosynovial Giant Cell Tumor? | In the context of Tenosynovial Giant Cell Tumor, the drug Pexidartinib Hydrochloride targets the gene fms related receptor tyrosine kinase 3, KIT proto-oncogene, receptor tyrosine kinase and colony stimulating factor 1 receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%tenosynovial giant cell tumor%" OR LOWER(efo_term) LIKE "%tenosynovial giant cell tumor%") AND (LOWER(drugName) LIKE "%pexidartinib hydrochloride%" OR LOWER(tradeNames_list) LIKE "%pexidartinib hydrochloride%" OR LOWER(syns_list) LIKE "%pexidartinib hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_933898', 'drugName': 'Pexidartinib Hydrochloride', 'tradeNames_list': "['Turalio']", 'syns_list': "['FP-113', 'PLX-3397 HCL', 'PLX3397 HCl', 'Pexidartinib hydrochloride']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Giant Cell Tumor of Tendon Sheath', 'efo_term': 'Tenosynovial Giant Cell Tumor', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_933901', 'drugName': 'Pexidartinib Hydrochloride', 'tradeNames_list': "['Turalio']", 'syns_list': "['FP-113', 'PLX-3397 HCL', 'PLX3397 HCl', 'Pexidartinib hydrochloride']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Giant Cell Tumor of Tendon Sheath', 'efo_term': 'Tenosynovial Giant Cell Tumor', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_933902', 'drugName': 'Pexidartinib Hydrochloride', 'tradeNames_list': "['Turalio']", 'syns_list': "['FP-113', 'PLX-3397 HCL', 'PLX3397 HCl', 'Pexidartinib hydrochloride']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Giant Cell Tumor of Tendon Sheath', 'efo_term': 'Tenosynovial Giant Cell Tumor', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_933903', 'drugName': 'Pexidartinib Hydrochloride', 'tradeNames_list': "['Turalio']", 'syns_list': "['FP-113', 'PLX-3397 HCL', 'PLX3397 HCl', 'Pexidartinib hydrochloride']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Giant Cell Tumor of Tendon Sheath', 'efo_term': 'Tenosynovial Giant Cell Tumor', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_933905', 'drugName': 'Pexidartinib Hydrochloride', 'tradeNames_list': "['Turalio']", 'syns_list': "['FP-113', 'PLX-3397 HCL', 'PLX3397 HCl', 'Pexidartinib hydrochloride']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Giant Cell Tumor of Tendon Sheath', 'efo_term': 'Tenosynovial Giant Cell Tumor', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_933906', 'drugName': 'Pexidartinib Hydrochloride', 'tradeNames_list': "['Turalio']", 'syns_list': "['FP-113', 'PLX-3397 HCL', 'PLX3397 HCl', 'Pexidartinib hydrochloride']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Giant Cell Tumor of Tendon Sheath', 'efo_term': 'Tenosynovial Giant Cell Tumor', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_933907', 'drugName': 'Pexidartinib Hydrochloride', 'tradeNames_list': "['Turalio']", 'syns_list': "['FP-113', 'PLX-3397 HCL', 'PLX3397 HCl', 'Pexidartinib hydrochloride']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Giant Cell Tumor of Tendon Sheath', 'efo_term': 'Tenosynovial Giant Cell Tumor', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_933909', 'drugName': 'Pexidartinib Hydrochloride', 'tradeNames_list': "['Turalio']", 'syns_list': "['FP-113', 'PLX-3397 HCL', 'PLX3397 HCl', 'Pexidartinib hydrochloride']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Giant Cell Tumor of Tendon Sheath', 'efo_term': 'Tenosynovial Giant Cell Tumor', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_933910', 'drugName': 'Pexidartinib Hydrochloride', 'tradeNames_list': "['Turalio']", 'syns_list': "['FP-113', 'PLX-3397 HCL', 'PLX3397 HCl', 'Pexidartinib hydrochloride']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Giant Cell Tumor of Tendon Sheath', 'efo_term': 'Tenosynovial Giant Cell Tumor', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_933911', 'drugName': 'Pexidartinib Hydrochloride', 'tradeNames_list': "['Turalio']", 'syns_list': "['FP-113', 'PLX-3397 HCL', 'PLX3397 HCl', 'Pexidartinib hydrochloride']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Giant Cell Tumor of Tendon Sheath', 'efo_term': 'Tenosynovial Giant Cell Tumor', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_933912', 'drugName': 'Pexidartinib Hydrochloride', 'tradeNames_list': "['Turalio']", 'syns_list': "['FP-113', 'PLX-3397 HCL', 'PLX3397 HCl', 'Pexidartinib hydrochloride']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Giant Cell Tumor of Tendon Sheath', 'efo_term': 'Tenosynovial Giant Cell Tumor', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_933914', 'drugName': 'Pexidartinib Hydrochloride', 'tradeNames_list': "['Turalio']", 'syns_list': "['FP-113', 'PLX-3397 HCL', 'PLX3397 HCl', 'Pexidartinib hydrochloride']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Giant Cell Tumor of Tendon Sheath', 'efo_term': 'Tenosynovial Giant Cell Tumor', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_933915', 'drugName': 'Pexidartinib Hydrochloride', 'tradeNames_list': "['Turalio']", 'syns_list': "['FP-113', 'PLX-3397 HCL', 'PLX3397 HCl', 'Pexidartinib hydrochloride']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Giant Cell Tumor of Tendon Sheath', 'efo_term': 'Tenosynovial Giant Cell Tumor', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_933916', 'drugName': 'Pexidartinib Hydrochloride', 'tradeNames_list': "['Turalio']", 'syns_list': "['FP-113', 'PLX-3397 HCL', 'PLX3397 HCl', 'Pexidartinib hydrochloride']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Giant Cell Tumor of Tendon Sheath', 'efo_term': 'Tenosynovial Giant Cell Tumor', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_933917', 'drugName': 'Pexidartinib Hydrochloride', 'tradeNames_list': "['Turalio']", 'syns_list': "['FP-113', 'PLX-3397 HCL', 'PLX3397 HCl', 'Pexidartinib hydrochloride']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Giant Cell Tumor of Tendon Sheath', 'efo_term': 'Tenosynovial Giant Cell Tumor', 'approvedSymbol': 'CSF1R', 'approvedName': 'colony stimulating factor 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_933918', 'drugName': 'Pexidartinib Hydrochloride', 'tradeNames_list': "['Turalio']", 'syns_list': "['FP-113', 'PLX-3397 HCL', 'PLX3397 HCl', 'Pexidartinib hydrochloride']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Giant Cell Tumor of Tendon Sheath', 'efo_term': 'Tenosynovial Giant Cell Tumor', 'approvedSymbol': 'CSF1R', 'approvedName': 'colony stimulating factor 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_933919', 'drugName': 'Pexidartinib Hydrochloride', 'tradeNames_list': "['Turalio']", 'syns_list': "['FP-113', 'PLX-3397 HCL', 'PLX3397 HCl', 'Pexidartinib hydrochloride']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Giant Cell Tumor of Tendon Sheath', 'efo_term': 'Tenosynovial Giant Cell Tumor', 'approvedSymbol': 'CSF1R', 'approvedName': 'colony stimulating factor 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_933920', 'drugName': 'Pexidartinib Hydrochloride', 'tradeNames_list': "['Turalio']", 'syns_list': "['FP-113', 'PLX-3397 HCL', 'PLX3397 HCl', 'Pexidartinib hydrochloride']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Giant Cell Tumor of Tendon Sheath', 'efo_term': 'Tenosynovial Giant Cell Tumor', 'approvedSymbol': 'CSF1R', 'approvedName': 'colony stimulating factor 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_933921', 'drugName': 'Pexidartinib Hydrochloride', 'tradeNames_list': "['Turalio']", 'syns_list': "['FP-113', 'PLX-3397 HCL', 'PLX3397 HCl', 'Pexidartinib hydrochloride']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Giant Cell Tumor of Tendon Sheath', 'efo_term': 'Tenosynovial Giant Cell Tumor', 'approvedSymbol': 'CSF1R', 'approvedName': 'colony stimulating factor 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_933922', 'drugName': 'Pexidartinib Hydrochloride', 'tradeNames_list': "['Turalio']", 'syns_list': "['FP-113', 'PLX-3397 HCL', 'PLX3397 HCl', 'Pexidartinib hydrochloride']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Giant Cell Tumor of Tendon Sheath', 'efo_term': 'Tenosynovial Giant Cell Tumor', 'approvedSymbol': 'CSF1R', 'approvedName': 'colony stimulating factor 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_933923', 'drugName': 'Pexidartinib Hydrochloride', 'tradeNames_list': "['Turalio']", 'syns_list': "['FP-113', 'PLX-3397 HCL', 'PLX3397 HCl', 'Pexidartinib hydrochloride']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Giant Cell Tumor of Tendon Sheath', 'efo_term': 'Tenosynovial Giant Cell Tumor', 'approvedSymbol': 'CSF1R', 'approvedName': 'colony stimulating factor 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_933925', 'drugName': 'Pexidartinib Hydrochloride', 'tradeNames_list': "['Turalio']", 'syns_list': "['FP-113', 'PLX-3397 HCL', 'PLX3397 HCl', 'Pexidartinib hydrochloride']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Giant Cell Tumor of Tendon Sheath', 'efo_term': 'Tenosynovial Giant Cell Tumor', 'approvedSymbol': 'CSF1R', 'approvedName': 'colony stimulating factor 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_933926', 'drugName': 'Pexidartinib Hydrochloride', 'tradeNames_list': "['Turalio']", 'syns_list': "['FP-113', 'PLX-3397 HCL', 'PLX3397 HCl', 'Pexidartinib hydrochloride']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Giant Cell Tumor of Tendon Sheath', 'efo_term': 'Tenosynovial Giant Cell Tumor', 'approvedSymbol': 'CSF1R', 'approvedName': 'colony stimulating factor 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_933927', 'drugName': 'Pexidartinib Hydrochloride', 'tradeNames_list': "['Turalio']", 'syns_list': "['FP-113', 'PLX-3397 HCL', 'PLX3397 HCl', 'Pexidartinib hydrochloride']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Giant Cell Tumor of Tendon Sheath', 'efo_term': 'Tenosynovial Giant Cell Tumor', 'approvedSymbol': 'CSF1R', 'approvedName': 'colony stimulating factor 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_933928', 'drugName': 'Pexidartinib Hydrochloride', 'tradeNames_list': "['Turalio']", 'syns_list': "['FP-113', 'PLX-3397 HCL', 'PLX3397 HCl', 'Pexidartinib hydrochloride']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Giant Cell Tumor of Tendon Sheath', 'efo_term': 'Tenosynovial Giant Cell Tumor', 'approvedSymbol': 'CSF1R', 'approvedName': 'colony stimulating factor 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_933924', 'drugName': 'Pexidartinib Hydrochloride', 'tradeNames_list': "['Turalio']", 'syns_list': "['FP-113', 'PLX-3397 HCL', 'PLX3397 HCl', 'Pexidartinib hydrochloride']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Giant Cell Tumor of Tendon Sheath', 'efo_term': 'Tenosynovial Giant Cell Tumor', 'approvedSymbol': 'CSF1R', 'approvedName': 'colony stimulating factor 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_933900', 'drugName': 'Pexidartinib Hydrochloride', 'tradeNames_list': "['Turalio']", 'syns_list': "['FP-113', 'PLX-3397 HCL', 'PLX3397 HCl', 'Pexidartinib hydrochloride']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Giant Cell Tumor of Tendon Sheath', 'efo_term': 'Tenosynovial Giant Cell Tumor', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_933896', 'drugName': 'Pexidartinib Hydrochloride', 'tradeNames_list': "['Turalio']", 'syns_list': "['FP-113', 'PLX-3397 HCL', 'PLX3397 HCl', 'Pexidartinib hydrochloride']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Giant Cell Tumor of Tendon Sheath', 'efo_term': 'Tenosynovial Giant Cell Tumor', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_933894', 'drugName': 'Pexidartinib Hydrochloride', 'tradeNames_list': "['Turalio']", 'syns_list': "['FP-113', 'PLX-3397 HCL', 'PLX3397 HCl', 'Pexidartinib hydrochloride']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Giant Cell Tumor of Tendon Sheath', 'efo_term': 'Tenosynovial Giant Cell Tumor', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_933893', 'drugName': 'Pexidartinib Hydrochloride', 'tradeNames_list': "['Turalio']", 'syns_list': "['FP-113', 'PLX-3397 HCL', 'PLX3397 HCl', 'Pexidartinib hydrochloride']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Giant Cell Tumor of Tendon Sheath', 'efo_term': 'Tenosynovial Giant Cell Tumor', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_933908', 'drugName': 'Pexidartinib Hydrochloride', 'tradeNames_list': "['Turalio']", 'syns_list': "['FP-113', 'PLX-3397 HCL', 'PLX3397 HCl', 'Pexidartinib hydrochloride']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Giant Cell Tumor of Tendon Sheath', 'efo_term': 'Tenosynovial Giant Cell Tumor', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_933913', 'drugName': 'Pexidartinib Hydrochloride', 'tradeNames_list': "['Turalio']", 'syns_list': "['FP-113', 'PLX-3397 HCL', 'PLX3397 HCl', 'Pexidartinib hydrochloride']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Giant Cell Tumor of Tendon Sheath', 'efo_term': 'Tenosynovial Giant Cell Tumor', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_933904', 'drugName': 'Pexidartinib Hydrochloride', 'tradeNames_list': "['Turalio']", 'syns_list': "['FP-113', 'PLX-3397 HCL', 'PLX3397 HCl', 'Pexidartinib hydrochloride']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Giant Cell Tumor of Tendon Sheath', 'efo_term': 'Tenosynovial Giant Cell Tumor', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_933899', 'drugName': 'Pexidartinib Hydrochloride', 'tradeNames_list': "['Turalio']", 'syns_list': "['FP-113', 'PLX-3397 HCL', 'PLX3397 HCl', 'Pexidartinib hydrochloride']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Giant Cell Tumor of Tendon Sheath', 'efo_term': 'Tenosynovial Giant Cell Tumor', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_933897', 'drugName': 'Pexidartinib Hydrochloride', 'tradeNames_list': "['Turalio']", 'syns_list': "['FP-113', 'PLX-3397 HCL', 'PLX3397 HCl', 'Pexidartinib hydrochloride']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Giant Cell Tumor of Tendon Sheath', 'efo_term': 'Tenosynovial Giant Cell Tumor', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_933895', 'drugName': 'Pexidartinib Hydrochloride', 'tradeNames_list': "['Turalio']", 'syns_list': "['FP-113', 'PLX-3397 HCL', 'PLX3397 HCl', 'Pexidartinib hydrochloride']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Giant Cell Tumor of Tendon Sheath', 'efo_term': 'Tenosynovial Giant Cell Tumor', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.896 | Q34 | What are the names of the genes that are targeted by the drug Naproxen Sodium in the treatment of ankylosing spondylitis? | In the context of ankylosing spondylitis, the drug Naproxen Sodium targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%ankylosing spondylitis%" OR LOWER(efo_term) LIKE "%ankylosing spondylitis%") AND (LOWER(drugName) LIKE "%naproxen sodium%" OR LOWER(tradeNames_list) LIKE "%naproxen sodium%" OR LOWER(syns_list) LIKE "%naproxen sodium%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_838133', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838184', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838201', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838218', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838252', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838269', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838286', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838303', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838167', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838099', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838065', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838048', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838235', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838150', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838116', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838082', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.954 | Q34 | What are the names of the genes that are targeted by the drug Meloxicam in the treatment of osteoarthritis? | In the context of osteoarthritis, the drug Meloxicam targets the gene prostaglandin-endoperoxide synthase 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%osteoarthritis%" OR LOWER(efo_term) LIKE "%osteoarthritis%") AND (LOWER(drugName) LIKE "%meloxicam%" OR LOWER(tradeNames_list) LIKE "%meloxicam%" OR LOWER(syns_list) LIKE "%meloxicam%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_842376', 'drugName': 'Meloxicam', 'tradeNames_list': "['Anjeso', 'Meloxicam', 'Mobic', 'Qmiiz odt', 'Vivlodex']", 'syns_list': "['Acticam', 'Contacera', 'Coxicam', 'Emdocam', 'Flexicam', 'Inflacam', 'LoxicomMelfax', 'Melosus', 'Melovem', 'Meloxicam', 'Meloxidolor', 'MeloxidylMeloxivet', 'Meloxoral', 'Metacam', 'Movatec', 'N-1539', 'N1539', 'RecocamRevitacam', 'Rheumocam', 'UH-AC 62XX', 'UH-AC-62 XX', 'UHAC-62XX']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842421', 'drugName': 'Meloxicam', 'tradeNames_list': "['Anjeso', 'Meloxicam', 'Mobic', 'Qmiiz odt', 'Vivlodex']", 'syns_list': "['Acticam', 'Contacera', 'Coxicam', 'Emdocam', 'Flexicam', 'Inflacam', 'LoxicomMelfax', 'Melosus', 'Melovem', 'Meloxicam', 'Meloxidolor', 'MeloxidylMeloxivet', 'Meloxoral', 'Metacam', 'Movatec', 'N-1539', 'N1539', 'RecocamRevitacam', 'Rheumocam', 'UH-AC 62XX', 'UH-AC-62 XX', 'UHAC-62XX']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842436', 'drugName': 'Meloxicam', 'tradeNames_list': "['Anjeso', 'Meloxicam', 'Mobic', 'Qmiiz odt', 'Vivlodex']", 'syns_list': "['Acticam', 'Contacera', 'Coxicam', 'Emdocam', 'Flexicam', 'Inflacam', 'LoxicomMelfax', 'Melosus', 'Melovem', 'Meloxicam', 'Meloxidolor', 'MeloxidylMeloxivet', 'Meloxoral', 'Metacam', 'Movatec', 'N-1539', 'N1539', 'RecocamRevitacam', 'Rheumocam', 'UH-AC 62XX', 'UH-AC-62 XX', 'UHAC-62XX']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842451', 'drugName': 'Meloxicam', 'tradeNames_list': "['Anjeso', 'Meloxicam', 'Mobic', 'Qmiiz odt', 'Vivlodex']", 'syns_list': "['Acticam', 'Contacera', 'Coxicam', 'Emdocam', 'Flexicam', 'Inflacam', 'LoxicomMelfax', 'Melosus', 'Melovem', 'Meloxicam', 'Meloxidolor', 'MeloxidylMeloxivet', 'Meloxoral', 'Metacam', 'Movatec', 'N-1539', 'N1539', 'RecocamRevitacam', 'Rheumocam', 'UH-AC 62XX', 'UH-AC-62 XX', 'UHAC-62XX']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842481', 'drugName': 'Meloxicam', 'tradeNames_list': "['Anjeso', 'Meloxicam', 'Mobic', 'Qmiiz odt', 'Vivlodex']", 'syns_list': "['Acticam', 'Contacera', 'Coxicam', 'Emdocam', 'Flexicam', 'Inflacam', 'LoxicomMelfax', 'Melosus', 'Melovem', 'Meloxicam', 'Meloxidolor', 'MeloxidylMeloxivet', 'Meloxoral', 'Metacam', 'Movatec', 'N-1539', 'N1539', 'RecocamRevitacam', 'Rheumocam', 'UH-AC 62XX', 'UH-AC-62 XX', 'UHAC-62XX']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842496', 'drugName': 'Meloxicam', 'tradeNames_list': "['Anjeso', 'Meloxicam', 'Mobic', 'Qmiiz odt', 'Vivlodex']", 'syns_list': "['Acticam', 'Contacera', 'Coxicam', 'Emdocam', 'Flexicam', 'Inflacam', 'LoxicomMelfax', 'Melosus', 'Melovem', 'Meloxicam', 'Meloxidolor', 'MeloxidylMeloxivet', 'Meloxoral', 'Metacam', 'Movatec', 'N-1539', 'N1539', 'RecocamRevitacam', 'Rheumocam', 'UH-AC 62XX', 'UH-AC-62 XX', 'UHAC-62XX']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842511', 'drugName': 'Meloxicam', 'tradeNames_list': "['Anjeso', 'Meloxicam', 'Mobic', 'Qmiiz odt', 'Vivlodex']", 'syns_list': "['Acticam', 'Contacera', 'Coxicam', 'Emdocam', 'Flexicam', 'Inflacam', 'LoxicomMelfax', 'Melosus', 'Melovem', 'Meloxicam', 'Meloxidolor', 'MeloxidylMeloxivet', 'Meloxoral', 'Metacam', 'Movatec', 'N-1539', 'N1539', 'RecocamRevitacam', 'Rheumocam', 'UH-AC 62XX', 'UH-AC-62 XX', 'UHAC-62XX']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842541', 'drugName': 'Meloxicam', 'tradeNames_list': "['Anjeso', 'Meloxicam', 'Mobic', 'Qmiiz odt', 'Vivlodex']", 'syns_list': "['Acticam', 'Contacera', 'Coxicam', 'Emdocam', 'Flexicam', 'Inflacam', 'LoxicomMelfax', 'Melosus', 'Melovem', 'Meloxicam', 'Meloxidolor', 'MeloxidylMeloxivet', 'Meloxoral', 'Metacam', 'Movatec', 'N-1539', 'N1539', 'RecocamRevitacam', 'Rheumocam', 'UH-AC 62XX', 'UH-AC-62 XX', 'UHAC-62XX']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842526', 'drugName': 'Meloxicam', 'tradeNames_list': "['Anjeso', 'Meloxicam', 'Mobic', 'Qmiiz odt', 'Vivlodex']", 'syns_list': "['Acticam', 'Contacera', 'Coxicam', 'Emdocam', 'Flexicam', 'Inflacam', 'LoxicomMelfax', 'Melosus', 'Melovem', 'Meloxicam', 'Meloxidolor', 'MeloxidylMeloxivet', 'Meloxoral', 'Metacam', 'Movatec', 'N-1539', 'N1539', 'RecocamRevitacam', 'Rheumocam', 'UH-AC 62XX', 'UH-AC-62 XX', 'UHAC-62XX']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842406', 'drugName': 'Meloxicam', 'tradeNames_list': "['Anjeso', 'Meloxicam', 'Mobic', 'Qmiiz odt', 'Vivlodex']", 'syns_list': "['Acticam', 'Contacera', 'Coxicam', 'Emdocam', 'Flexicam', 'Inflacam', 'LoxicomMelfax', 'Melosus', 'Melovem', 'Meloxicam', 'Meloxidolor', 'MeloxidylMeloxivet', 'Meloxoral', 'Metacam', 'Movatec', 'N-1539', 'N1539', 'RecocamRevitacam', 'Rheumocam', 'UH-AC 62XX', 'UH-AC-62 XX', 'UHAC-62XX']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842346', 'drugName': 'Meloxicam', 'tradeNames_list': "['Anjeso', 'Meloxicam', 'Mobic', 'Qmiiz odt', 'Vivlodex']", 'syns_list': "['Acticam', 'Contacera', 'Coxicam', 'Emdocam', 'Flexicam', 'Inflacam', 'LoxicomMelfax', 'Melosus', 'Melovem', 'Meloxicam', 'Meloxidolor', 'MeloxidylMeloxivet', 'Meloxoral', 'Metacam', 'Movatec', 'N-1539', 'N1539', 'RecocamRevitacam', 'Rheumocam', 'UH-AC 62XX', 'UH-AC-62 XX', 'UHAC-62XX']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842301', 'drugName': 'Meloxicam', 'tradeNames_list': "['Anjeso', 'Meloxicam', 'Mobic', 'Qmiiz odt', 'Vivlodex']", 'syns_list': "['Acticam', 'Contacera', 'Coxicam', 'Emdocam', 'Flexicam', 'Inflacam', 'LoxicomMelfax', 'Melosus', 'Melovem', 'Meloxicam', 'Meloxidolor', 'MeloxidylMeloxivet', 'Meloxoral', 'Metacam', 'Movatec', 'N-1539', 'N1539', 'RecocamRevitacam', 'Rheumocam', 'UH-AC 62XX', 'UH-AC-62 XX', 'UHAC-62XX']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842316', 'drugName': 'Meloxicam', 'tradeNames_list': "['Anjeso', 'Meloxicam', 'Mobic', 'Qmiiz odt', 'Vivlodex']", 'syns_list': "['Acticam', 'Contacera', 'Coxicam', 'Emdocam', 'Flexicam', 'Inflacam', 'LoxicomMelfax', 'Melosus', 'Melovem', 'Meloxicam', 'Meloxidolor', 'MeloxidylMeloxivet', 'Meloxoral', 'Metacam', 'Movatec', 'N-1539', 'N1539', 'RecocamRevitacam', 'Rheumocam', 'UH-AC 62XX', 'UH-AC-62 XX', 'UHAC-62XX']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842466', 'drugName': 'Meloxicam', 'tradeNames_list': "['Anjeso', 'Meloxicam', 'Mobic', 'Qmiiz odt', 'Vivlodex']", 'syns_list': "['Acticam', 'Contacera', 'Coxicam', 'Emdocam', 'Flexicam', 'Inflacam', 'LoxicomMelfax', 'Melosus', 'Melovem', 'Meloxicam', 'Meloxidolor', 'MeloxidylMeloxivet', 'Meloxoral', 'Metacam', 'Movatec', 'N-1539', 'N1539', 'RecocamRevitacam', 'Rheumocam', 'UH-AC 62XX', 'UH-AC-62 XX', 'UHAC-62XX']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842391', 'drugName': 'Meloxicam', 'tradeNames_list': "['Anjeso', 'Meloxicam', 'Mobic', 'Qmiiz odt', 'Vivlodex']", 'syns_list': "['Acticam', 'Contacera', 'Coxicam', 'Emdocam', 'Flexicam', 'Inflacam', 'LoxicomMelfax', 'Melosus', 'Melovem', 'Meloxicam', 'Meloxidolor', 'MeloxidylMeloxivet', 'Meloxoral', 'Metacam', 'Movatec', 'N-1539', 'N1539', 'RecocamRevitacam', 'Rheumocam', 'UH-AC 62XX', 'UH-AC-62 XX', 'UHAC-62XX']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842361', 'drugName': 'Meloxicam', 'tradeNames_list': "['Anjeso', 'Meloxicam', 'Mobic', 'Qmiiz odt', 'Vivlodex']", 'syns_list': "['Acticam', 'Contacera', 'Coxicam', 'Emdocam', 'Flexicam', 'Inflacam', 'LoxicomMelfax', 'Melosus', 'Melovem', 'Meloxicam', 'Meloxidolor', 'MeloxidylMeloxivet', 'Meloxoral', 'Metacam', 'Movatec', 'N-1539', 'N1539', 'RecocamRevitacam', 'Rheumocam', 'UH-AC 62XX', 'UH-AC-62 XX', 'UHAC-62XX']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842331', 'drugName': 'Meloxicam', 'tradeNames_list': "['Anjeso', 'Meloxicam', 'Mobic', 'Qmiiz odt', 'Vivlodex']", 'syns_list': "['Acticam', 'Contacera', 'Coxicam', 'Emdocam', 'Flexicam', 'Inflacam', 'LoxicomMelfax', 'Melosus', 'Melovem', 'Meloxicam', 'Meloxidolor', 'MeloxidylMeloxivet', 'Meloxoral', 'Metacam', 'Movatec', 'N-1539', 'N1539', 'RecocamRevitacam', 'Rheumocam', 'UH-AC 62XX', 'UH-AC-62 XX', 'UHAC-62XX']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1055 | Q34 | What are the names of the genes that are targeted by the drug Fluorouracil in the treatment of cancer? | In the context of cancer, the drug Fluorouracil targets the gene thymidylate synthetase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cancer%" OR LOWER(efo_term) LIKE "%cancer%") AND (LOWER(drugName) LIKE "%fluorouracil%" OR LOWER(tradeNames_list) LIKE "%fluorouracil%" OR LOWER(syns_list) LIKE "%fluorouracil%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_919463', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919443', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919457', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Esophageal Neoplasms', 'efo_term': 'esophageal cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919452', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Biliary Tract Neoplasms', 'efo_term': 'biliary tract cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919456', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919427', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919449', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Kidney Neoplasms', 'efo_term': 'kidney cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919451', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919450', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Liver Neoplasms', 'efo_term': 'liver cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919425', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'oral cavity cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919435', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectum cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919444', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919426', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Pharyngeal Neoplasms', 'efo_term': 'pharynx cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919445', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Anus Neoplasms', 'efo_term': 'anus cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919389', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Merkel Cell', 'efo_term': 'Merkel cell skin cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919394', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urethral Neoplasms', 'efo_term': 'urethra cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919392', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Digestive System Neoplasms', 'efo_term': 'digestive system cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919393', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Bile Duct Neoplasms', 'efo_term': 'bile duct cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919391', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneum cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919395', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919366', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Glioma', 'efo_term': 'central nervous system cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1337 | Q34 | What are the names of the genes that are targeted by the drug Capsaicin in the treatment of Arthralgia? | In the context of Arthralgia, the drug Capsaicin targets the gene transient receptor potential cation channel subfamily V member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%arthralgia%" OR LOWER(efo_term) LIKE "%arthralgia%") AND (LOWER(drugName) LIKE "%capsaicin%" OR LOWER(tradeNames_list) LIKE "%capsaicin%" OR LOWER(syns_list) LIKE "%capsaicin%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_993221', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthralgia', 'efo_term': 'Arthralgia', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_993147', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthralgia', 'efo_term': 'Arthralgia', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_993073', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthralgia', 'efo_term': 'Arthralgia', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_993036', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthralgia', 'efo_term': 'Arthralgia', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_993258', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthralgia', 'efo_term': 'Arthralgia', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_993184', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthralgia', 'efo_term': 'Arthralgia', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_993110', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthralgia', 'efo_term': 'Arthralgia', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1356 | Q34 | What are the names of the genes that are targeted by the drug Donepezil Hydrochloride in the treatment of Alzheimer disease? | In the context of Alzheimer disease, the drug Donepezil Hydrochloride targets the gene acetylcholinesterase (Cartwright blood group). | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%alzheimer disease%" OR LOWER(efo_term) LIKE "%alzheimer disease%") AND (LOWER(drugName) LIKE "%donepezil hydrochloride%" OR LOWER(tradeNames_list) LIKE "%donepezil hydrochloride%" OR LOWER(syns_list) LIKE "%donepezil hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_993848', 'drugName': 'Donepezil Hydrochloride', 'tradeNames_list': "['Adlarity', 'Aricept', 'Aricept evess', 'Aricept odtDonepezil hydrochloride']", 'syns_list': "['Adlarity', 'BNAG', 'Donepezil hcl', 'Donepezil hydrochloride', 'E-2020E2020', 'NSC-737535', 'NSC-758882']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'approvedSymbol': 'ACHE', 'approvedName': 'acetylcholinesterase (Cartwright blood group)'}, {'UUID': 'DrugTargetsIndication121923_text_993884', 'drugName': 'Donepezil Hydrochloride', 'tradeNames_list': "['Adlarity', 'Aricept', 'Aricept evess', 'Aricept odtDonepezil hydrochloride']", 'syns_list': "['Adlarity', 'BNAG', 'Donepezil hcl', 'Donepezil hydrochloride', 'E-2020E2020', 'NSC-737535', 'NSC-758882']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'approvedSymbol': 'ACHE', 'approvedName': 'acetylcholinesterase (Cartwright blood group)'}, {'UUID': 'DrugTargetsIndication121923_text_993896', 'drugName': 'Donepezil Hydrochloride', 'tradeNames_list': "['Adlarity', 'Aricept', 'Aricept evess', 'Aricept odtDonepezil hydrochloride']", 'syns_list': "['Adlarity', 'BNAG', 'Donepezil hcl', 'Donepezil hydrochloride', 'E-2020E2020', 'NSC-737535', 'NSC-758882']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'approvedSymbol': 'ACHE', 'approvedName': 'acetylcholinesterase (Cartwright blood group)'}, {'UUID': 'DrugTargetsIndication121923_text_993908', 'drugName': 'Donepezil Hydrochloride', 'tradeNames_list': "['Adlarity', 'Aricept', 'Aricept evess', 'Aricept odtDonepezil hydrochloride']", 'syns_list': "['Adlarity', 'BNAG', 'Donepezil hcl', 'Donepezil hydrochloride', 'E-2020E2020', 'NSC-737535', 'NSC-758882']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'approvedSymbol': 'ACHE', 'approvedName': 'acetylcholinesterase (Cartwright blood group)'}, {'UUID': 'DrugTargetsIndication121923_text_993932', 'drugName': 'Donepezil Hydrochloride', 'tradeNames_list': "['Adlarity', 'Aricept', 'Aricept evess', 'Aricept odtDonepezil hydrochloride']", 'syns_list': "['Adlarity', 'BNAG', 'Donepezil hcl', 'Donepezil hydrochloride', 'E-2020E2020', 'NSC-737535', 'NSC-758882']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'approvedSymbol': 'ACHE', 'approvedName': 'acetylcholinesterase (Cartwright blood group)'}, {'UUID': 'DrugTargetsIndication121923_text_993944', 'drugName': 'Donepezil Hydrochloride', 'tradeNames_list': "['Adlarity', 'Aricept', 'Aricept evess', 'Aricept odtDonepezil hydrochloride']", 'syns_list': "['Adlarity', 'BNAG', 'Donepezil hcl', 'Donepezil hydrochloride', 'E-2020E2020', 'NSC-737535', 'NSC-758882']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'approvedSymbol': 'ACHE', 'approvedName': 'acetylcholinesterase (Cartwright blood group)'}, {'UUID': 'DrugTargetsIndication121923_text_993956', 'drugName': 'Donepezil Hydrochloride', 'tradeNames_list': "['Adlarity', 'Aricept', 'Aricept evess', 'Aricept odtDonepezil hydrochloride']", 'syns_list': "['Adlarity', 'BNAG', 'Donepezil hcl', 'Donepezil hydrochloride', 'E-2020E2020', 'NSC-737535', 'NSC-758882']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'approvedSymbol': 'ACHE', 'approvedName': 'acetylcholinesterase (Cartwright blood group)'}, {'UUID': 'DrugTargetsIndication121923_text_993872', 'drugName': 'Donepezil Hydrochloride', 'tradeNames_list': "['Adlarity', 'Aricept', 'Aricept evess', 'Aricept odtDonepezil hydrochloride']", 'syns_list': "['Adlarity', 'BNAG', 'Donepezil hcl', 'Donepezil hydrochloride', 'E-2020E2020', 'NSC-737535', 'NSC-758882']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'approvedSymbol': 'ACHE', 'approvedName': 'acetylcholinesterase (Cartwright blood group)'}, {'UUID': 'DrugTargetsIndication121923_text_993824', 'drugName': 'Donepezil Hydrochloride', 'tradeNames_list': "['Adlarity', 'Aricept', 'Aricept evess', 'Aricept odtDonepezil hydrochloride']", 'syns_list': "['Adlarity', 'BNAG', 'Donepezil hcl', 'Donepezil hydrochloride', 'E-2020E2020', 'NSC-737535', 'NSC-758882']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'approvedSymbol': 'ACHE', 'approvedName': 'acetylcholinesterase (Cartwright blood group)'}, {'UUID': 'DrugTargetsIndication121923_text_993800', 'drugName': 'Donepezil Hydrochloride', 'tradeNames_list': "['Adlarity', 'Aricept', 'Aricept evess', 'Aricept odtDonepezil hydrochloride']", 'syns_list': "['Adlarity', 'BNAG', 'Donepezil hcl', 'Donepezil hydrochloride', 'E-2020E2020', 'NSC-737535', 'NSC-758882']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'approvedSymbol': 'ACHE', 'approvedName': 'acetylcholinesterase (Cartwright blood group)'}, {'UUID': 'DrugTargetsIndication121923_text_993788', 'drugName': 'Donepezil Hydrochloride', 'tradeNames_list': "['Adlarity', 'Aricept', 'Aricept evess', 'Aricept odtDonepezil hydrochloride']", 'syns_list': "['Adlarity', 'BNAG', 'Donepezil hcl', 'Donepezil hydrochloride', 'E-2020E2020', 'NSC-737535', 'NSC-758882']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'approvedSymbol': 'ACHE', 'approvedName': 'acetylcholinesterase (Cartwright blood group)'}, {'UUID': 'DrugTargetsIndication121923_text_993920', 'drugName': 'Donepezil Hydrochloride', 'tradeNames_list': "['Adlarity', 'Aricept', 'Aricept evess', 'Aricept odtDonepezil hydrochloride']", 'syns_list': "['Adlarity', 'BNAG', 'Donepezil hcl', 'Donepezil hydrochloride', 'E-2020E2020', 'NSC-737535', 'NSC-758882']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'approvedSymbol': 'ACHE', 'approvedName': 'acetylcholinesterase (Cartwright blood group)'}, {'UUID': 'DrugTargetsIndication121923_text_993860', 'drugName': 'Donepezil Hydrochloride', 'tradeNames_list': "['Adlarity', 'Aricept', 'Aricept evess', 'Aricept odtDonepezil hydrochloride']", 'syns_list': "['Adlarity', 'BNAG', 'Donepezil hcl', 'Donepezil hydrochloride', 'E-2020E2020', 'NSC-737535', 'NSC-758882']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'approvedSymbol': 'ACHE', 'approvedName': 'acetylcholinesterase (Cartwright blood group)'}, {'UUID': 'DrugTargetsIndication121923_text_993836', 'drugName': 'Donepezil Hydrochloride', 'tradeNames_list': "['Adlarity', 'Aricept', 'Aricept evess', 'Aricept odtDonepezil hydrochloride']", 'syns_list': "['Adlarity', 'BNAG', 'Donepezil hcl', 'Donepezil hydrochloride', 'E-2020E2020', 'NSC-737535', 'NSC-758882']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'approvedSymbol': 'ACHE', 'approvedName': 'acetylcholinesterase (Cartwright blood group)'}, {'UUID': 'DrugTargetsIndication121923_text_993812', 'drugName': 'Donepezil Hydrochloride', 'tradeNames_list': "['Adlarity', 'Aricept', 'Aricept evess', 'Aricept odtDonepezil hydrochloride']", 'syns_list': "['Adlarity', 'BNAG', 'Donepezil hcl', 'Donepezil hydrochloride', 'E-2020E2020', 'NSC-737535', 'NSC-758882']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'approvedSymbol': 'ACHE', 'approvedName': 'acetylcholinesterase (Cartwright blood group)'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1432 | Q34 | What are the names of the genes that are targeted by the drug Amlodipine Besylate in the treatment of stroke? | In the context of stroke, the drug Amlodipine Besylate targets the gene calcium voltage-gated channel subunit alpha1 C, calcium voltage-gated channel subunit alpha1 S, calcium voltage-gated channel subunit alpha1 D and calcium voltage-gated channel subunit alpha1 F. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%stroke%" OR LOWER(efo_term) LIKE "%stroke%") AND (LOWER(drugName) LIKE "%amlodipine besylate%" OR LOWER(tradeNames_list) LIKE "%amlodipine besylate%" OR LOWER(syns_list) LIKE "%amlodipine besylate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1043736', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043778', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043792', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043806', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043834', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043848', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043862', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043890', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043904', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043918', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043932', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043960', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043974', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043988', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043876', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043764', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043708', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043680', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043666', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043946', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043820', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043750', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043722', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043694', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.890 | Q34 | What are the names of the genes that are targeted by the drug Diclofenac in the treatment of migraine disorder? | In the context of migraine disorder, the drug Diclofenac targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%migraine disorder%" OR LOWER(efo_term) LIKE "%migraine disorder%") AND (LOWER(drugName) LIKE "%diclofenac%" OR LOWER(tradeNames_list) LIKE "%diclofenac%" OR LOWER(syns_list) LIKE "%diclofenac%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_837136', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837226', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837256', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837286', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837346', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837376', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837406', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837466', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837496', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837526', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837556', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837616', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837646', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837676', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837706', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837736', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837766', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837796', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837826', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837856', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837886', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837946', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837976', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838006', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838036', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842894', 'drugName': 'Diclofenac Potassium', 'tradeNames_list': "['Cambia', 'Cataflam', 'Diclofenac potassium', 'Voltarol joint painVoltarol pain-eze', 'Voltarol pain-eze extra strgh', 'Voltarol rapidZipsor']", 'syns_list': "['CGP 45840B', 'CGP-45840B', 'Diclofenac potassiumDiclofenac potassium salt', 'Potassium diclofenac']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842912', 'drugName': 'Diclofenac Potassium', 'tradeNames_list': "['Cambia', 'Cataflam', 'Diclofenac potassium', 'Voltarol joint painVoltarol pain-eze', 'Voltarol pain-eze extra strgh', 'Voltarol rapidZipsor']", 'syns_list': "['CGP 45840B', 'CGP-45840B', 'Diclofenac potassiumDiclofenac potassium salt', 'Potassium diclofenac']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842921', 'drugName': 'Diclofenac Potassium', 'tradeNames_list': "['Cambia', 'Cataflam', 'Diclofenac potassium', 'Voltarol joint painVoltarol pain-eze', 'Voltarol pain-eze extra strgh', 'Voltarol rapidZipsor']", 'syns_list': "['CGP 45840B', 'CGP-45840B', 'Diclofenac potassiumDiclofenac potassium salt', 'Potassium diclofenac']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842930', 'drugName': 'Diclofenac Potassium', 'tradeNames_list': "['Cambia', 'Cataflam', 'Diclofenac potassium', 'Voltarol joint painVoltarol pain-eze', 'Voltarol pain-eze extra strgh', 'Voltarol rapidZipsor']", 'syns_list': "['CGP 45840B', 'CGP-45840B', 'Diclofenac potassiumDiclofenac potassium salt', 'Potassium diclofenac']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842939', 'drugName': 'Diclofenac Potassium', 'tradeNames_list': "['Cambia', 'Cataflam', 'Diclofenac potassium', 'Voltarol joint painVoltarol pain-eze', 'Voltarol pain-eze extra strgh', 'Voltarol rapidZipsor']", 'syns_list': "['CGP 45840B', 'CGP-45840B', 'Diclofenac potassiumDiclofenac potassium salt', 'Potassium diclofenac']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842948', 'drugName': 'Diclofenac Potassium', 'tradeNames_list': "['Cambia', 'Cataflam', 'Diclofenac potassium', 'Voltarol joint painVoltarol pain-eze', 'Voltarol pain-eze extra strgh', 'Voltarol rapidZipsor']", 'syns_list': "['CGP 45840B', 'CGP-45840B', 'Diclofenac potassiumDiclofenac potassium salt', 'Potassium diclofenac']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842957', 'drugName': 'Diclofenac Potassium', 'tradeNames_list': "['Cambia', 'Cataflam', 'Diclofenac potassium', 'Voltarol joint painVoltarol pain-eze', 'Voltarol pain-eze extra strgh', 'Voltarol rapidZipsor']", 'syns_list': "['CGP 45840B', 'CGP-45840B', 'Diclofenac potassiumDiclofenac potassium salt', 'Potassium diclofenac']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842966', 'drugName': 'Diclofenac Potassium', 'tradeNames_list': "['Cambia', 'Cataflam', 'Diclofenac potassium', 'Voltarol joint painVoltarol pain-eze', 'Voltarol pain-eze extra strgh', 'Voltarol rapidZipsor']", 'syns_list': "['CGP 45840B', 'CGP-45840B', 'Diclofenac potassiumDiclofenac potassium salt', 'Potassium diclofenac']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842975', 'drugName': 'Diclofenac Potassium', 'tradeNames_list': "['Cambia', 'Cataflam', 'Diclofenac potassium', 'Voltarol joint painVoltarol pain-eze', 'Voltarol pain-eze extra strgh', 'Voltarol rapidZipsor']", 'syns_list': "['CGP 45840B', 'CGP-45840B', 'Diclofenac potassiumDiclofenac potassium salt', 'Potassium diclofenac']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842984', 'drugName': 'Diclofenac Potassium', 'tradeNames_list': "['Cambia', 'Cataflam', 'Diclofenac potassium', 'Voltarol joint painVoltarol pain-eze', 'Voltarol pain-eze extra strgh', 'Voltarol rapidZipsor']", 'syns_list': "['CGP 45840B', 'CGP-45840B', 'Diclofenac potassiumDiclofenac potassium salt', 'Potassium diclofenac']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842993', 'drugName': 'Diclofenac Potassium', 'tradeNames_list': "['Cambia', 'Cataflam', 'Diclofenac potassium', 'Voltarol joint painVoltarol pain-eze', 'Voltarol pain-eze extra strgh', 'Voltarol rapidZipsor']", 'syns_list': "['CGP 45840B', 'CGP-45840B', 'Diclofenac potassiumDiclofenac potassium salt', 'Potassium diclofenac']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843002', 'drugName': 'Diclofenac Potassium', 'tradeNames_list': "['Cambia', 'Cataflam', 'Diclofenac potassium', 'Voltarol joint painVoltarol pain-eze', 'Voltarol pain-eze extra strgh', 'Voltarol rapidZipsor']", 'syns_list': "['CGP 45840B', 'CGP-45840B', 'Diclofenac potassiumDiclofenac potassium salt', 'Potassium diclofenac']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843011', 'drugName': 'Diclofenac Potassium', 'tradeNames_list': "['Cambia', 'Cataflam', 'Diclofenac potassium', 'Voltarol joint painVoltarol pain-eze', 'Voltarol pain-eze extra strgh', 'Voltarol rapidZipsor']", 'syns_list': "['CGP 45840B', 'CGP-45840B', 'Diclofenac potassiumDiclofenac potassium salt', 'Potassium diclofenac']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843020', 'drugName': 'Diclofenac Potassium', 'tradeNames_list': "['Cambia', 'Cataflam', 'Diclofenac potassium', 'Voltarol joint painVoltarol pain-eze', 'Voltarol pain-eze extra strgh', 'Voltarol rapidZipsor']", 'syns_list': "['CGP 45840B', 'CGP-45840B', 'Diclofenac potassiumDiclofenac potassium salt', 'Potassium diclofenac']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843029', 'drugName': 'Diclofenac Potassium', 'tradeNames_list': "['Cambia', 'Cataflam', 'Diclofenac potassium', 'Voltarol joint painVoltarol pain-eze', 'Voltarol pain-eze extra strgh', 'Voltarol rapidZipsor']", 'syns_list': "['CGP 45840B', 'CGP-45840B', 'Diclofenac potassiumDiclofenac potassium salt', 'Potassium diclofenac']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843038', 'drugName': 'Diclofenac Potassium', 'tradeNames_list': "['Cambia', 'Cataflam', 'Diclofenac potassium', 'Voltarol joint painVoltarol pain-eze', 'Voltarol pain-eze extra strgh', 'Voltarol rapidZipsor']", 'syns_list': "['CGP 45840B', 'CGP-45840B', 'Diclofenac potassiumDiclofenac potassium salt', 'Potassium diclofenac']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843047', 'drugName': 'Diclofenac Potassium', 'tradeNames_list': "['Cambia', 'Cataflam', 'Diclofenac potassium', 'Voltarol joint painVoltarol pain-eze', 'Voltarol pain-eze extra strgh', 'Voltarol rapidZipsor']", 'syns_list': "['CGP 45840B', 'CGP-45840B', 'Diclofenac potassiumDiclofenac potassium salt', 'Potassium diclofenac']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843056', 'drugName': 'Diclofenac Potassium', 'tradeNames_list': "['Cambia', 'Cataflam', 'Diclofenac potassium', 'Voltarol joint painVoltarol pain-eze', 'Voltarol pain-eze extra strgh', 'Voltarol rapidZipsor']", 'syns_list': "['CGP 45840B', 'CGP-45840B', 'Diclofenac potassiumDiclofenac potassium salt', 'Potassium diclofenac']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843065', 'drugName': 'Diclofenac Potassium', 'tradeNames_list': "['Cambia', 'Cataflam', 'Diclofenac potassium', 'Voltarol joint painVoltarol pain-eze', 'Voltarol pain-eze extra strgh', 'Voltarol rapidZipsor']", 'syns_list': "['CGP 45840B', 'CGP-45840B', 'Diclofenac potassiumDiclofenac potassium salt', 'Potassium diclofenac']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837916', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837436', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837196', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837076', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837016', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836986', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842903', 'drugName': 'Diclofenac Potassium', 'tradeNames_list': "['Cambia', 'Cataflam', 'Diclofenac potassium', 'Voltarol joint painVoltarol pain-eze', 'Voltarol pain-eze extra strgh', 'Voltarol rapidZipsor']", 'syns_list': "['CGP 45840B', 'CGP-45840B', 'Diclofenac potassiumDiclofenac potassium salt', 'Potassium diclofenac']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837586', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837316', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837166', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837106', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837046', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1658 | Q34 | What are the names of the genes that are targeted by the drug Spironolactone in the treatment of cardiovascular disease? | In the context of cardiovascular disease, the drug Spironolactone targets the gene nuclear receptor subfamily 3 group C member 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cardiovascular disease%" OR LOWER(efo_term) LIKE "%cardiovascular disease%") AND (LOWER(drugName) LIKE "%spironolactone%" OR LOWER(tradeNames_list) LIKE "%spironolactone%" OR LOWER(syns_list) LIKE "%spironolactone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1094538', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094652', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094614', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094462', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094348', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094386', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094576', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094500', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094424', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.856 | Q34 | What are the names of the genes that are targeted by the drug Aspirin in the treatment of Myalgia? | In the context of Myalgia, the drug Aspirin targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%myalgia%" OR LOWER(efo_term) LIKE "%myalgia%") AND (LOWER(drugName) LIKE "%aspirin%" OR LOWER(tradeNames_list) LIKE "%aspirin%" OR LOWER(syns_list) LIKE "%aspirin%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_834426', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_834897', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835054', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835211', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835525', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835682', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835839', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835996', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_834740', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_834112', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833798', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833641', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_835368', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_834583', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_834269', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833955', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.739 | Q34 | What are the names of the genes that are targeted by the drug Morphine Sulfate in the treatment of Chronic pain? | In the context of Chronic pain, the drug Morphine Sulfate targets the gene opioid receptor mu 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%chronic pain%" OR LOWER(efo_term) LIKE "%chronic pain%") AND (LOWER(drugName) LIKE "%morphine sulfate%" OR LOWER(tradeNames_list) LIKE "%morphine sulfate%" OR LOWER(syns_list) LIKE "%morphine sulfate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_763495', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763552', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763571', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763590', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763628', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763647', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763666', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763704', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763723', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763742', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763761', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763799', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763818', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763837', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763856', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763875', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763894', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763913', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763932', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763951', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763970', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764008', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764027', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763989', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763685', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763533', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763419', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763400', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763457', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763780', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763609', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763514', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763476', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763438', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.722 | Q34 | What are the names of the genes that are targeted by the drug Encorafenib in the treatment of cutaneous melanoma? | In the context of cutaneous melanoma, the drug Encorafenib targets the gene B-Raf proto-oncogene, serine/threonine kinase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cutaneous melanoma%" OR LOWER(efo_term) LIKE "%cutaneous melanoma%") AND (LOWER(drugName) LIKE "%encorafenib%" OR LOWER(tradeNames_list) LIKE "%encorafenib%" OR LOWER(syns_list) LIKE "%encorafenib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_752306', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752348', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752362', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752376', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752404', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752418', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752432', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752460', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752474', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752488', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752502', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752530', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752544', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752558', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752572', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752586', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752600', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752614', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752628', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752642', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752656', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752670', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752446', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752334', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752278', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752250', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752236', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752516', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752390', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752320', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752292', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752264', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.458 | Q34 | What are the names of the genes that are targeted by the drug Phenylephrine Hydrochloride in the treatment of hypotension? | In the context of hypotension, the drug Phenylephrine Hydrochloride targets the gene adrenoceptor alpha 1A, adrenoceptor alpha 1D and adrenoceptor alpha 1B. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%hypotension%" OR LOWER(efo_term) LIKE "%hypotension%") AND (LOWER(drugName) LIKE "%phenylephrine hydrochloride%" OR LOWER(tradeNames_list) LIKE "%phenylephrine hydrochloride%" OR LOWER(syns_list) LIKE "%phenylephrine hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_416700', 'drugName': 'Phenylephrine Hydrochloride', 'tradeNames_list': "['Afrin 4 hour nasal spray', 'Biomydrin', 'Biorphen', 'Fenilfar', 'FenoxMydfrin', 'Nazex', 'Neo-synephrine', 'Neosynephrine', 'NostrilNurofen sinus pain relief', 'Phenylephrine hydrochloride', 'PrefrinVazculep']", 'syns_list': "['Metaoxedrine chloride', 'NSC-757273', 'Phenylephrine HClPhenylephrine hydrochloride']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotension', 'efo_term': 'hypotension', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_416628', 'drugName': 'Phenylephrine Hydrochloride', 'tradeNames_list': "['Afrin 4 hour nasal spray', 'Biomydrin', 'Biorphen', 'Fenilfar', 'FenoxMydfrin', 'Nazex', 'Neo-synephrine', 'Neosynephrine', 'NostrilNurofen sinus pain relief', 'Phenylephrine hydrochloride', 'PrefrinVazculep']", 'syns_list': "['Metaoxedrine chloride', 'NSC-757273', 'Phenylephrine HClPhenylephrine hydrochloride']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotension', 'efo_term': 'hypotension', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_416610', 'drugName': 'Phenylephrine Hydrochloride', 'tradeNames_list': "['Afrin 4 hour nasal spray', 'Biomydrin', 'Biorphen', 'Fenilfar', 'FenoxMydfrin', 'Nazex', 'Neo-synephrine', 'Neosynephrine', 'NostrilNurofen sinus pain relief', 'Phenylephrine hydrochloride', 'PrefrinVazculep']", 'syns_list': "['Metaoxedrine chloride', 'NSC-757273', 'Phenylephrine HClPhenylephrine hydrochloride']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotension', 'efo_term': 'hypotension', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_416664', 'drugName': 'Phenylephrine Hydrochloride', 'tradeNames_list': "['Afrin 4 hour nasal spray', 'Biomydrin', 'Biorphen', 'Fenilfar', 'FenoxMydfrin', 'Nazex', 'Neo-synephrine', 'Neosynephrine', 'NostrilNurofen sinus pain relief', 'Phenylephrine hydrochloride', 'PrefrinVazculep']", 'syns_list': "['Metaoxedrine chloride', 'NSC-757273', 'Phenylephrine HClPhenylephrine hydrochloride']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotension', 'efo_term': 'hypotension', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_416682', 'drugName': 'Phenylephrine Hydrochloride', 'tradeNames_list': "['Afrin 4 hour nasal spray', 'Biomydrin', 'Biorphen', 'Fenilfar', 'FenoxMydfrin', 'Nazex', 'Neo-synephrine', 'Neosynephrine', 'NostrilNurofen sinus pain relief', 'Phenylephrine hydrochloride', 'PrefrinVazculep']", 'syns_list': "['Metaoxedrine chloride', 'NSC-757273', 'Phenylephrine HClPhenylephrine hydrochloride']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotension', 'efo_term': 'hypotension', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_416646', 'drugName': 'Phenylephrine Hydrochloride', 'tradeNames_list': "['Afrin 4 hour nasal spray', 'Biomydrin', 'Biorphen', 'Fenilfar', 'FenoxMydfrin', 'Nazex', 'Neo-synephrine', 'Neosynephrine', 'NostrilNurofen sinus pain relief', 'Phenylephrine hydrochloride', 'PrefrinVazculep']", 'syns_list': "['Metaoxedrine chloride', 'NSC-757273', 'Phenylephrine HClPhenylephrine hydrochloride']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotension', 'efo_term': 'hypotension', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.266 | Q34 | What are the names of the genes that are targeted by the drug Budesonide in the treatment of chronic bronchitis? | In the context of chronic bronchitis, the drug Budesonide targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%chronic bronchitis%" OR LOWER(efo_term) LIKE "%chronic bronchitis%") AND (LOWER(drugName) LIKE "%budesonide%" OR LOWER(tradeNames_list) LIKE "%budesonide%" OR LOWER(syns_list) LIKE "%budesonide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_222617', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222752', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222797', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222842', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222932', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222977', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223022', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223112', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223157', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223202', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223247', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223337', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223382', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223427', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223472', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223517', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223562', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223607', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223652', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223697', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223742', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223832', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223877', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223922', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223967', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224012', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224102', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224147', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224192', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224237', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224282', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224327', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224372', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224417', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224462', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224507', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224552', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224597', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224642', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224687', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224732', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224777', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224822', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224867', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224912', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224957', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225002', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225047', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225092', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225137', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225182', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225272', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225317', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225362', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225407', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225227', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223787', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222707', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222527', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222437', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222392', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223067', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224057', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223292', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222887', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222662', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222572', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222482', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.77 | Q34 | What are the names of the genes that are targeted by the drug Bromocriptine Mesylate in the treatment of adenoma? | In the context of adenoma, the drug Bromocriptine Mesylate targets the gene dopamine receptor D2, dopamine receptor D3 and dopamine receptor D4. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%adenoma%" OR LOWER(efo_term) LIKE "%adenoma%") AND (LOWER(drugName) LIKE "%bromocriptine mesylate%" OR LOWER(tradeNames_list) LIKE "%bromocriptine mesylate%" OR LOWER(syns_list) LIKE "%bromocriptine mesylate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_201373', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201394', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201401', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201408', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201422', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201429', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201436', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201450', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201457', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201464', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201471', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201485', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201492', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201499', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201506', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201513', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201520', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201527', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201534', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201541', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201548', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201562', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201569', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201576', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201583', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201590', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201604', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201611', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201618', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201625', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201632', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201639', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201646', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201653', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201660', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201667', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201674', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201681', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201688', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201695', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201702', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201709', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201716', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201723', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201730', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201737', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201744', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201751', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201758', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201765', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201772', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201786', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201793', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201800', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201807', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201814', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201821', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201835', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201842', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201849', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201856', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201863', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201870', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201877', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201884', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201891', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201898', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201905', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201912', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201919', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201926', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201933', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201940', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201947', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201954', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201961', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201968', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201975', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201982', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201989', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201996', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_202003', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_202010', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_202017', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_202024', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_202031', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201779', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201555', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201443', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201387', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201359', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201345', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201338', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201828', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201597', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201478', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201415', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201380', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201366', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201352', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenoma', 'efo_term': 'adenoma', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1643 | Q34 | What are the names of the genes that are targeted by the drug Tadalafil in the treatment of pulmonary arterial hypertension? | In the context of pulmonary arterial hypertension, the drug Tadalafil targets the gene phosphodiesterase 5A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%pulmonary arterial hypertension%" OR LOWER(efo_term) LIKE "%pulmonary arterial hypertension%") AND (LOWER(drugName) LIKE "%tadalafil%" OR LOWER(tradeNames_list) LIKE "%tadalafil%" OR LOWER(syns_list) LIKE "%tadalafil%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1094101', 'drugName': 'Tadalafil', 'tradeNames_list': "['Adcirca', 'Cialis', 'Tadliq']", 'syns_list': "['IC-351', 'IC351', 'LY-450190', 'LY450190', 'NSC-750236', 'NSC-759172Tadalafil', 'Tadalafil mylan', 'Trans-tadalafil']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PDE5A', 'approvedName': 'phosphodiesterase 5A'}, {'UUID': 'DrugTargetsIndication121923_text_1094102', 'drugName': 'Tadalafil', 'tradeNames_list': "['Adcirca', 'Cialis', 'Tadliq']", 'syns_list': "['IC-351', 'IC351', 'LY-450190', 'LY450190', 'NSC-750236', 'NSC-759172Tadalafil', 'Tadalafil mylan', 'Trans-tadalafil']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PDE5A', 'approvedName': 'phosphodiesterase 5A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.448 | Q34 | What are the names of the genes that are targeted by the drug Epinephrine in the treatment of septic shock? | In the context of septic shock, the drug Epinephrine targets the gene adrenoceptor alpha 1A, adrenoceptor beta 2, adrenoceptor beta 1, adrenoceptor beta 3, adrenoceptor alpha 1D, adrenoceptor alpha 1B, adrenoceptor alpha 2A, adrenoceptor alpha 2C and adrenoceptor alpha 2B. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%septic shock%" OR LOWER(efo_term) LIKE "%septic shock%") AND (LOWER(drugName) LIKE "%epinephrine%" OR LOWER(tradeNames_list) LIKE "%epinephrine%" OR LOWER(syns_list) LIKE "%epinephrine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_361095', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361254', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361307', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361360', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361466', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361519', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361572', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361678', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361731', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361784', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361837', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361943', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361996', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362049', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362102', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362155', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362208', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362261', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362314', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362367', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362420', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362526', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362579', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362632', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362685', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362738', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362844', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362897', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362950', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363003', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363056', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363109', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363162', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363215', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363268', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363321', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363374', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363427', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363480', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363533', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363586', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363639', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363692', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363745', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363798', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363851', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363904', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363957', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364010', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364063', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364116', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364222', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364275', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364328', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364381', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364434', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364487', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364593', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364646', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364699', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364752', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364805', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364858', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364911', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364964', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365017', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365070', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365123', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365176', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365229', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365282', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365335', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365388', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365441', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365494', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365547', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365600', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365653', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365706', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365759', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365812', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365865', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365918', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365971', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_366024', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_366077', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364169', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362473', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361625', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361201', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_360989', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_360883', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_360830', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364540', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362791', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361890', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361413', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361148', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361042', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_360936', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.398 | Q34 | What are the names of the genes that are targeted by the drug Fluocinolone Acetonide in the treatment of uveitis? | In the context of uveitis, the drug Fluocinolone Acetonide targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%uveitis%" OR LOWER(efo_term) LIKE "%uveitis%") AND (LOWER(drugName) LIKE "%fluocinolone acetonide%" OR LOWER(tradeNames_list) LIKE "%fluocinolone acetonide%" OR LOWER(syns_list) LIKE "%fluocinolone acetonide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_242257', 'drugName': 'Fluocinolone Acetonide', 'tradeNames_list': "['Capex', 'Derma-smoothe/fs', 'Dermotic', 'Fluocet', 'Fluocinolone acetonideFluonid', 'Fluotrex', 'Fs shampoo', 'Iluvien', 'Retisert', 'SynalarSynalar fte', 'Synalar-c', 'Synalar-hp', 'Synalar-n', 'Synandone', 'Yutiq']", 'syns_list': "['Flucinolone acetonide', 'Fluocinolide (acetate)', 'FluocinoloneFluocinolone acetonide', 'NSC-92339', 'Oto-synalar']", 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis', 'efo_term': 'uveitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_242241', 'drugName': 'Fluocinolone Acetonide', 'tradeNames_list': "['Capex', 'Derma-smoothe/fs', 'Dermotic', 'Fluocet', 'Fluocinolone acetonideFluonid', 'Fluotrex', 'Fs shampoo', 'Iluvien', 'Retisert', 'SynalarSynalar fte', 'Synalar-c', 'Synalar-hp', 'Synalar-n', 'Synandone', 'Yutiq']", 'syns_list': "['Flucinolone acetonide', 'Fluocinolide (acetate)', 'FluocinoloneFluocinolone acetonide', 'NSC-92339', 'Oto-synalar']", 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis', 'efo_term': 'uveitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_242231', 'drugName': 'Fluocinolone Acetonide', 'tradeNames_list': "['Capex', 'Derma-smoothe/fs', 'Dermotic', 'Fluocet', 'Fluocinolone acetonideFluonid', 'Fluotrex', 'Fs shampoo', 'Iluvien', 'Retisert', 'SynalarSynalar fte', 'Synalar-c', 'Synalar-hp', 'Synalar-n', 'Synandone', 'Yutiq']", 'syns_list': "['Flucinolone acetonide', 'Fluocinolide (acetate)', 'FluocinoloneFluocinolone acetonide', 'NSC-92339', 'Oto-synalar']", 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uveitis, Posterior', 'efo_term': 'posterior uveitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_242247', 'drugName': 'Fluocinolone Acetonide', 'tradeNames_list': "['Capex', 'Derma-smoothe/fs', 'Dermotic', 'Fluocet', 'Fluocinolone acetonideFluonid', 'Fluotrex', 'Fs shampoo', 'Iluvien', 'Retisert', 'SynalarSynalar fte', 'Synalar-c', 'Synalar-hp', 'Synalar-n', 'Synandone', 'Yutiq']", 'syns_list': "['Flucinolone acetonide', 'Fluocinolide (acetate)', 'FluocinoloneFluocinolone acetonide', 'NSC-92339', 'Oto-synalar']", 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uveitis, Posterior', 'efo_term': 'posterior uveitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.178 | Q34 | What are the names of the genes that are targeted by the drug Prednisone in the treatment of gout? | In the context of gout, the drug Prednisone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%gout%" OR LOWER(efo_term) LIKE "%gout%") AND (LOWER(drugName) LIKE "%prednisone%" OR LOWER(tradeNames_list) LIKE "%prednisone%" OR LOWER(syns_list) LIKE "%prednisone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_218684', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Gouty', 'efo_term': 'gout', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219308', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Gouty', 'efo_term': 'gout', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219516', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Gouty', 'efo_term': 'gout', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219724', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Gouty', 'efo_term': 'gout', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220140', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Gouty', 'efo_term': 'gout', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220348', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Gouty', 'efo_term': 'gout', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220556', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Gouty', 'efo_term': 'gout', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220764', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Gouty', 'efo_term': 'gout', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219100', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Gouty', 'efo_term': 'gout', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218268', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Gouty', 'efo_term': 'gout', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217852', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Gouty', 'efo_term': 'gout', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217644', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Gouty', 'efo_term': 'gout', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219932', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Gouty', 'efo_term': 'gout', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218892', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Gouty', 'efo_term': 'gout', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218476', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Gouty', 'efo_term': 'gout', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218060', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Gouty', 'efo_term': 'gout', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1049 | Q34 | What are the names of the genes that are targeted by the drug Pemetrexed in the treatment of cancer? | In the context of cancer, the drug Pemetrexed targets the gene thymidylate synthetase, phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase and dihydrofolate reductase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cancer%" OR LOWER(efo_term) LIKE "%cancer%") AND (LOWER(drugName) LIKE "%pemetrexed%" OR LOWER(tradeNames_list) LIKE "%pemetrexed%" OR LOWER(syns_list) LIKE "%pemetrexed%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_918729', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919107', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_919170', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_918477', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919044', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'GART', 'approvedName': 'phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918855', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'GART', 'approvedName': 'phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919359', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_919233', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_918666', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919296', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_918918', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'GART', 'approvedName': 'phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918540', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918603', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918981', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'GART', 'approvedName': 'phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918792', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'GART', 'approvedName': 'phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919231', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_918312', 'drugName': 'Pemetrexed Disodium', 'tradeNames_list': "['Alimta']", 'syns_list': "['LY-231514 DISODIUM SALT', 'LY231514 DISODIUM SALT', 'Pemetrexed disodiumPemetrexed disodium heptahydrate', 'Pemetrexed sodium hydratePemetrexed sodium salt']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'GART', 'approvedName': 'phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918790', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'GART', 'approvedName': 'phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918347', 'drugName': 'Pemetrexed Disodium', 'tradeNames_list': "['Alimta']", 'syns_list': "['LY-231514 DISODIUM SALT', 'LY231514 DISODIUM SALT', 'Pemetrexed disodiumPemetrexed disodium heptahydrate', 'Pemetrexed sodium hydratePemetrexed sodium salt']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'GART', 'approvedName': 'phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918979', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'GART', 'approvedName': 'phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918277', 'drugName': 'Pemetrexed Disodium', 'tradeNames_list': "['Alimta']", 'syns_list': "['LY-231514 DISODIUM SALT', 'LY231514 DISODIUM SALT', 'Pemetrexed disodiumPemetrexed disodium heptahydrate', 'Pemetrexed sodium hydratePemetrexed sodium salt']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918852', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'GART', 'approvedName': 'phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918242', 'drugName': 'Pemetrexed Disodium', 'tradeNames_list': "['Alimta']", 'syns_list': "['LY-231514 DISODIUM SALT', 'LY231514 DISODIUM SALT', 'Pemetrexed disodiumPemetrexed disodium heptahydrate', 'Pemetrexed sodium hydratePemetrexed sodium salt']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918789', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'GART', 'approvedName': 'phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918916', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'GART', 'approvedName': 'phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918726', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918664', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918600', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918537', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919166', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_919041', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'GART', 'approvedName': 'phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918474', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919355', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_919168', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_918473', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919356', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_919104', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_919230', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_919292', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_919105', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_918914', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'GART', 'approvedName': 'phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918853', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'GART', 'approvedName': 'phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919040', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'GART', 'approvedName': 'phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918915', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'GART', 'approvedName': 'phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918851', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'GART', 'approvedName': 'phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919357', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_918417', 'drugName': 'Pemetrexed Disodium', 'tradeNames_list': "['Alimta']", 'syns_list': "['LY-231514 DISODIUM SALT', 'LY231514 DISODIUM SALT', 'Pemetrexed disodiumPemetrexed disodium heptahydrate', 'Pemetrexed sodium hydratePemetrexed sodium salt']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_918725', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918727', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919293', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_918538', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919229', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_918977', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'GART', 'approvedName': 'phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918663', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918601', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918978', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'GART', 'approvedName': 'phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918788', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'GART', 'approvedName': 'phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918382', 'drugName': 'Pemetrexed Disodium', 'tradeNames_list': "['Alimta']", 'syns_list': "['LY-231514 DISODIUM SALT', 'LY231514 DISODIUM SALT', 'Pemetrexed disodiumPemetrexed disodium heptahydrate', 'Pemetrexed sodium hydratePemetrexed sodium salt']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_919167', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_919042', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'GART', 'approvedName': 'phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918536', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919103', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_919294', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_918599', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918662', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918475', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918519', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneum cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918520', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918227', 'drugName': 'Pemetrexed Disodium', 'tradeNames_list': "['Alimta']", 'syns_list': "['LY-231514 DISODIUM SALT', 'LY231514 DISODIUM SALT', 'Pemetrexed disodiumPemetrexed disodium heptahydrate', 'Pemetrexed sodium hydratePemetrexed sodium salt']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918521', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'fallopian tube cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918522', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Liver Neoplasms', 'efo_term': 'liver cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918583', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918587', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918524', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918525', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Esophageal Neoplasms', 'efo_term': 'esophageal cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918578', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectum cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918367', 'drugName': 'Pemetrexed Disodium', 'tradeNames_list': "['Alimta']", 'syns_list': "['LY-231514 DISODIUM SALT', 'LY231514 DISODIUM SALT', 'Pemetrexed disodiumPemetrexed disodium heptahydrate', 'Pemetrexed sodium hydratePemetrexed sodium salt']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_918368', 'drugName': 'Pemetrexed Disodium', 'tradeNames_list': "['Alimta']", 'syns_list': "['LY-231514 DISODIUM SALT', 'LY231514 DISODIUM SALT', 'Pemetrexed disodiumPemetrexed disodium heptahydrate', 'Pemetrexed sodium hydratePemetrexed sodium salt']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_918582', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneum cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918369', 'drugName': 'Pemetrexed Disodium', 'tradeNames_list': "['Alimta']", 'syns_list': "['LY-231514 DISODIUM SALT', 'LY231514 DISODIUM SALT', 'Pemetrexed disodiumPemetrexed disodium heptahydrate', 'Pemetrexed sodium hydratePemetrexed sodium salt']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneum cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_918230', 'drugName': 'Pemetrexed Disodium', 'tradeNames_list': "['Alimta']", 'syns_list': "['LY-231514 DISODIUM SALT', 'LY231514 DISODIUM SALT', 'Pemetrexed disodiumPemetrexed disodium heptahydrate', 'Pemetrexed sodium hydratePemetrexed sodium salt']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918297', 'drugName': 'Pemetrexed Disodium', 'tradeNames_list': "['Alimta']", 'syns_list': "['LY-231514 DISODIUM SALT', 'LY231514 DISODIUM SALT', 'Pemetrexed disodiumPemetrexed disodium heptahydrate', 'Pemetrexed sodium hydratePemetrexed sodium salt']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'GART', 'approvedName': 'phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918370', 'drugName': 'Pemetrexed Disodium', 'tradeNames_list': "['Alimta']", 'syns_list': "['LY-231514 DISODIUM SALT', 'LY231514 DISODIUM SALT', 'Pemetrexed disodiumPemetrexed disodium heptahydrate', 'Pemetrexed sodium hydratePemetrexed sodium salt']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_918371', 'drugName': 'Pemetrexed Disodium', 'tradeNames_list': "['Alimta']", 'syns_list': "['LY-231514 DISODIUM SALT', 'LY231514 DISODIUM SALT', 'Pemetrexed disodiumPemetrexed disodium heptahydrate', 'Pemetrexed sodium hydratePemetrexed sodium salt']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urethral Neoplasms', 'efo_term': 'urethra cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_918231', 'drugName': 'Pemetrexed Disodium', 'tradeNames_list': "['Alimta']", 'syns_list': "['LY-231514 DISODIUM SALT', 'LY231514 DISODIUM SALT', 'Pemetrexed disodiumPemetrexed disodium heptahydrate', 'Pemetrexed sodium hydratePemetrexed sodium salt']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urethral Neoplasms', 'efo_term': 'urethra cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918523', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Biliary Tract Neoplasms', 'efo_term': 'biliary tract cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918298', 'drugName': 'Pemetrexed Disodium', 'tradeNames_list': "['Alimta']", 'syns_list': "['LY-231514 DISODIUM SALT', 'LY231514 DISODIUM SALT', 'Pemetrexed disodiumPemetrexed disodium heptahydrate', 'Pemetrexed sodium hydratePemetrexed sodium salt']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'GART', 'approvedName': 'phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918372', 'drugName': 'Pemetrexed Disodium', 'tradeNames_list': "['Alimta']", 'syns_list': "['LY-231514 DISODIUM SALT', 'LY231514 DISODIUM SALT', 'Pemetrexed disodiumPemetrexed disodium heptahydrate', 'Pemetrexed sodium hydratePemetrexed sodium salt']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_918581', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918586', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Biliary Tract Neoplasms', 'efo_term': 'biliary tract cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918373', 'drugName': 'Pemetrexed Disodium', 'tradeNames_list': "['Alimta']", 'syns_list': "['LY-231514 DISODIUM SALT', 'LY231514 DISODIUM SALT', 'Pemetrexed disodiumPemetrexed disodium heptahydrate', 'Pemetrexed sodium hydratePemetrexed sodium salt']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_918299', 'drugName': 'Pemetrexed Disodium', 'tradeNames_list': "['Alimta']", 'syns_list': "['LY-231514 DISODIUM SALT', 'LY231514 DISODIUM SALT', 'Pemetrexed disodiumPemetrexed disodium heptahydrate', 'Pemetrexed sodium hydratePemetrexed sodium salt']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneum cancer', 'approvedSymbol': 'GART', 'approvedName': 'phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918374', 'drugName': 'Pemetrexed Disodium', 'tradeNames_list': "['Alimta']", 'syns_list': "['LY-231514 DISODIUM SALT', 'LY231514 DISODIUM SALT', 'Pemetrexed disodiumPemetrexed disodium heptahydrate', 'Pemetrexed sodium hydratePemetrexed sodium salt']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_918375', 'drugName': 'Pemetrexed Disodium', 'tradeNames_list': "['Alimta']", 'syns_list': "['LY-231514 DISODIUM SALT', 'LY231514 DISODIUM SALT', 'Pemetrexed disodiumPemetrexed disodium heptahydrate', 'Pemetrexed sodium hydratePemetrexed sodium salt']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_918262', 'drugName': 'Pemetrexed Disodium', 'tradeNames_list': "['Alimta']", 'syns_list': "['LY-231514 DISODIUM SALT', 'LY231514 DISODIUM SALT', 'Pemetrexed disodiumPemetrexed disodium heptahydrate', 'Pemetrexed sodium hydratePemetrexed sodium salt']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918300', 'drugName': 'Pemetrexed Disodium', 'tradeNames_list': "['Alimta']", 'syns_list': "['LY-231514 DISODIUM SALT', 'LY231514 DISODIUM SALT', 'Pemetrexed disodiumPemetrexed disodium heptahydrate', 'Pemetrexed sodium hydratePemetrexed sodium salt']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'GART', 'approvedName': 'phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918585', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Liver Neoplasms', 'efo_term': 'liver cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918301', 'drugName': 'Pemetrexed Disodium', 'tradeNames_list': "['Alimta']", 'syns_list': "['LY-231514 DISODIUM SALT', 'LY231514 DISODIUM SALT', 'Pemetrexed disodiumPemetrexed disodium heptahydrate', 'Pemetrexed sodium hydratePemetrexed sodium salt']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urethral Neoplasms', 'efo_term': 'urethra cancer', 'approvedSymbol': 'GART', 'approvedName': 'phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918584', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'syns_list': "['LY-2315', 'LY-231514', 'LY231514', 'NSC-698037', 'Pemetrexed']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'fallopian tube cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918402', 'drugName': 'Pemetrexed Disodium', 'tradeNames_list': "['Alimta']", 'syns_list': "['LY-231514 DISODIUM SALT', 'LY231514 DISODIUM SALT', 'Pemetrexed disodiumPemetrexed disodium heptahydrate', 'Pemetrexed sodium hydratePemetrexed sodium salt']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1719 | Q34 | What are the names of the genes that are targeted by the drug Ezetimibe in the treatment of homozygous familial hypercholesterolemia? | In the context of homozygous familial hypercholesterolemia, the drug Ezetimibe targets the gene NPC1 like intracellular cholesterol transporter 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%homozygous familial hypercholesterolemia%" OR LOWER(efo_term) LIKE "%homozygous familial hypercholesterolemia%") AND (LOWER(drugName) LIKE "%ezetimibe%" OR LOWER(tradeNames_list) LIKE "%ezetimibe%" OR LOWER(syns_list) LIKE "%ezetimibe%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1097390', 'drugName': 'Ezetimibe', 'tradeNames_list': "['Ezetimibe', 'Ezetrol', 'Zetia']", 'syns_list': "['Ezetimibe', 'MK0653', 'NSC-758923', 'SCH-58235', 'SCH58235']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia', 'approvedSymbol': 'NPC1L1', 'approvedName': 'NPC1 like intracellular cholesterol transporter 1'}, {'UUID': 'DrugTargetsIndication121923_text_1097327', 'drugName': 'Ezetimibe', 'tradeNames_list': "['Ezetimibe', 'Ezetrol', 'Zetia']", 'syns_list': "['Ezetimibe', 'MK0653', 'NSC-758923', 'SCH-58235', 'SCH58235']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia', 'approvedSymbol': 'NPC1L1', 'approvedName': 'NPC1 like intracellular cholesterol transporter 1'}, {'UUID': 'DrugTargetsIndication121923_text_1097348', 'drugName': 'Ezetimibe', 'tradeNames_list': "['Ezetimibe', 'Ezetrol', 'Zetia']", 'syns_list': "['Ezetimibe', 'MK0653', 'NSC-758923', 'SCH-58235', 'SCH58235']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia', 'approvedSymbol': 'NPC1L1', 'approvedName': 'NPC1 like intracellular cholesterol transporter 1'}, {'UUID': 'DrugTargetsIndication121923_text_1097411', 'drugName': 'Ezetimibe', 'tradeNames_list': "['Ezetimibe', 'Ezetrol', 'Zetia']", 'syns_list': "['Ezetimibe', 'MK0653', 'NSC-758923', 'SCH-58235', 'SCH58235']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia', 'approvedSymbol': 'NPC1L1', 'approvedName': 'NPC1 like intracellular cholesterol transporter 1'}, {'UUID': 'DrugTargetsIndication121923_text_1097369', 'drugName': 'Ezetimibe', 'tradeNames_list': "['Ezetimibe', 'Ezetrol', 'Zetia']", 'syns_list': "['Ezetimibe', 'MK0653', 'NSC-758923', 'SCH-58235', 'SCH58235']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia', 'approvedSymbol': 'NPC1L1', 'approvedName': 'NPC1 like intracellular cholesterol transporter 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1386 | Q34 | What are the names of the genes that are targeted by the drug Brimonidine Tartrate in the treatment of Erythema? | In the context of Erythema, the drug Brimonidine Tartrate targets the gene adrenoceptor alpha 2A, adrenoceptor alpha 2C and adrenoceptor alpha 2B. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%erythema%" OR LOWER(efo_term) LIKE "%erythema%") AND (LOWER(drugName) LIKE "%brimonidine tartrate%" OR LOWER(tradeNames_list) LIKE "%brimonidine tartrate%" OR LOWER(syns_list) LIKE "%brimonidine tartrate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1034125', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034170', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034185', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034200', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034230', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034245', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034260', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034290', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034305', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034320', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034335', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034365', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034380', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034395', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034410', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034425', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034440', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034455', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034470', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034485', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034500', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034530', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034545', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034560', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034575', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034590', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034620', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034635', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034650', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034665', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034680', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034695', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034710', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034725', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034740', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034755', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034770', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034785', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034800', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034815', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034830', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034845', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034860', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034875', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034890', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1034905', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1034920', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1034935', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1034950', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1034965', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1034980', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1035010', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1035025', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1035040', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1035055', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1035070', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1035085', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1035115', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1035130', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1035145', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1035160', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1035175', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1035190', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1035205', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1035220', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1035235', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1035250', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1035265', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1035280', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1035295', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1034995', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1034515', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034275', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034155', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034095', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034065', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034050', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1035100', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1034605', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1034350', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034215', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034140', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034110', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034080', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'syns_list': "['AGN 190342-LF', 'AGN-190342-LF', 'AGN-190342LF', 'Brimonidine d-tartrateBrimonidine tartrate', 'Bromoxidine tartrate', 'Cd-07805', 'OCU-300OCU300', 'UK-14304-18', 'UK-1430418']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.